TWI313680B - Acylaminothiazole derivatives, their preparation and their therapeutic application - Google Patents
Acylaminothiazole derivatives, their preparation and their therapeutic application Download PDFInfo
- Publication number
- TWI313680B TWI313680B TW092119408A TW92119408A TWI313680B TW I313680 B TWI313680 B TW I313680B TW 092119408 A TW092119408 A TW 092119408A TW 92119408 A TW92119408 A TW 92119408A TW I313680 B TWI313680 B TW I313680B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- phenyl
- alkyl
- alkoxy
- substituted
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title description 8
- 230000001225 therapeutic effect Effects 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims description 107
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 71
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 63
- 125000003545 alkoxy group Chemical group 0.000 claims description 54
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- -1 benzopyrylene Chemical group 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 38
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 37
- 125000001424 substituent group Chemical group 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 125000004076 pyridyl group Chemical group 0.000 claims description 13
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 12
- 239000000460 chlorine Substances 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 11
- 125000004043 oxo group Chemical group O=* 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 9
- 150000001412 amines Chemical class 0.000 claims description 9
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 9
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 238000005897 peptide coupling reaction Methods 0.000 claims description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 7
- 239000011737 fluorine Substances 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 6
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 125000006612 decyloxy group Chemical group 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 208000019553 vascular disease Diseases 0.000 claims description 5
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 229930192474 thiophene Natural products 0.000 claims description 4
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical group 0.000 claims description 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- RKCAIXNGYQCCAL-UHFFFAOYSA-N porphin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 RKCAIXNGYQCCAL-UHFFFAOYSA-N 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- QSJNAFJALFWFMT-UHFFFAOYSA-N meridine Chemical compound N1C=CC(=O)C2=C1C(=O)C1=NC=CC3=C(C=CC=C4)C4=NC2=C13 QSJNAFJALFWFMT-UHFFFAOYSA-N 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical group O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- NYIGEYYREVRXES-UHFFFAOYSA-N pyrazol-1-amine Chemical compound NN1C=CC=N1 NYIGEYYREVRXES-UHFFFAOYSA-N 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 125000004354 sulfur functional group Chemical group 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 155
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 114
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- 238000005481 NMR spectroscopy Methods 0.000 description 58
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 54
- 235000019439 ethyl acetate Nutrition 0.000 description 52
- 239000000243 solution Substances 0.000 description 50
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
- 239000000203 mixture Substances 0.000 description 42
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 38
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 34
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 33
- 239000012074 organic phase Substances 0.000 description 32
- 229920006395 saturated elastomer Polymers 0.000 description 30
- 239000003208 petroleum Substances 0.000 description 29
- 239000012429 reaction media Substances 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 239000002585 base Substances 0.000 description 18
- 239000000843 powder Substances 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- 101150041968 CDC13 gene Proteins 0.000 description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000001704 evaporation Methods 0.000 description 12
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 11
- 230000008020 evaporation Effects 0.000 description 11
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000004702 methyl esters Chemical class 0.000 description 9
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- IGGNSAVLXJKCNH-UHFFFAOYSA-N 2-(3,5-difluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC(F)=CC(F)=C1 IGGNSAVLXJKCNH-UHFFFAOYSA-N 0.000 description 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 5
- 125000004212 difluorophenyl group Chemical group 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 5
- 239000000052 vinegar Substances 0.000 description 5
- 235000021419 vinegar Nutrition 0.000 description 5
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 4
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 4
- 206010059245 Angiopathy Diseases 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical group [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- KUWWRNNYEYGSBQ-UHFFFAOYSA-N methyl 1,3-thiazole-4-carboxylate Chemical compound COC(=O)C1=CSC=N1 KUWWRNNYEYGSBQ-UHFFFAOYSA-N 0.000 description 4
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- PHMLPPFFMSRWBK-UHFFFAOYSA-N 2-(3,5-difluorophenyl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CC(F)=CC(F)=C1 PHMLPPFFMSRWBK-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- YWWNNLPSZSEZNZ-UHFFFAOYSA-N n,n-dimethyldecan-1-amine Chemical compound CCCCCCCCCCN(C)C YWWNNLPSZSEZNZ-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 3
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- VNTAONUWHQBAMC-UHFFFAOYSA-N 3-phenothiazin-10-ylpropanoic acid Chemical compound C1=CC=C2N(CCC(=O)O)C3=CC=CC=C3SC2=C1 VNTAONUWHQBAMC-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- PAZJFXNRVLDLFO-UHFFFAOYSA-N 4-sulfanylmorpholine Chemical compound SN1CCOCC1 PAZJFXNRVLDLFO-UHFFFAOYSA-N 0.000 description 2
- 108010011619 6-Phytase Proteins 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- HCCMDFJOQCDTJQ-UHFFFAOYSA-N C(CCCCCCCCC)OC(=O)C=1N=COC1 Chemical compound C(CCCCCCCCC)OC(=O)C=1N=COC1 HCCMDFJOQCDTJQ-UHFFFAOYSA-N 0.000 description 2
- UDODQZLHXZBDJC-UHFFFAOYSA-N CC(CCCCCCCCCC#N)(C)C Chemical compound CC(CCCCCCCCCC#N)(C)C UDODQZLHXZBDJC-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 241000995070 Nirvana Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000004715 keto acids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- JZSAEGOONAZWSA-UHFFFAOYSA-N methyl 1,3-oxazole-4-carboxylate Chemical compound COC(=O)C1=COC=N1 JZSAEGOONAZWSA-UHFFFAOYSA-N 0.000 description 2
- VOWFMWURKUOVSJ-UHFFFAOYSA-N n,n-bis(sulfanyl)formamide Chemical compound SN(S)C=O VOWFMWURKUOVSJ-UHFFFAOYSA-N 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- ABMDIECEEGFXNC-UHFFFAOYSA-N n-ethylpropanamide Chemical compound CCNC(=O)CC ABMDIECEEGFXNC-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229940085127 phytase Drugs 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical class C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- SAMVPMGKGGLIPF-ZETCQYMHSA-N (2s)-2-(3-chlorophenyl)-2-hydroxyacetic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC(Cl)=C1 SAMVPMGKGGLIPF-ZETCQYMHSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- QFGMPXZFCIHYIR-QMMMGPOBSA-N (2s)-2-amino-3-(3,5-difluorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC(F)=CC(F)=C1 QFGMPXZFCIHYIR-QMMMGPOBSA-N 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- JBCFJMYPJJWIRG-UHFFFAOYSA-N 1,3-oxazole-4-carboxylic acid Chemical compound OC(=O)C1=COC=N1 JBCFJMYPJJWIRG-UHFFFAOYSA-N 0.000 description 1
- HMVYYTRDXNKRBQ-UHFFFAOYSA-N 1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC=N1 HMVYYTRDXNKRBQ-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
- QLSWIGRIBOSFMV-UHFFFAOYSA-N 1h-pyrrol-2-amine Chemical compound NC1=CC=CN1 QLSWIGRIBOSFMV-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- UNNGUFMVYQJGTD-UHFFFAOYSA-N 2-Ethylbutanal Chemical compound CCC(CC)C=O UNNGUFMVYQJGTD-UHFFFAOYSA-N 0.000 description 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
- KTWNXVSKBCNPGP-UHFFFAOYSA-N 2-amino-5-propyl-1,3-thiazole-4-carboxylic acid Chemical compound CCCC=1SC(N)=NC=1C(O)=O KTWNXVSKBCNPGP-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- OXWBKEDWTSRPJB-UHFFFAOYSA-N 2-fluoro-2-hydroxy-2-phenylacetic acid Chemical compound OC(=O)C(O)(F)C1=CC=CC=C1 OXWBKEDWTSRPJB-UHFFFAOYSA-N 0.000 description 1
- ATPPNMLQNZHDOG-UHFFFAOYSA-N 2-fluoro-2-phenylacetic acid Chemical compound OC(=O)C(F)C1=CC=CC=C1 ATPPNMLQNZHDOG-UHFFFAOYSA-N 0.000 description 1
- MJFNDTXMFBKSLR-UHFFFAOYSA-N 2-hydroxy-2-(2-phenylmethoxyphenyl)acetic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1OCC1=CC=CC=C1 MJFNDTXMFBKSLR-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- ZJSQZQMVXKZAGW-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrate Chemical compound O.OC1=CC=CC2=C1N=NN2 ZJSQZQMVXKZAGW-UHFFFAOYSA-N 0.000 description 1
- YDAQQRLZYMYLDB-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrochloride Chemical compound Cl.OC1=CC=CC2=C1N=NN2 YDAQQRLZYMYLDB-UHFFFAOYSA-N 0.000 description 1
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
- MBJNVIFBWMTUSE-UHFFFAOYSA-N 3-ethyl-2-hydroxypentanoic acid Chemical compound CCC(CC)C(O)C(O)=O MBJNVIFBWMTUSE-UHFFFAOYSA-N 0.000 description 1
- FVSWNQYFMNGPLF-UHFFFAOYSA-N 3-phenylpyrrolidine-2,5-dione Chemical compound O=C1NC(=O)CC1C1=CC=CC=C1 FVSWNQYFMNGPLF-UHFFFAOYSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- YJKJAYFKPIUBAW-UHFFFAOYSA-N 9h-carbazol-1-amine Chemical class N1C2=CC=CC=C2C2=C1C(N)=CC=C2 YJKJAYFKPIUBAW-UHFFFAOYSA-N 0.000 description 1
- IGLKULAEHPBIJL-UHFFFAOYSA-N 9h-carbazol-2-amine Chemical compound C1=CC=C2C3=CC=C(N)C=C3NC2=C1 IGLKULAEHPBIJL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 101100048435 Caenorhabditis elegans unc-18 gene Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical group FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 1
- 241001669573 Galeorhinus galeus Species 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000882381 Scoparia lii Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- AZFNGPAYDKGCRB-XCPIVNJJSA-M [(1s,2s)-2-amino-1,2-diphenylethyl]-(4-methylphenyl)sulfonylazanide;chlororuthenium(1+);1-methyl-4-propan-2-ylbenzene Chemical compound [Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC(C)=CC=C1S(=O)(=O)[N-][C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 AZFNGPAYDKGCRB-XCPIVNJJSA-M 0.000 description 1
- DHUZHIZMMSDVEX-UHFFFAOYSA-N [C-]#N.S(=O)(=O)(OC)OC Chemical compound [C-]#N.S(=O)(=O)(OC)OC DHUZHIZMMSDVEX-UHFFFAOYSA-N 0.000 description 1
- PWSRBALQAYBHNY-UHFFFAOYSA-N [Cl-].S[NH2+]S Chemical compound [Cl-].S[NH2+]S PWSRBALQAYBHNY-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical group C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000003976 azacycloalkanes Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- IFVTZJHWGZSXFD-UHFFFAOYSA-N biphenylene Chemical group C1=CC=C2C3=CC=CC=C3C2=C1 IFVTZJHWGZSXFD-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- TUTWLYPCGCUWQI-UHFFFAOYSA-N decanamide Chemical compound CCCCCCCCCC(N)=O TUTWLYPCGCUWQI-UHFFFAOYSA-N 0.000 description 1
- 150000001954 decanoic acid esters Chemical class 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- CATSNJVOTSVZJV-UHFFFAOYSA-N heptan-2-one Chemical compound CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- LLLQJQUWSSBNHX-UHFFFAOYSA-N hydrazine 4-methylmorpholine Chemical compound CN1CCOCC1.NN LLLQJQUWSSBNHX-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HKMLRUAPIDAGIE-UHFFFAOYSA-N methyl 2,2-dichloroacetate Chemical compound COC(=O)C(Cl)Cl HKMLRUAPIDAGIE-UHFFFAOYSA-N 0.000 description 1
- SUWMNBGRQNCMEV-ZETCQYMHSA-N methyl 2-[[(2s)-2-amino-3-methoxypropanoyl]amino]-5-propan-2-yl-1,3-thiazole-4-carboxylate Chemical compound COC[C@H](N)C(=O)NC1=NC(C(=O)OC)=C(C(C)C)S1 SUWMNBGRQNCMEV-ZETCQYMHSA-N 0.000 description 1
- MOYUJTBTBINSHM-UHFFFAOYSA-N methyl 5-propan-2-yl-1,3-thiazole-4-carboxylate Chemical compound COC(=O)C=1N=CSC=1C(C)C MOYUJTBTBINSHM-UHFFFAOYSA-N 0.000 description 1
- CFWHNKGYMFMIPW-UHFFFAOYSA-N methyl 9h-carbazole-4-carboxylate Chemical compound N1C2=CC=CC=C2C2=C1C=CC=C2C(=O)OC CFWHNKGYMFMIPW-UHFFFAOYSA-N 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- SVEUVITYHIHZQE-UHFFFAOYSA-N n-methylpyridin-2-amine Chemical compound CNC1=CC=CC=N1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- FWFGVMYFCODZRD-UHFFFAOYSA-N oxidanium;hydrogen sulfate Chemical compound O.OS(O)(=O)=O FWFGVMYFCODZRD-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 1
- 229940100684 pentylamine Drugs 0.000 description 1
- 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000004304 potassium nitrite Substances 0.000 description 1
- 235000010289 potassium nitrite Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical class [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 description 1
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical class [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Description
1313680 玖、發明說明: 【發明所屬之技術領域】 本發明有關醯胺基嘧唑衍生物、並制# Ώ # ^具製備及其治療應用 【先前技術】 /3 -搬粉樣月太(月-A4)為一種赫4* ^ ?又大則驅物蛋白質(稱為 ΑΡΡ)(澱粉樣前驅物蛋白質)之片段,並你+ ;丄 乂〜/7权’其係在人類或動物組 織中各種細胞中產生並存在。但其在腦組財藉蛋白酶類 酵素斷裂導致形成/5-Α4肽,其以殿粉樣斑型態累積。負責 產生殿粉樣狀之兩種蛋白酶稱為心及Τ _分泌酶(w〇lfe MS, 阿兹海默氏疾病之分泌酶標的:鐘定及治療潛力,醫藥化 學期刊,2001 年 6 月 21 曰;44 (13): 2039-60)。 目前已知点-A4肽之此逐漸沉積具神經毒性且在阿茲海 默氏疾病中扮演重要角色。 據此,藉r -蛋白酶之抑制作用而作為石-澱粉樣肽(石_A4) 產生之抑制劑者可用以治療如老年痴呆、阿茲海默氏 (A1Zheimer’s)疾病、道氏(Down's)徵候群 '帕金森氏 (ParkmSonis)疾病、澱粉樣血管病及/或心臟血管障礙等病 理。 【發明内容】 本發明首先有關通式(I)之化合物:
其中 86214 (I) 1313680 R1代表: 1 視情況經一至三個選自鹵素、羥基、三氟曱基、ci 6烷氧基、
Cl_6硫燒基、嘧吩或苯基之取代基取代之cN6境基;或 C3·7環k基、p塞吩、苯并p塞吩、p比咬基、咬喃基或苯基; 該苯基可視情況經一至三個選自_素原子、C16烷基、ci 6 烷氧基、羥基、亞甲二氧基、苯氧基或苄氧基之取代基取 代; R2及R’2彼此獨立代表氫原予、齒素原子、羥基、3烷氧基、 CN3烷基、c3.7環烷基、〇_c(〇)_Cn6烷基,或化與尺、一起形 成氧代基; R3代表氫原子、視情況經羥基或Ci·3烷氧基取代之Cw烷基; R4及Rs彼此獨立代表: 氫原子、視情況經CP環烷基或苯基取代之Ci7烷基;或 Gw環烷基、苯基、萘基或_C(X)R6; 孩環烷基及苯基視情況經—或多個選自齒素原子 '羥 基、Cw烷基、Cl_3烷氧基、三氟甲基、三氟甲氧基、苯基、 苯氧基、爷氧基、心2〇_苯基、基之取代基取 代; 三個選自齒素、三氟甲基、甲基 該苄氧基可視情況經一至 之取代基取代; 但條件為至少-似4駐5基代表仰队之基; X代表氧原子或硫原子; 8之基;該C!.6烷氧基可視
Rs代表CU6烷氧基、羥基或_nr^r 情況經苯基取代; R_7及Rs彼此獨立代表. 86214 -9- 1313680 氫原子、視情況經C3·7環烷基、Cw環烯基' cu;3垸氧基、_ 基、嗎啉基或吡啶基取代之C1_6烷基;或 R7及Rs與其所帶有之氮原子形成氮雜環丙燒、氮雜環 烷、吡咯啶、哌啶或嗎啉環; P玄C 3 _7 丨元基及冬基可視情況經^一或兩個選自c i 3境基 一 基、C 1 -3 $元乳基或齒素原子之取代基取代。 式(I)化合物中’第一類較佳化合物為其中:
Ri代表: 視情況經一至三個選自氟、羥基、三氟甲基、C1·4硫烷基(較 好為硫甲基)、嘍吩或苯基之取代基取代之C1·5烷基,較好 為甲基、乙基、1-甲基乙基、2-甲基丙基、第三丁基、工 基丙基;或
Co7環烷基(較好為環丙基或環己基)、呋喃基、噻吩、笨并 噻吩、吡啶基或苯基;該苯基可視情況經一至三個選自鹵 素原子(較好為氟或氣)、羥基、芊氧基或亞甲二氧基之取代 基取代;及/或 R:及R’2彼此獨立代表氫原子、鹵素原子(較好為氟)、羥基、 Cw烷基(較好為甲基或乙基)、(:3_7環烷基(較好為環己基)、 Cw烷氧基(較好為曱氧基)、〇_c(0)_Cl_4烷基(較好為 〇-C(0)-CH3)’或R2與r'2一起形成氧代基;及/或 R3代表視情況經Cw烷氧基(較好為甲氧基)取代之c14燒 基,較好為曱基'乙基、丙基或丁基; R·4及R5彼此獨立代表: 氫原子、視情況經笨基或C3_7環烷基(較好為環己基)取代之 C!-7烷基’較好為甲基、乙基' i—甲基乙基、正丙基、丁基、 86214 -10- 1313680 2-甲基丙基、第三丁基、3-甲基丁基、1-乙基丙基、2,2_二 曱基丙基、己基、5-甲基己基;或 C3-7環烷基(較好為環丙基或環己基)、苯基、萘基或 -C(X)R_6,該苯基視情況經一或兩個選自自素(較好為漠)、 Ci_3:t元基(較好為甲基或ι_甲基乙基)、經基、匚丨^燒氧基(較 好為甲氧基或乙氧基)、三氟甲基、三氟甲氧基、苯基、苯 氧基、芊氧基、-CH2〇-苯基、-OCH2-吡啶基之取代基取代; 該苄氧基可視情況經選自函素(較好為氯或氟)、三氟甲基或 曱基之取代基取代; 但條件為至少一個A或Rs基代表_C(X)R6之基;及/或 X代表氧原子;及/或 R6代表Cw烷氧基(較好為甲氧基、乙氧基、第三丁氧基)、 羥基或-NR?R8之基;該Cl_6烷氧基可視情況經苯基取代;及/或 1^7及R8彼此獨立代表: 氫原子、視情況經C1-3烷氧基(較好為甲氧基)、C37環烯基(較 好為環己浠基)、苯基、嗎啉基或吡啶基取代之烷基(較 好為甲基6基或1_甲基乙基);Ci3燒氧基(較好為甲氧 基);或 C3-6環统基(較好為環己基);或 117及118與八所帶有之氮原子形成氮雜環丙燒、喊違或嗎口林 環; 該苯基係視情況經一式忐佃 ^ ^ A兩個Cw烷氧基(較好為甲氧基)之 取代基取代。 通式(I)之化合物中’第二類較佳化合物為其中: R i代表: 86214 -11 - 1313680 視情況經一或兩個選自羥基、Ci 6烷氧基、ci 6硫烷基、$ 氟甲基、噻吩或苯基之取代基取代之C卜6烷基;或 Cw環烷基、嘧吩、苯并噻吩、吡啶基、呋喃基或苯基; 孩苯基可視情況經一至三個選自_素原子、烷基、Cu 烷氧基、羥基、亞曱二氧基、苯氧基或苄氧基之取代基取 代;及/或 R2及R’2彼此獨立代表氫原子、鹵素原子、羥基、Ci3烷氧基、 Ch烷基、c3.7環烷基、0_c(0)_Ci 6烷基,或R#R,2一起形 成氧代基;及/或 R3代表氮原子或視情況經羥基或Ci 3烷氧基取代之Cl-6烷 基;及/或 R4及Rs彼此獨立代表: 氮原子、視情況經c:3·7環烷基或苯基取代之Ciw烷基;或 <:3_7壤烧基、苯基、莕基4_C(X)R6;該c3 7環烷基及苯基視 情況經一或多個選自卣素原子、羥基、C13烷基、Cw烷氧 基、苯基、苯氧基、苄氧基之取代基取代; 但條件為至少一個R4或I基代表-c(x)R6之基;及/或 X代表氧原子或硫原子;及/或 R6代表Ck烷氧基、羥基或_NR7Rs之基;及/或 R·/及Rs彼此獨立代表: 氫原子、視情況經C:3.7環烷基、環缔基、苯基或吡啶基 取代之C 1 _ 6坑基;或
Cp環烷基、Cw烷氧基或苯基;或 r7及r8與其所帶有之氮原子形成氮雜環丙烷、氮雜環丁 烷、吡咯啶、哌啶或嗎啉環; 86214 •12- 1313680 該C3_7環坑基及苯基係視情況經CN3燒基、幾基、Cw垸氧基· 或鹵素原子取代。 通式(I)之化合物中,第三類較佳化合物為其中: I代表: 視情況經一或兩個選自羥基、Cw硫烷基(較好為硫甲基)、 二氟甲基、p塞吩或冬基之取代基取代之(^_5燒基,較好為甲 基、乙基、1-甲基乙基、2-甲基丙基、第三丁基、丨_乙基丙 基;或 C4_7環坑基(較好為環丙基或環己基);咬喃基、p塞吩、苯并 噻吩、吡啶基或苯基;該苯基可視情況經一或兩個選自齒 素原子(較好為氟或氯)、羥基、苄氧基或亞甲二氧基之取代 基取代;及/或 R2及R’2彼此獨立代表氫原子、鹵素原子(;較好為氟)、羥基、 Cw烷基(較好為甲基或乙基)、c3-7環烷基(較好為環己基)、 Cu烷氧基(較好為甲氧基)、0_c(0)_Cn4烷基(較好為 0-C(0)-CH3) ’或R_2與R'2—起形成氧代基;及/或 R·3代表視情況經C!·3規氧基(較好為甲氧基)取代之c i_4燒 基’較好為甲基、乙基、丙基或丁基;及/或 R_4及R5彼此獨立代表: 氫原子、視情況經苯基或C3_7環烷基(較好為環己基)取代之 Cm纟充基’較好為甲基、乙基、丨_曱基乙基、正丙基、丁基、 2-甲基丙基、第三丁基、3_曱基丁基、卜乙基丙基、2,2-二 甲基丙基、己基、5-甲基己基;或 C3_7環烷基(較好為環丙基或環己基);苯基、苯基或_c(x)R6; 該苯基視情況經一或兩個選自C U烷基(較好為丨_甲基乙 86214 -13· 1313680 代表含1至6個碳原子之直鏈或分支碳鏈 基、丙基、1-甲甚Λ其、丁装、显丁真 個碳原子之直鏈或分支碳鏈,更佳為甲基、&-1-甲基乙基、丁基、異丁基、第二丁基、第三 丁基等’較好為甲基、乙基、丙基或1-甲基乙基; -環燒基需了解意指環狀烷基;例如C3_7環烷基代表含3至 7個碳原子之環狀碳鏈,更好為環丙基、環丁基、環戊基、 5哀己基、環庚基,較好為環戊基或環己基; -環烯基需了解意指單-或多不飽和環狀烷基;例如c3 7環 缔基代表含3至7個碳原子之單_或多不飽和環狀碳鏈’更尤 其是%丙烯基、環丁烯基、環戊烯基、環己浠基、環庚浠 基’較好為環戊烯基或環己埽基; _硫燒基需了解意指含直鏈或分支飽和脂族鏈之S-烷基; 烷氧基需了解意指含直鏈或分支飽和脂族鏈之烷氧基; • _素原子需了解代表氟、氯、溴或碘;及 _ ’’R2及R’2—起形成氧代基"需了解意指下式基:
通式(I)之化合物可包含一或多個不對稱碳。因此其可存 在對映異構物或非對映異構物態。該等對映異構物及非對 映異構物及其混合物(包含消旋混合物)形成本發明之一部 分。當帶有R2及R’2之碳及/或帶有汉3之後為不對稱時,較好
碳為(S)組態。
86214 -15- I313680 基)、羥基、Ch烷氧基(較好為甲氧基或乙氧基)、苯氧基肴 卞氧基之取代基取代; 但條件為至少一個L或Rs基代表_C(X)R6之基;及/或 X代表氧原子;及/或 h代表Cw烷氧基(較好為曱氧基、乙氧基、第三丁氧基)、 m基或-nr7r8之基;及/或 1及R8彼此獨立代表: 氫原子、視情況經Cp環締基(較好為環己烯基)、苯基或吡 π基取代之Cl-3烷基(較好為甲基、乙基或1_甲基乙基);或 C!-3烷氧基(較好為甲氧基)、Cw環烷基(較好為環己基);或 R7及Rs與其所帶有之氮原子形成氮雜環丙烷、哌啶或嗎啉 環。 對其中 X、Ri、R2、r,2、r3、r4、r5、、仏及以之一及 同時如較佳化合物類中之定義之化合物為特佳,且尤其為 其中下列之化合物: I代表燒基(較好為丨_甲基乙基或第三丁基)或經兩個氟 原子取代之苯基;及/或 汉2代表羥基及R'2代表氫原子;及/或 I代表Cw烷基(較好為甲基、乙基或丙基);及/或 X代表氧原子。 本發明說明書中: -Ct-z其中1及2可為1至7之值’需了解意指可具有t至z個碳 原子之碳鍵’例如CK3 ’可具有1至3個碳原子之碳鏈;C36, 具有3至6個碳原予之碳鏈等; ^基需了解意指直鏈或分支飽和脂族基;例如Ci 6烷基 86214 .14- 1313680 亦形成本發明之一邵分。 : 通式(I)之化合物可存在為水合物或溶劑化物態,亦即與 一或多個分子之水或溶劑聯合或組合。此水合物及溶劑化 物亦形成本發明之一部分。 本發明又提供一種製備式(I)化合物之方法。 因此該等化合物可藉下列反應圖所說明之方法製備,其 操作條件為熟知本技藝所悉知者。 保護基需了解意指可在可影響之化學反應期間阻斷官能 基或位置之反應性之基,並依據本技藝已知方法斷裂後可 釋出該分子。保護基實例及保護及去保護方法見於有機合 成保護基,Greene等人,第 2版(John Wiley & Sons, Inc.,紐 約)。 86214 -16- 1313680 反應圖1
R
(IV)
+ co2h h2n 1 丫 c〇2pg (V)
肽 偶合
Ο) 依據反應圖1 ’式(I)化合物可藉式(111)之2_胺基嘍唑與式 (Π)之酸基胺基酸依據本技藝已知條件予以肽偶合而製 備例如在苯并二吐·i_基氧基參(咐4 <基)_鱗六氣鱗酸鹽 (PyBOP)或年并三唆小基氧基參(二甲胺基)鱗六氟蹲酸鹽 (BOP)及Ν·乙基嗎琳或N_甲基嗎啦存在下在惰性溶劑如二 甲基甲醯胺、乙腈或二氯甲烷中,在可自代至
範圍内進行。 K 式(Π)化合物可藉式(IV)之化合物與式⑺之經 中Pg代表保護基合1^ ^ 予以肽偶合而製備。 如上Μ 86214 1313680 所得之化合物隨後去保護。當保護作用為爷基時,該化 合物可在鈀/碳存在下,在絕對乙醇中,在氫大氣壓下,在 周圍溫度氫化’獲得式(π)化合物。 或者’式(I)化合物可依據反應圖2製備。 反應圖2
86214 -18*· 1313680 依據此反應圖,式⑴化合物可藉式(IV)之化合物與式(VI今 之胺依據本技藝已知方法予以肽偶合而製備,例如在羥基 苯并三唑鹽酸鹽(HOBt)及1-乙基-3-(3-二甲胺基丙基)碳二 醯亞胺(EDAC,HC1)存在下反應。式(VI)化合物可藉式(III) 之2-胺基嘧唑與式(VII)之經保護胺依據本技藝悉知之方法 (如上述)予以肽偶合而製備。該胺可藉例如N-第三丁氧基羰 基(Boc)依據本技藝已知方法予以保護,接著藉酸性水解在 溶於無水溶劑之氣態鹽酸或三氟乙酸存在下去保護。 其中112及11'2形成氧代基之式(I)化合物可藉使其中心或 R'2代表羥基之式(I)化合物之羥基氧化而獲得。該反應可在 本技藝已知條件下進行,例如與迪斯-馬:i1 丁(Dess-Martin)試 劑反應。該等化合物亦可藉其中R2及R’2—起形成氧代基之 式(IV)之酮基酸與式(VI)之胺依據本技藝已知條件直接偶 合。製備此酮基酸之方法微本技藝悉知者。 其中R4=-C(0)-R6代表Cw烷氧基之式(III)化合物可依據 反應圖3獲得。 反應圖3 〇 a ο (X)
C^CHCORg
〇 (VIII) ㈤
NaOCH3, 依據此反應圖,式(III)化合物可藉其中R5如前述定義之式 (VIII)之醛與其中R6代表視情況經苯基取代之Cw烷氧基之 式(IX)之二氯乙酸甲酯及例如甲氧化鈉或乙氧化鈉在0°C, 採用武田所述方法(Bull. Chem. Soc. JP,1970,卷43,第2997 頁)反應而製備。所得之產物(X)及(XI)之混合物在例如甲醇 86214 -19- 1313680 或乙醇存在下,以硫脲回流處理4或8小時,獲得式(III)化合 物。其中R4=-C(0)-R6aR6代表羥基之式(III)化合物可藉使 其中r6代表視情況經苯基取代之CN6烷氧基之上述化合物 依據本技藝已知條件水解而獲得。 其中R5=-C(0)-R6a R6代表CN6烷氧基之式(III)化合物可 依據反應圖4製備。 反應圖4 -, Τ Ύ β^.η,ο Br NH2CSNH: 0 NaH.THF.A υ ° ' 0 0 (XIV) / (ΧΗΙ) (XII) 丫 1)CDI,THF,A .2) Rb0CH2C02K ρο/a) (XlVa) MgC^.THF (III)
依據反應圖4,式(III)化合物之製備可藉使其中R6代表視 情況經苯基取代之Cw烷氧基之式(XIII)之/S-酮基酯溴化, 接著與硫脲採用 A. Barton, Breukelman, Kaye (LC.S. Perkin I,1982,第159頁)反應,獲得式(XII)化合物。
式(XIII)之卢-酮基酯可使其中R4如上述定義之式(XIV)之 酮與其中R6代表視情況經苯基取代之CN6烷氧基之式(XV) 之碳酸二燒酯,採用 L. Crombie,R.C.F. Jones 及 C.J. Palmer 之方法(J.C.S. Perkin Trans. I, 1987,第 323 頁)反應。式(XIII) 之/3-酮基酯亦可藉以羰基二咪唑(CDI)活化之式(XlVa)之酸 與其中R6代表視情況經苯基取代之烷氧基之式(XVa)之 丙二酸醋,採用例如D.W.Brooks,L.D.-L.Lu&S.Masamune (Angew. Chem. Int. Ed. Engl·,18,1979,第 72頁)反應而獲得。 當R4代表氫原子時,式(ΧΙΠ)化合物之製備係採用例如四 86214 -20- 1313680 面體通訊,42,2001,第2101頁所述 一 、万去進行。其中R尸-C(0)-Rb 且R·6代表經基之式(III)化合物可葬你叶山 , ^ 』精使其中心代表<^·6烷氧 基(上述化合物依據本技藝已知方 乃古水解而製備。 其中 R4 或 R〇_代表式-C(0)-NH> 7 8足式(HI)化合物可依據反 應圖5獲得。
PgHN S〜^R5(orC02H】R乂 X +hnS N/\c〇2H(orR4) 7 1)月太偶合2ΓΪ55" (XVI) (XVII) h2n 乂
O (III) R5(〇r -NR7R8) Rr Ra{〇r R4) 依據此反應圖,式(III)化合物係藉其中匕或心代表羧基且 Pg代表保護基如Boc之式(χνΐ)化合物與其中心及R8如前述 足義之式(XVII)化合物,在例如HOBt及(EDAC,HC1)存在下 予以肽偶合而製備。所得化合物接著依據本技藝已知條件 去保$蔓。其中Pg代表Boc之式(XVI)化合物之製備,可藉使 其中R4或Rs代表-C(0)R6且R0為視情況經苯基取代之心^烷 氧基之式(III)化合物’藉二碳酸二-第三丁基酯在無水四氫 吱喃中,在二甲胺基吡啶存在下在周圍溫度下作用予以保 護’接著使幾酸酿依據本技藝已知條件例如以氫氧化鐘在 7:3 (v/v)四氫呋喃/水混合物中在60°c水解。 起始化合物,特別是式(IV)、(v)、(VII)、(VIII)、(IX)、 (XIV)、(XlVa)、(XV)、(XVa)及(XVII)之化合物可商業獲得 或如文獻所述般獲得,或可藉本文所述方法或本技藝已知 方法製備。其中R2或R'2代表羥基之式(IV)化合物可藉由將 二甲基石夕坑基氰化物添加至酸中,採用D.A. Evans等人 86214 -21 - 1313680 (J.C.S·,Chem. Comm. 1973 笛 55 百)所妯、、, ,罘 > 貝)所述万法或使亞硝酸鉀 與α-胺基酸採用I. Shinn等人(有機化學期刊,2〇〇, 65第 7667頁)之方法反應而製備。 當化合物之官能基具反應性,例如當心含羥基時,其可 能必須在反應前料料。熟知本技藝者料決定是否需 要事先保護。 式(II)至(XVII)化合物中,Ri、r2、R,2、κ、n、 R_6、R7及Rs之意義如式⑴之定義。 式(II)、(III)及(VI)化合物為新穎且亦形成本發明之一部 分。其可作為製備通式⑴化合物之合成中間物。 【實施方式】 下列實例描述本發明某些化合物之製備。該等實例並非 用以限制僅用以說明本發明。所例舉之化合物編號代表後 續表中所列之編號。所得化合物結構以元素微分析及 NMR、IR或質譜確認。 實例1 : 2-胺基-5-(1-甲基乙基)喳唑_4_羧酸甲酯 14_4克異丁醛於400毫升乙醚之溶液在〇。〇與246克二氯 乙酸甲酯混合接著逐滴與4〇〇毫升之甲氧化鈉(〇·5μ)之甲醇 溶液混合。在(TC歷時丨小時後,添加1〇〇毫升飽和氯化鈉溶 液且混合物以乙醚萃取。有機相以無水硫酸鈉乾燥。僅蒸 發乙謎,留下甲醇,添加8克硫脲且混合物回流加熱叫時: 反應介質蒸發至乾且殘留物置入乙酸乙酯中並以ι〇%氫氧 化銨水溶〉夜洗滌接著以飽和氯化鈉溶液洗滌。有機相以無 水硫酸納&燥接著濃縮。$留物置人i⑽毫升乙_中並以多 孔玻璃過遽。獲得18.6克白色固體。 、 86214 •22- 1313680 NMR 300 MHz (CDC13) δ ppm: 1_25 (d,6H); 3.35 (s,3抑 4.10 (m,1H); 5.50 (s,2H)。 ’ 實例2 : 2-胺基-4-(2,2-二甲基丙基)-嘆吐叛酸乙圉旨 4克4,4_二甲基戊酮之1 〇〇毫升無水四氫呋喃溶液與3克 600/。氫化鈉混合接著與8.2克碳酸二乙酯逐滴混合。反麻介 質回流加熱5小時。冷卻並以50毫升蒸餾水水解。蒸發四氣 呋喃。殘留物以乙酸乙酯萃取。有機相以硫酸鈉乾燥接著 蒸發。獲得4.9克無色油。 NMR 300 ΜΗζ δ in ppm (CDC13): 1.05 (s, 9H); 1.28 (t 3H)· 2·42 (s,2H); 3.40 〇, 2H); 4.18 (q,4H)。 ’ 4.9克上述所得之/3-酮基酯於75毫升蒸餾水之懸浮液在〇 它與1.4毫升溴逐滴混合。反應介質在〇〇c攪拌丨小時接著以 乙酸乙酯萃取。有機相以飽和氯化鈉溶液洗滌接著以硫酸 鈉乾燥。蒸發獲得4 · 1克橘色油。 NMR 300 MHz (CDC13) δ ppm: 1.00 (s, 9H); 1.30 (t, 3H); 2.60 (ms,2H); 4_25 (q,2H); 4.75 (s,1H)。 4.10克溴-点-酮基酯於60毫升乙醇之溶液與克硫脲混 合。反應介質回流加熱6小時,接著蒸發至乾。 殘留物置入乙酸乙醋中並以10%氫氧化銨水溶液洗鲦接 著以飽和氯化鈉水溶液洗絡並以硫酸鈉乾燥。 蒸發後,殘留物自乙酸乙酯/戊烷混合物再結晶。獲得21 克白色固體。 NMR 300 MHz (CDC13) δ ppm: 0.97 (s, 9H); 1.21 (t, 3H); 2.92 (s,2H); 4.25 (q,2H); 5.65 (s,2H)。 X例3 : 2-[2-[2-(3,5-二氟苯基)乙醯基_胺基]丙醯基胺基]_5_ 86214 -23 - 1313680 丙基嘍唑-4-羧酸甲酯(化合物2) , 實例3.1 : N-3,5-二氟苯基乙醯基_(s)_丙胺酸 172克3,5-二氟苯基乙酸於5〇毫升二曱基甲醯胺之溶液 在〇 C與l.oi克N_甲基嗎啉、5 72克PyB〇p、2.15克(3)_丙胺 阪爷自a鹽酸鹽及1 · 〇 1克N-甲基嗎B林混合。使混合物回至周 圍溫度並攪拌18小時。反應介質蒸發且殘留物置入乙酸乙 酉s中並以飽和碳酸氫鈉洗滌2次,以硫酸氫鉀溶液(1M)接著 以紀和鼠化制水j液洗務。有機相以無水硫酸鋼乾燥。殘 留物在矽膠管柱上層析,以7:3 (v/v)石油醚/乙酸乙酯混合 物溶離,獲得1.9克白色固體。 NMR 300 MHz (CDC13) δ ppm: 1.40 (d, 3H); 3.54 (s, 2H); 4.62 (m, 1H); 5.18 (m, 2H); 6.10 (d, 1H); 6.73 (t, 2H); 6.80 (d, 1H); 7.32 (m,5H)。 1·9克N-3,5-一氟木基乙酿基- (S)-丙胺酸爷自旨於80毫升絕 對乙醇之溶液與300毫克10%鈀/碳混合。反應介質在大氣壓 及周圍溫度下氫化8小時》反應介質經濾紙過濾,以絕對乙 醇洗滌接著蒸發。獲得1.37克白色固體。 NMR 300 MHz (CDC13) δ ppm: 1.36 (d, 3H); 3.48 (s, 2H); 3.7〇 (s, 1H); 4.40 (m, 1H); 6.65 (t, 2H); 6.70 (d, 1H); 6.95 (d, 1H) 〇 實例3.2: 2-[2-[2-(3,5-二氟苯基)乙醯基胺基]丙醯基胺基] 丙基嘍唑-4-羧酸甲酯 0.24克之依實例1所述方法製備之2-胺基-5-丙基噻唑_4-羧酸甲酯於25毫升二曱基曱醯胺之溶液在〇°c與0,1 2克N-甲 基嗎琳、0·69克PyBOP混合接著與275克實例3步驟3 · 1所得 之化合物混合。使反應回到周圍溫度且混合物攪拌i 8小時。 86214 •24- 1313680 备發溶劑,且殘留物置入乙酸乙酯並以飽和碳酸氫鈉水 〉谷液洗滌2次’以水洗滌1次及以1N硫酸氫鉀水溶液洗滌1 次接著以飽和氯化鈉水溶液洗滌。 有機相以無水硫酸鈉乾燥並濃縮。殘留物在矽膠管柱上 層析’以1:1 (v/v)石油醚/乙酸乙酯混合物溶離,獲得〇 22 克白色粉末。 LC/MS : MH+ = 426。 NMR 500 MHz (CDC13) δ ppm: 0.91 (q, 3H); 1.30 (d, 3H); 1-61 (m, 2H); 3.06 (t, 2H); 3.53 (s, 2H); 3.77 (s, 3H); 4.38 (m, 1H); 6.98 (m, 2H); 7.08 (m,1H); 8.57 (d,1H); 12.49 (s,1H)。 實例4 : 2-[2-[2-(3,5-二氟苯基)乙醯基-胺基]丙醯基胺基]_4_ 丙基嘍唑-5-羧酸甲酯(化合物144) 〇.3克之實例2所述方法製備之2-胺基-4-丙基噻唑羧酸 甲酿於30毫升二甲基甲醯胺溶液在與〇·101克N_甲基嗎 啉、〇,86克PyBOP及0.34克N-3,5-二氟苯基乙醯基_(S)_丙胺 酸(實例3步驟3.1所得)混合。反應介質回到周圍溫度接著授 拌18小時。蒸發溶劑後,殘留物置入乙酸乙酯中並以飽和 碳酸氫鈉水溶液洗滌2次,以水洗滌2次,以1M硫酸氫_水 溶液洗滌1次接著以飽和氯化鈉水溶液洗滌。有機相以無水 石觅1¾鋼乾燥接奢濃縮。殘留物在碎膠管柱上層析,以3 :7 (v/v) 乙乙自a /石油链混合物落離,獲得〇. 4 5克白色粉末。 LC/MS : MH+ = 426。 NMR 500 MHz (DMSO) δ ppm: 0.88 (t, 3H); 1.32 (d, 3H); 1.66 (m, 2H), 2.95 (m, 2H); 3.54 (s, 2H); 3.76 (s, 3H); 4.47 (m 2H)· 6.97及7.10(2111,3?1);8.63((1,出);12.66(3,出)。 86214 -25 - 1313680 只丫'J5. 2_[2’[2_(3,5_二氟苯基)乙酷基_胺基]_(叫_戊醯基胺: ]5 (1甲基乙基)p塞唑_4_幾酸甲酯(化合物1 貫Ή5.1 . 2-(2-胺基_(2S)-戊醯基胺基)_5_(丨_甲基乙基)p塞唑 -4-羧酸甲酯 2.3克之2-胺基_5-(1-甲基乙基)_u塞唑_4_羧酸甲酯(實例j 所铎)於100¾升二甲基甲醯胺之溶液在〇艺與丨义克斗甲基 、、林6’34克PyB〇P混合接著與2.65克(S)-B〇c-正纈胺酸混 T。使反應介質回至周圍溫度接著攪拌16小時。蒸發後, 2田物置入乙酸乙酯中並以飽和碳酸氫鈉水溶液洗滌2 久,以水洗滌2次,以1N硫酸氫鉀水溶液洗滌丨次接著以飽 和虱化鈉水溶液洗滌。有機相以無水硫酸鈉乾燥接著濃縮。 殘留物在矽膠管柱上層析,以3:7(v/v)乙酸乙酯/石油醚混 合物溶離。獲得3.5克白色固體。 醒R 300 MHz (CDCh) δ Ppm: 〇,97 (t,3H); 1.37 (d,6H); 1.45 (s, 9H); 1.67 (m, 2H); 1.90 (m, 2H); 3.90 (s, 3H); 4.10 (m, 1H); 4.38 (未解析之錯合物,1H); 4.9〇 (未解析之錯合物,a)。 3,3克上述所得產物於6〇毫升三氟乙酸之溶液在周圍溫 度攪拌30分鐘,接著蒸發。殘留物置入乙酸乙酯並以飽和 碳酸鈉水溶液洗滕2次接著以飽和氯化納水溶液洗條。有機 相以無水硫酸鈉乾燥接著蒸發獲得2克白色固體。 NMR 300 MHz (CDC13) δ ppm: 0.97 (t, 3H); 1.35 (d, 6H)· 1 4〇 1.60 (m, 2H); 1.80 (m, 2H); 3.60 (m, 1H); 3.97 (s, 3H)| 4.12 (m,1H) 〇 實例5.2 : 2-[2-[2_(3,5-二氟苯基)乙酿基_胺基]_(2S)_戊酿基 胺基]-5-(1-曱基乙基)噻唑_4_羧酸甲酯 86214 -26- 1313680 〇·7克2-(2-胺基_(2S)-戊醯基胺基)_5_(1_甲基乙基)嘍唑_如 羧酸甲酯(實例5步驟5_丨所得)於3〇毫升二甲基^醯胺之溶 欲在0C與0.255克N-甲基嗎啉、丨.30克PyB〇p混合接著與 0.43克3,5-一氟苯基乙酸混合。反應回至周圍溫度且混合物 攪拌1 8小時。反應介質蒸發。殘留物置入乙酸乙酯並以飽 和峡酸氫鈉水落液洗滌2次,以水洗滌2次,以丨%硫酸氫鉀 水溶液洗滌1次接著以飽和氯化鈉溶液洗滌。有機相以無水 硫酸鈉乾燥接著濃縮。殘留物在矽膠管柱上層析,以丨:丨(v/v) 石油醚/乙酸乙酯混合物溶離,獲得〇·7克白色固體。 LC/MS : ΜΗ+ = 454。 NMR 500 MHz (DMSO) δ ppm: 0.85 (t, 3H); 1.26 (d, 6H); 1.28-1.65 (m, 4H); 3.53 (m, 2H); 3.78 (s, 3H); 3.97 (m, 1H); 4.36 (m, 1H); 6.96 (d, 2H); 7.08 (m, 1H); 8.49 (d, 1H); 12.52 (s, 1H) 〇 實例6 : 2-[2-[2-(3,5-二氟苯基)乙醯基-胺基]_(2S)_戊醯基胺 基]-4-(1-曱基乙基)嘍唑-5-羧酸甲酯(化合物146) 重複實例5之程序,以2-胺基-4-(1-甲基乙基)嘍唑_5_羧酸 甲酯(依實例2之方法製備)替代2-胺基_5_(1_甲基乙基)噻唑 -4-羧酸甲酯。 LC/MS : MH+ = 454。 NMR 500 MHz (DMSO) δ ppm: 0.87 (t, 3H); 1.27 (d 6H)· 1.35 (m, 2H); 1.64 (m, 2H); 3.54 (s, 2H); 3.77 (s, 3H); 3.90 (m, 1H); 4.45 (m, 1H), 6.96-7.09 (m, 3H); 8.53 (d, 1H); 12.69 (s, 1H) 0 實例7 . 2-[2-[2-(3,5-二氟苯基)_2_幾基乙醯基胺基]-(2S卜戊 醞基胺基]-5-(1-甲基乙基)p塞唑-4-幾酸甲酯(化合物丨9及2〇) 86214 -27- 1313680 1克2-(2-胺基-(2S)-戊醯基胺基)_5_(1_甲基乙基)噻唑_4; 破酸甲醋(實例5步驟5.1所得)於80毫升二甲基甲醯胺之溶 液在0 C與0.366克N-甲基嗎啉、1.87克PyBOP混合接著與 0.677克3,5-二氟扁桃酸混合。反應回至周圍溫度,攪拌w 小時接著濃縮。殘留物置入乙酸乙酯並以飽和碳酸氫鈉水 /谷液洗滌2次,以水洗滌2次,以1M硫酸氫鉀水溶液洗滌工 次接著以飽和氯化鈉溶液洗滌。有機相以無水硫酸鈉乾燥 接著濃縮。殘留物在矽膠管柱上層析,以7:3 (1:1) (v/v)石 '由酸與乙酸乙酯之混合物溶離。依此方式可獲得兩種異構 物(S,S)及(R,S)。獲得0.45克白色粉末((S,S)異構物)及〇.5〇克 (兩種非對映異構物之混合物)。 兩種非對映異構物之混合物(0.50克)在碎膠管柱上再層 析,以7:3 (v/v)至(1:1)石油醚/乙酸乙酯混合物溶離,獲得 〇·25克白色粉末((r,s)異構物)。 (S,S)異構物: LC/MS : MH+ = 470。 NMR 500 MHz (DMS0) δ ppm: 0.80 (t, 3H); 1.18 (m, 2H); 1.22 (d5 6H); 1.68 (m, 2H); 3.78 (s, 3H); 3.97 (m, 1H); 4.43 (m, 1H); 5.05 (d, 1H); 6.55 (d, 1H); 7.13 (m, 3H); 8.24 (d, 1H); 12.46 (s,1H)。 a" = -53° (c = 1/MeOH) (R,S)異構物: LC/MS : MH+ = 470。 NMR 500 MHz (DMSO) δ ppm: 0.82 (t,3H); 1.26 (d, 6H); 1.26 (m, 2H); 1.68 (m, 2H); 3.78 (s, 3H); 3.97 (m, 1H); 4.40 (m, 86214 -28- 1313680 1H); 5.07 (d, 1H); 6.42 (d, 1H); 7.12 (m, 3H); 8,27 (d, 1Η)ί 12.51 (s, 1H) 〇 20 a〇 = -83° (c = 1/MeOH) 貫例8 · 2-[2-[2-(3,5-二氟苯基)-2-經基乙醯基胺基]_(2S)-戊 酿基胺基]-4-(1-甲基乙基)峰峻-5-叛酸甲酯(化合物1 5〇及 151) 重複實例7之程序,以2-(2-(S)-戊醯基胺基)4-0-甲基乙 基)嘧唑_5-羧酸甲酯(實例5步驟5.1所述方法製備)替代 2-(2-(2S)-戊酿基胺基)-5-(1-甲基乙基)p塞唾_4_複酸甲酯。 (S,S)異構物: LC/MS : MH+ = 471。 NMR 500 MHz (DMSO) δ ppm: 0.81 (t, 3H); 1.18 (d, 6H); 1.22 (m, 2H); 1.71 (m, 2H); 3.77 (s, 3H); 3.90 (m, 1H); 4.50 (m, 1H); 5.06 (s, 1H); 6.54 (s, 1H); 7.12 (m, 3H); 8.30 (d, 1H); 12.66 (s,1H)。 al = -73° (c = 1/MeOH) (R,S)異構物: LC/MS : MH+ = 471 (95%純度)。 NMR 500 MHz (DMSO) δ ppm: 0.83 (t, 3H); 1.19 (d, 6H); 1.22 (m, 2H); 1.70 (m, 2H); 3.77 (s, 3H); 3.91 (m, 1H); 4.48 (m, 1H); 5.07 (s, 1H); 6.42 (s, 1H); 7.12 (m, 3H); 8.34 (d, 1H); 12.67 (s,1H)。 a2° = _i〇4〇 (c = 1/MeOH) 實例9 : 2-[2-[2-(3,5-二氟苯基)乙醯基胺基]-(2S)-戊醯基胺 基]-5-(1-甲基乙基)嘧唑-4-N,N-二甲基羧醯胺(化合物26) 86214 -29- 1313680 只例9.1 2-第三丁氧基羰基胺基_5_(1_甲基乙基卜塞咬_4_幾酸 4.4克2-胺基-5-(1-甲基乙基>塞唑_4_羧酸甲酯(實例I所得) 之150毫升四氫呋喃溶液與5·27克二碳酸二_第三丁酯及 0.13克二甲胺基吡啶混合。混合物在周圍溫度攪拌μ小時。 蒸發反應介質。殘留物置入乙酸乙酯中並以0.5N鹽酸水溶 液洗滌2次,以水洗滌丨次接著以飽和氯化鈉水溶液洗滌\ 有機相以無水硫酸鈉乾燥並濃縮。獲得61克固態之經保護 之胺基嘍唑衍生物,其未經純化使用。 NMR 300 MHz (CDC13) δ ppm: 1.25 (d, 6H); 1.50 (s, 9H); 3.85 (s,3H); 3_97 (m,1H)。 LC/MS : MH+ = 301 (M-Boc)+ = 201 6.10克上述所得產物於150毫升四氫呋喃之溶液在周圍溫 度與1 · 6 8克氫氧化鋰之8 0毫升蒸餾水溶液混合。四氫呋喃反 應混合物回流加熱16小時接著濃縮《殘留物置入水中並以 乙奴乙酯洗務2次。水相以1N鹽酸水溶液酸化至pH約4,以 氯化鈉飽和並以乙酸乙酯萃取2次。有機相以無水硫酸鈉乾 燥接著濃縮。獲得5_10克白色固體。 LC/MS : MH+ = 287。 NMR 300 MHz (CDC13) δ ppm: 1.19 (d, 6H); 1.45 (s, 9H); 3.80 (s,3H); 3.90 (未解析之錯合物 s,1H); 4 15 (m,1H)。 實例9.2 ·· 2-第三丁氧羰基胺基_5_(ι·甲基乙基)噻唑_4_N,N_ 二曱基羧醯胺 2克2-第三丁氧基羰基胺基- 基乙基)ρ塞峻_4_幾酸 (步驟9_1所得)之80毫升二甲基甲醯胺溶液與1〇7克經基笨 并二峻水合物、1.33克(EDAC,HC1)混合接著與0.57克Ν,Ν- 86214 -30- 1313680 二曱基胺鹽酸鹽及〇·77克N-甲基嗎啉混合。反應混合物在 周圍溫度攪拌16小時接著濃縮。殘留物置入乙酸乙酯中並 以飽和碳酸氫鈉水溶液洗滌2次,以1M硫酸氫鉀水溶液洗 滌2次,以水洗滌丨次接著以飽和氯化鈉水溶液洗滌。有機 相以無水硫酸鈉乾燥並濃縮。獲得145克白色固體。 LC/MS : MH+ = 314 NMR 300 MHz (CDC13) δ ppm: 1.3〇 (dj 6Η); ! 53 (s? 9H); 2.98 (s, 3H); 3.09 (s3 3H); 3.40 (m, 1H); 8.0〇 (s, 1H) 〇 實例9.3 . 2-胺基-5-(1-甲基乙基)嘍唑_4_N,N_二甲基羧醯胺 1.4克2-第二丁氧羰基胺基彳气^甲基乙基)噻唑_4_N,N_二 甲基羧醞胺(步驟9.2所得)與30毫升三氟乙酸混合。混合物 在周圍溫度攪拌30分鐘接著濃縮。殘留物置入乙酸乙酯中 並以飽和碳酸氫鈉水溶液洗滌2次接著以飽和氯化鈉水溶 液洗滌。有機相以無水硫酸鈉乾燥接著濃縮。獲得〇 9〇克白 色固體。 LC/MS : MH+ = 214 NMR 300 MHz (CDCh) δ DDm- 1 ^ . 、^13; 〇 ppm. 1.22 (d, 6H); 3.00 (Sj 3H); 3.30 (m,1H); 4.90 (s,1H)。 實例9.4 : 2-((2S)-戊醯基胺基)_5_(1_甲基乙基)禮也冬n,n_ 二甲基羧醯胺 〇·9克2胺基-5-(1-曱基乙基塞唆_4_N,N_二甲基幾酿胺 (步驟9.3所得)藉實例5步驟所述方法與i克⑻_b〇c_正願 胺酸偶合。在秒膠上層析,以1:1(v/v)之乙酸乙酿及石油酸 曰曰 之混合物絲’獲得克黏稠油,其在周圍溫度結 LC/MS : MH+ - 413 86214 -31 - 1313680 職遍廳(CDCl3)Sppm:G.97(t,3H);i 3G(d 6H) i4e (s, 9H); 1.65 (m, 2H); 1.90 (m, 2H); 2.95 (s, 3H); 3.08 (s, 3H); 3·48 (m,1H); 4.30 (m,1H); 5 25 (未解析之錯合物,汨)。 1.1克上述所得化合物於2〇毫升三氟乙酸中藉步驟9.3所 述方法去保護,獲得0.77克白色固 LC/MS : MH+ = 313 NMR 300 MHz (CDC13) δ ppm: 0.98 (t, 3H); 1.60 (d, 6H); l.3〇-l_95 (未解析之錯合物,4H); 2 % (s,3H); 3 〇8 (s,邱; 3.40 (m,1H); 3.58 (m,1H)。 實例9.5: 2-[2-[2-(3,5-二氟苯基)乙醯基胺基H2S)-戊醯基胺 基]-5-(1-甲基乙基)塞唆_4-N,N-二甲基幾酿胺 0.23克2-((2S)-戊醯基胺基)-5-(1-甲基乙基)嘍唑-4_n,n_ 二甲基羧醯胺(步驟9.4所得)於15毫升二曱基甲醯胺中,在〇 °(:與〇.〇88克冰曱基嗎啉混合接著與〇.416克?730?及〇.138 克3,5 -二氟苯基乙酸混合。反應介質回至周圍溫度歷時μ 小時接著濃縮。殘留物置入乙酸乙酯中並以0.5N鹽酸水溶 液洗滌2次,以水洗滌1次接著以飽和氯化鈉水溶液洗滌。 有機相以無水硫酸鋼乾燥並濃縮。在碎膠管柱上層析,以 1:1 (v/v)乙酸乙酯及石油醚之混合物溶離’獲得0.26克白色 固體。 LC/MS : MH+ = 467。 NMR 500 MHz (DMSO) δ ppm: 〇·87 (t, 3H); 1.24 (d, 6H); 1.29-1.67 (m, 4H); 2.86 (s, 3H); 2.95 (s, 3H); 3.22 (m, 1H); 3.54 (m, 2H); 4.41 (m, 1H); 6.98 (d, 2H); 7.08 (m, 1H); 8.49 (d, 1H); 12.21 (s,1H)。 86214 -32- 1313680
Oil ~ "74° (c = 1.0, MeOH) 實例10 : 2-[2-[2-(3,5-二氟苯基)_2_羥基_(2S)_乙醯基胺 基]-(2S)-戊醯基胺基]-5-(1-甲基乙基)p塞唆_4_n,n_二甲基幾 醯胺(化合物88)及2-[2-[2-(3,5-二氟苯基)_2_羥基_(2R)_乙醯 基胺基]-(2S)-戊醯基胺基]-5-(1-甲基乙基)嘧唑_4_N,N_二甲 基羧醯胺(化合物89) 藉實例9步驟9 · 5所述之方法’使實例9之步驟9.4所得之 〇·77克2-((2S)-戊醯基胺基)-5-(1-甲基乙基)ρ塞唑_4_N,N_: 甲基叛Si胺,在0.28克N-甲基嗎P林及1,4克PyBOP存在下’ 在0C與0.51克3,5 - 一氟扁桃酸偶合,並在碎膠管柱上層 析’以75:25 (v/v)之乙红乙g旨及石油鍵之混合物溶離,獲得 〇·80克白色固體。 LC/MS : MH+ = 483 (2峰:2種非對映異構物(R,S)及(s,s))。 NMR 500 MHz (DMSO) δ ppm: 0.72 (t, 3H); 1.06 (m, 1H); 1.16 (m, 1H); 1.27 (d, 6H); 1.58 (m, 2H); 2.10 (s, 3H); 3.78 (s, 3H); 3.96 (m, 1H); 4.37 (m, 1H); 5.97 (s, 1H); 7.34^.7.47 (2m, 5H); 8,62 (s, 1H); 12.49 (s,1H)。 a〇 = -67° (c = 1-0, /MeOH) 該兩種非對映異構物藉製備性hplc在C18管柱上以乙腈 /出0於23分鐘内自95:5 (Wv)至5:95梯度溶離而分離。 獲得〇_1克((S,S)異構物)白色固體, LC/MS : MH+ = 483。 NMR 500 MHz (DMSO) δ ppm; 〇.8〇 (t> 3H); 1.25 (d, 6H); 1.28 (m, 2H); 1.75 (m, 2H); 2.80 (s, 3H); 3.00 (s, 3H); 3.25 (m, 1H); 4.49 (m, 1H); 5.08 (s, 1H); 6.55 (ts, 1H); 7.13 (d, 3H); 8.25 86214 •33· 1313680 (d,1H); 12.15 (s,1H)。 二 及0.17克((R,S)異構物)白色固體。 LC/MS: MH+ = 483。 NMR 500 MHz (DMSO) δ ppm: 0.88 (t, 3H); 1-22 (d, 6H); 1.30 (m, 2H); 1.68 (m, 2H); 2.87 (s, 3H); 2.98 (s, 3H); 3.25 (m, 1H); 4.45 (m, 1H); 5.10 (s, 1H); 6.42 (s, 1H); 7.18 (m, 5H); 8.30 (d, 1H); 12.20 (s,1H)。 實例11 : 2-[2-[2-羥基-2-苯基-(2S)-乙醯基胺基]_(2S)-戊醯基 胺基]-5-(1-甲基乙基)嘍唑-4-羧酸甲酯(化合物30)及2-[2-[2-羥基-2-苯基-(2R)-乙醯基胺基]-(2S)-戊醯基胺基]-5-(1-曱 基乙基)噻唑-4-羧酸曱酯(化合物31) 0.3 5克2-(2-胺基-(2S)-戊醯基胺基)-5-(1-曱基乙基)嘍唑 -4-羧酸甲酯(實例5步驟5.1所得)於20毫升二曱基甲醯胺之 溶液,在〇°C與0.13克N-曱基嗎啉、0.67克PyBOP混合接著 與0.20克(S)-扁桃酸或(R)-扁桃酸混合。反應介質回至周圍 溫度接著攪拌16小時並濃縮。殘留物置入乙酸乙醋中並以 貫例7所述方法洗務。有機相蒸發後,殘留物在碎膠管柱上 層析,以1:1 (v/v)乙酸乙酯/石油醚混合物溶離。獲得〇 36 克(S,S)非對映異構物及〇_37克(R,S)非對映異構物,為白色 粉末態。 (S,S)異構物: LC/MS : MH+ = 434。 NMR 500 MHz (DMS0) δ ppm: 〇.8〇 (t,3H); 1.16 (m,2H). 1.26 (s, 9H); 1.68 (m, 2H); 3.78 (s, 3H); 3.97 (m, 1H); 4.43 (mj 1H); 4.98 (d,1H); 6.31 (d,1H); 7.32 (m,5H); 8.14 (d,1H); 86214 -34- 1313680 12.46 (s,1H)。 方
Oil = -51° (c = 1.0, /MeOH) (R,S)異構物: LC/MS : MH+ = 434。 NMR 500 MHz (DMSO) δ ppm: 0.85 (t, 3H); 1.28 (d, 6H); 1.28 (m, 2H); 1.68 (m, 2H); 3.78 (s, 3H); 3.97 (m, 1H); 4.44 (m> 1H); 5.00 (d, 1H); 6.17 (d, 1H); 7.30 (m, 5H); 8.17 (d, 1H); 12.51 (s,1H)。 al = -110° (C = l.o, /MeOH) 實例12 : 2-[2-[2-(3,5-二氟苯基)-2-氧代乙醯基胺基]_(2S)_ 戊醯基胺基]-5-(1-甲基乙基>塞唑-4-羧酸曱酯(化合物75) 0.3克2-[2-[2-(3,5-二氣私基)-2-輕基乙酿基胺基]-(2S) -戊 醯基胺基]-5-(1-甲基乙基)嘍唑-4-羧酸甲酯(實例7所得)於 40毫升以戊烯安定化之絕對二氯曱烷之溶液中,與〇 55克迪 斯-馬汀(Dess-Martin)過碘烷試劑及〇.〇9克第三丁醇混合。 反應混合物在周圍溫度攪拌20小時接著蒸發。殘留物在石夕 膠管柱上層析(未經前處理)’以8:2 (v/v)石油醚/乙酸乙酯混 合物溶離。獲得0.20克白色粉末。 LC/MS : MH+ = 468 (純度 100%) NMR 500 MHz (DMSO) δ ppm: 0.97 (t, 3H); 1.20 (d, 6H); 1.40 (m, 2H); 1.80 (m, 2H); 3.87 (s, 3H); 4.05 (m, 1H); 4.60 (m, 1H); 7.60 (m, 2H); 7.80 (m, 1H); 7.99 (m, 2H); 9.30 (d, 1H); 12.70 (s,1H)。 實例13 : 2-[2-[2-(3,5)-二氟苯基_2-羥基-(2S)-乙醯基胺 基]-(2S)-戊醯基胺基]-4-甲基噻唑_5_羧酸甲酯(化合物165) 86214 -35-
08號專利申請案 替換頁(98年4月) 藉實例7及8所述之方法獲得標題化合物。 ㈣克實例5 · 1所述方法獲得之2_(2_胺基_(2s)_戊酿基胺 基)-4-(曱基)喧嗤-5-㈣甲輯於乃毫升之二甲基甲酿胺溶 液’在0C與0.306克N-甲基嗎啉、} S7克PyB〇p混合接著與 0.677克3,5-二氟扁桃酸混合。反應介質回至周圍溫度並攪 拌16小時接著濃縮。殘留物置入乙酸乙酯中並以飽和碳酸 虱鈉水溶液洗滌2次,以水洗滌2次,以(1M)硫酸氫鉀水溶 液洗滌1次接著以飽和氯化鈉水溶液洗滌。有機相以無水硫 酸鈉乾燥接著濃縮。殘留物以矽膠管柱層析,以8:2至7:3 (v/v)範圍内之石油醚與乙酸乙酯之混合物梯度溶離,獲得 0.1克白色粉末(S,S)異構物及〇·7克(2種非對映異構物之混 合物)。 (s,s)異構物: LC/MS : MH+ = 442 NMR 500 MHz (DMSO) δ ppm: 0.82 (t, 3H); 1.26 (m, 2H): 1.69 (m, 2H), 2.63 (s, 3H); 3.77 (s, 3H); 4.50 (m, 1H); 5.07 (d, 1H); 6.55 (d, 1H); 7.16 (m, 3H); 8.31 (d, 1H); 12.65 (s5 1H) 〇 實例14 : 2-[2-[2-(3,5-二氟苯基)-2-氧代乙醯基胺基]_(2S)_ 戊醯基胺基]-4-曱基p塞唾-5-叛酸甲g旨(化合物167) 0.7克之貫例13所得2-[2-[2-(3,5)-二氟苯基_2_經基_(2S)_ 乙醯基胺基]-(2S)-戊醯基胺基]-4-甲基嘍唑_5_羧酸曱醋於 80毫升之以戊烯穩定化之絕對二氯甲烷溶液與丨·35克迪斯_ 馬汀過碘烷試劑及0.24克第三丁醇混合。反應混合物在周圍 溫度攪拌2〇小時接著蒸發。殘留物經矽膠管柱層析(未經預 處理)’以8:2 (v/v)石油鰱/乙酸乙自旨混合物梯度溶離,獲得 86214-980420.doc -36- 1313680 0.6 8克白色粉末。 : LC/MS : MH+ = 440 (£1 = -87° (〇=1, MeOH) NMR 500 MHz (DMSO) δ ppm: 0.90 (t,3H); 1.38 (m,2H); 1.75 (m, 2H); 2.63 (s, 3H); 3.78 (s, 3H); 4.61 (m, 1H); 7.69 (m, 3H); 9.43 (d,1H)。 實例15 : 2-[2-[2-羥基-3,3-二甲基_(2S)_丁醯基胺基]-(2S)-戊 醯基胺基]-5-(1-曱基乙基)_P塞嗅_4_羧酸甲酯(化合物97) 0.24克實例5步驟5·1所得之2-(2-胺基-(2S)-戊醯基胺 基)-5-(1-甲基乙基)p塞也叛酸甲酯於1〇毫升二甲基甲縫 胺之溶液在0C與97微升N-甲基嗎I»林、0.116克(S)-(-)-2-經基 -3,3-二曱基丁酸混合接著與〇46克1^]6〇?混合。反應介質攪 拌18小時後回至周圍溫度接著減壓濃縮。殘留物置入50毫 升乙酸乙酯中並依序以50毫升飽和KHS04之H20溶液、50 毫升飽和K:2C03之H2〇溶液、50毫升飽和NaCl溶液及50毫升 H2〇洗滌。有機相乾燥及蒸發後,殘留物在矽膠(40克)管柱 上層析’以100%石油醚至30/70石油醚/乙酸乙酯(v/v)之混 合物梯度溶離。獲得0.269克白色結晶。 LC/MS : MH+ = 414。 NMR 500 MHz (DMSO) δ ppm: 0.90 (t, 3H); 0.93 (s, 9H); 1.30 (d, 6H); 1.32 (m, 2H); 1.71 (m, 2H); 3.58 (d, 1H); 3.82 (s, 3H); 4.02 (m, 1H); 4.52 (m, 1H); 5.60 (d, 1H); 7.82 (d, 1H); 12.45 (s, 1H)。 a〇 = -74° (c = 1.0, MeOH) 實例16 : 2-[2-(2-氟-2-苯基-(2S)-乙醯基胺基-(2S)-戊醯基胺 86214 -37- 1313680 基)-5-(1-甲基乙基)塞唑_4_羧酸甲酯(化合物98)及2_[2_(2兰 氣-2-笨基_(2R)-乙醯基胺基_(2S)_戊醯基胺基)-5-(1-甲基乙 基 >塞唾-4-羧酸曱酯(化合物99) 0·60克實例5步驟5.1所得之2-(2-胺基-(2S)-戊醯基胺 基)-5-(1-甲基乙基)噻唑_4_羧酸甲酯於15毫升二甲基甲醯 胺《溶液在〇。〇與242微升N-甲基嗎啉、0.34克α-氟苯基乙 酸混合接著與Μ44克PyBOP混合。反應介質攪拌18小時後 回至周圍溫度接著減壓濃縮。殘留物置入50毫升乙酸乙酯 中並依序以50毫升飽和KHS04之H20溶液、50毫升飽和 ICO3之Ηβ溶液、50毫升飽和NaCl溶液及50毫升H20洗 條。有機相乾燥及蒸發後,殘留物在矽膠(40克)管柱上層 析,以100%石油醚至30/70石油醚/乙酸乙酯(v/v)之混合物 梯度溶離。獲得123毫克(S,S)異構物及177毫克(R,S)異構物。 (S,S)異構物: LC/MS : MH+ = 436。 NMR 500 MHz (DMS0) δ ppm: 0.87 (t, 3H); 1.22 (d, 6H); 1.32 (m, 2H); 1.70 (m, 2H); 3.78 (s, 3H); 3.98 (m, 1H); 4.52 (m, 1H); 5.90及6.00 (2s,1H); 7.44 (m,5H); 8.70 (d,1H); 12.55 (s, 1H) 〇 a2l = -55° (c = 1.0, MeOH) (R,S)異構物: LC/MS : MH+ = 436 〇 NMR 500 MHz (DMSO) δ ppm: 0.90 (t, 3H); 1.24 (m, 2H); 1.30 (s, 6H); 1.77 (m, 2H); 3.85 (s, 3H); 4.05 (m, 1H); 4.48 (m, lH);5.97&6.05(2s,lH);7.50(m,5H);8.80(d,lH);12.62(s, 86214 -38- 1313680 1H)。 1 al = -71.3° (c = 1.0, MeOH) 實例17 : 2-[2-[2-(3-氯)-2-羥基-(2S)-乙醯基胺基]_(2S)_戊醯 基胺基]-5-(1-曱基乙基)—塞吐_4_叛酸甲酯(化合物1〇7) 實例17· 1 : 2-(3-氯苯基)-2-羥基-(2S)-乙酸 2.85毫升3-氯苯甲醛之20毫升二氯甲烷溶液小心與3.66 毫升三甲基矽烷基氰化物混合接著與催化量之碘化鋅(Znl2) 混合。反應介質在周圍溫度攪拌3小時接著在60 °C攪拌2小 時。反應介質冷卻至〇°C並添加9毫升濃HC1。反應介質在周 園溫度攪拌18小時接著回流1小時◊冷卻後,反應混合物倒 入水中並以50毫升AcOEt萃取2次。合併之有機相以100毫升 7.5N NaOH在4°C萃取。分離後,水相以3x 50毫升AcOEt洗 滌。水相以70毫升12N HC1酸化並以3x 50毫升AcOEt萃取。 合併之有機相乾燥並蒸發溶劑。 藉結晶法分離呈(R)-(+)_苯基乙胺鹽之(r)_3_氣扁桃酸。 自母液藉結晶法獲得呈(S)-(-)-苯基乙胺鹽之(S)-3-氯扁桃 酸。獲得7 8毫克白色結晶。 所得酸未經進一步純化用於下一步驟。 實例17_2 : 2-[2-[2-(3-氯)-2-羥基-(2S)-乙醯基胺基]-(2S)-戊 醯基胺基]-5-(1-甲基乙基)_u塞唑_4_複酸甲酯 〇.〇72克實例5步驟5.1所得之2-(2-胺基-(2S)-戊醯基胺 基)-5-(1-曱基乙基),塞唑_4-羧酸甲酯於5毫升二甲基甲醯胺 之溶液在0°C與29微升N-甲基嗎啉、0.081克(S)-3-氯扁桃酸 混合接著與0.137克PyB〇P混合。反應介質攪拌4〇小時後回 至周圍溫度接著減壓濃縮。殘留物置入5 0毫升乙酸乙酯中 86214 -39- Ϊ313680 並依序以50毫升飽和KHS〇4之Ηβ溶液、50毫升飽和K2CCb 之H2〇溶液、50毫升飽和NaCl溶液及50毫升H2〇洗務。有機 相乾燥及蒸發後,殘留物在矽膠(40克)管柱上層析,以100〇/〇 石油醚至100%乙酸乙酯梯度溶離。獲得0.059毫克白色結 晶。 LC/MS : MH+ = 468 〇 NMR 500 MHz (DMSO) δ ppm: 0.87 (t, 3H); 1.20 (m, 2H); 1-22 (d, 6H); 1.70 (m, 2H); 3.80 (s, 3H); 4.00 (m, 1H); 4.43 (m, 1H); 5.02 (s, 1H); 6.44 (s, 1H); 7.30 (m, 3H); 7.45 (s, 1H); 8.20 (d,1H); 12.45 (s, 1H)。 實例18: 2-[2-(3-乙基-2-羥基-(2S)-戊醯基胺基)-(2S)-戊醯基 胺基]-5-(1-甲基乙基)p塞吐-4-幾酸甲酯(化合物log)及2-[2· (3 -乙基-2-幾基-(2R)-戊醯基胺基)-(2S)-戊醯基胺基]_5-(1-甲基乙基)嘍唑-4-羧酸甲酯(化合物1〇9) 實例1δ·1 : 3_乙基-2-羥基戊酸 1.24毫升2-乙基丁醛於丨8毫升無水二氯甲烷之溶液小心 與1.5毫升三甲基碎燒基氰化物混合接著與催化量之Znl2混 合。反應介質在周圍溫度攪拌2小時接著在6〇t攪拌3.5小 時。反應介質冷卻至〇。(:並添加3.5毫升濃HC1。反應介質在 周圍溫度攪拌18小時接著回流1小時。冷卻後,反應混合物 倒入水中並以50毫升Ac0Et萃取2次。合併之有機相以1〇〇 笔升7.5N NaOH在4°C萃取。分離後,水相以3x 50毫升AcOEt 洗滌。水相以70毫升12N HC1酸化並以3x 50毫升AcOEt萃 取。合併之有機相乾燥並蒸發溶劑。 所得酸未經進一步純化用於下一步驟。 86214 •40- I313680 實例18.2 : 2_[2_(3_乙基羥基_(2S)_戊醯基胺基h2S)_戊皞 , 基胺基]-5-(1-甲基乙基)3塞唑_4_幾酸曱酯及2_[2_(3_乙基_2_ · 經基-(2R)-戊酿基胺基)_(2S)_戊醯基胺基]_5_(1-甲基乙基) 嘍0i-4-羧酸甲酯 0.457克實例5步驟5.1所得之2-(2-胺基-(2S)-戊醯基胺 . 基)_5_(1-甲基乙基)嘍唑-4-羧酸甲酯於15毫升二甲基甲醯 · 胺之溶液在0°C與181微升N-甲基嗎I、0.45克3-乙基-2-(S)-喪基戊酸混合接著與〇.858克PyB〇p混合。反應介質攪拌18 小時後回至周圍溫度接著減壓濃縮。殘留物置入5〇毫升乙 ## 酸乙酯中並依序以50毫升飽和KHS04之H20溶液、50毫升飽 和K:2C〇3之Ηβ溶液、50毫升飽和NaCl溶液及50毫升H20洗 滌。有機相乾燥及蒸發後,殘留物在矽膠(40克)管柱上層 析’以100%石油酸至20/80石油醚/乙酸乙酯(v/v)之混合物 梯度溶離。獲得78毫克(S,S)異構物及131毫克(R,S)異構物。 (S,S)異構物: LC/MS : MH+ = 428。 NMR 500 MHz (DMSO) δ ppm: 0.86 (t, 3H); 0.93 (m, 6H); 1.24 (m, 2H); 1.32 (d, 6H); 1.38 (m, 4H); 1.55 (m, 1H); 1.72 · (m, 2H); 3.78 (s, 3H); 3.98 (m, 1H); 4.05 (m, 1H); 4.55 (m, 1H); 5.55 (d,1H); 7.92 (d,1H); 12.50 (s,1H)。 α2〇0 = -53.9。(c = 1.0, MeOH)。 (R,S)異構物: LC/MS : MH+ = 436。 NMR 500 MHz (DMSO) δ ppm: 0.80 (t, 3H); 0.90 (m, 6H); 1.20 (m, 2H); 1.30 (d, 6H); 1.34 (m, 4H); 1.55 (m, 1H); 1.74 86214 -41- 1313680 (m, 2H); 3.86 (s, 3H); 4.00 (m, 2H); 4.53 (m, 1H); 5.42 (d, ΙΗφ; 8.00 (d, 1H); 12.54 (s, 1H)。 al = -26.9° (c = 1.0, MeOH) 實例19 : 2-[2-[3-(3,5-二氟苯基)_2-羥基_(2S)-丙醯基胺基]- (2S)-戊醞基胺基]-5-(^甲基乙基)嘍唑_4_羧酸甲酯(化合物 110) 實例19.1 . 3-(3,5-二氟苯基)-2-幾基_(2S)-丙酸 1.6克(S)-3,5-二氟苯基丙胺酸之5.3毫升h2S〇4(2.5N)懸浮 液在0°C與0.829克亞硝酸鈉之4.2毫升ϋ20逐滴混合。反應混 合物在0 C攪拌2小時接著在周圍溫度攪拌丨7小時。反應混 合物以2χ 100毫升AcOEt萃取。合併之有機相以1〇〇毫升飽 和NaCl之HzO溶液洗滌《乾燥獲得1197克黃色結晶。 所知之酸未經進一步純化用於次一步驟。 實例19.2: 2-[2-[3-(3,5-二氟苯基)·2_羥基-(2S)-丙醯基胺基]· (2S)-戊醯基胺基]-5-(1-甲基乙基)_嘍唑_4_羧酸甲酯 0.897克實例5步驟5.1所得之2-(2-胺基-(2S)-戊醯基胺 基)-5-(1-甲基乙基)噻唑-4-羧酸甲酯於1〇毫升二甲基甲醯 胺之溶液在0°C與363微升N-甲基嗎淋、0.666克3-(3,5-二氟 苯基)-2-羥基丙酸混合接著與丨,72克pyB〇P混合。反應介質 攪拌17小時後回至周圍溫度接著減壓濃縮。殘留物置入50 毫升乙酸乙酯中並依序以50毫升飽和KHS04之H20溶液、50 毫升飽和K2C03之H20溶液、50毫升飽和NaCl溶液及50毫升 Ηβ洗滌。有機相乾燥及蒸發後,殘留物在矽膠(9〇克)管柱 上層析’以100%石油醚至10/90石油醚/乙酸乙酯(v/v)混合 物梯度溶離。獲得〇·43克白色結晶。 86214 •42· 1313680 LC/MS : MH+ = 484。 r NMR 500 MHz (DMSO) δ ppm: 0.82 (m,3H); 1.10 (m, 2H); 1.27 (m, 6H); 1.61 (m,2H); 2.83 及 2.95 (2m,1H); 3.77 (s, 3H); 3.96(m,lH);4.21(m,lH);4.43(m,lH);5.68&5.81(2d,lH); 6.93-7.01 (m,3H); 7.84及 7.97 (2d,1H); 12.46 (s,1H)。 al = -32.8° (c = 1.0, MeOH) 實例20 : 2-[2-[2-(2-苄氧基苯基)-2-羥基乙醯基胺基]_(2S)_ 戊醯基胺基]-5-(1-甲基乙基)-嘍唑-4-羧酸甲酯(化合物122) 實例20.1 : (2-苄氧基苯基)羥基乙酸 1.24毫升2 -芊氧基苯甲醛之1〇毫升無水二氯曱烷溶液小 心與4_4毫升三甲基矽烷基氰化物混合接著與催化量之Znl2 混合。反應介質在周圍溫度攪拌2.5小時接著在60°C攪拌4 小時。反應介質冷卻至〇°C並添加10.5毫升濃HC1。反應介 質在周圍溫度攪拌18小時接著回流1小時。冷卻後,反應混 合物倒入水中並以50毫升AcOEt萃取2次。合併之有機相以 100毫升7.5N NaOH在4°C萃取。分離後,水相以3x 50毫升 AcOEt洗滌。水相以70毫升12N HC1酸化並以3x 50毫升 AcOEt萃取。合併之有機相乾燥並蒸發溶劑。 所得酸未經進一步純化用於下一步驟。 實例20.2: 2-[2-[2-(2-苄氧基苯基)_2_羥基乙醯基胺基]-(2S)· 戊醯基胺基]-5-(1-甲基乙基)p塞峻_4_幾酸甲酯 1.88克實例5步驟5.1所得之2_(2_胺基_(2S)_戊醯基胺 基)-5-(1-甲基乙基)嘍唑羧酸甲酯於毫升二甲基甲醯 胺之溶液在0°C與760微升N-甲基嗎啉、13克(2-苄氧基苯基) 輕基乙酸混合接著與3 6克PyB〇p混合。反應混合物攪拌i 7 86214 •43 - 1313680 小時後回至周圍溫度接著減壓濃縮。殘留物置入1〇〇毫升D 酸乙醋中並依序以100毫升飽和KHS〇4iH2〇溶液、100毫升 飽和K:2C〇3之%0溶液、1〇〇毫升飽和Naci溶液及100毫升 H2〇洗蘇。有機相乾燥及蒸發後,殘留物在矽膠(90克)管拄 上層析,以100%石油醚至30/70石油醚/乙酸乙酉旨(v/v)混合 物梯度溶離。獲得0.43克白色發泡體。 LC/MS : MH+ = 540。 〜=-87.0。(c = 1.0, MeOH)。 NMR 500 MHz (DMSO) δ ppm: 0.85 (m, 3H); 1.26 (m, 2H); 1.28 (d, 6H); 1.69 (m, 2H); 3.78 (s, 3H); 3.98 (m, 1H); 4.47 (m, 1H); 5.22 (s,2H); 5.33 (2d,1H); 6.07&6.11(2d,lH);6.90-7.50 (m,8H); 8,00 (m,1H); 12.48 (s,1H)。 實例21 : 2-[2-[2-羥基-2-(2-羥基苯基)-乙醯基胺基]-(2S)-戊 醯基胺基]-5-(1-曱基乙基)-嘧唑-4-羧酸甲酯(化合物128) 1.187克實例20所得之2-[2-[2-(2-苄氧基苯基)-2-羥基乙醯 基胺基]-(2S)-戊醯基胺基]-5-(1-甲基乙基)嘍唑-4-羧酸曱酯 之10毫升乙醇溶液在氮氣壓下與144毫克Pd/C(10%)混合。 反應混合物在H2氣壓中攪拌24小時》過濾移除觸媒並減壓 蒸發溶劑。殘留物在矽膠(90克)管柱上層析,以100%石油 醚至40/60石油醚/乙酸乙酯(v/v)之混合物梯度溶離。獲得 0.68克白色結晶。 LC/MS : MH+ = 450。 (xl = -89.5° (c = 1.0, MeOH) 0 NMR 500 MHz (DMSO) δ ppm: 〇·91 (m,3H); 1·28 (m,2H); 1.30 (d, 6H); 1.80 (m, 2H); 3-85 (s, 3H); 4.07 (m, 1H); 4.53 (m, 86214 -44 - 1313680 1H); 5.31 及 5·35 (2s,1H); 6.87 (m,2H); 7.13 (m,1H); 7.27 (m, 1H); 8.17 (m,1H); 9.66 (寬 s,1H); 12.49 (s,1H)。 實例22 : 2-[2-[2-(3,5-二氟苯基)-2-禮基-(2S)-乙酷基胺基]_ (2S)-(3-甲氧基丙醯基)-胺基]-5-(1-甲基乙基)-噻唑-4-羧酸 甲酯(化合物60)及2-[2-[2-(3,5-二氟苯基)-2-羥基-(2R)-乙醯 基胺基]-(2S)-(3-甲氧基丙醯基)-胺基]-5-(1-甲基乙基)-嘍唑 -4-羧酸甲酯(化合物61) 實例22_1 : 2-[(2S)-2-胺基-3-甲氧基丙酿基胺基]-5-(1-甲基 乙基)噻唑-4-羧酸甲酯 2.00克實例1所得之2-胺基-5-(1-甲基乙基)噻唑-4-羧酸甲 酯於100毫升二甲基甲醯胺之溶液在〇°C與1_〇1克N-甲基嗎 啉、5_72克PyBOP混合接著與2.40克(S)-BOC-O-曱基絲胺 酸、二環己基胺混合。反應回至周圍溫度並攪拌丨8小時。 蒸發溶劑且殘留物置入乙酸乙酯中並以飽和碳酸氫鈉水 溶液洗滌2次,以水洗滌丨次及以1N硫酸氫鉀水溶液洗滌1 次接著以飽和氣化鈉水溶液洗滌。 有機相以無水硫酸鈉乾燥並濃縮。殘留物在矽膠管柱上 層析’以8:2 (ν/ν)石油醚/乙酸乙酯混合物溶離,獲得2.7〇 克白色粉末。 LC/MS : MH+ = 402。 NMR 300 MHz (CDC13): 1.33 (d, 6H); 1.48 (s, 9H); 3.32 (s, 3H); 3.33^3.99 (2m, 2H); 3.55 (m, 1H); 3.92 (s, 3H); 4.13 (m, 1H); 4.5 (寬 s,1H); 5.40 (d, 1H)。 依上述方式所得4.30克產物於6〇毫升三氟乙酸之溶液在 周圍溫度攪拌30分鐘接著蒸發溶液。 86214 •45- 1313680 殘邊物置入乙酸乙酯中並以飽和碳酸氫鈉水溶液接著吠 匕和氯化鈉水洛液洗滌。有機相以無水硫酸鈉乾燥接著蒸 發獲得0.50克白色固體,其未經純化用於下一步驟。 J 2 2 [2-[2-(3,5-_氟苯基)_2_經基-(2S)-乙驢基胺基]_ (2S)-(3-甲氧基丙酿基)胺基]巧_(1_甲基乙基卜塞唑_4_羧酸 甲酉曰及2 [2-[2-(3,5-二氟苯基)_2.經基_(2R)_乙基胺基 (2SH3-甲氧基丙醯基)胺基]_5·〇•〒基乙基)嘍唑_4—羧酸甲酯 〇_29克步驟22」所得之2_[(2S)_2_胺基_3_甲氧基丙酿基= 基]-5-(1-甲基乙基)噻唑-4-羧酸甲酯於8〇毫升二甲基甲醯 胺之溶液在(TC與(M06克N-甲基嗎啉、155克1>沖〇1>混合^ 著與0.20克3,5-二氟扁桃酸混合。反應介質回至周圍溫度並 攪拌16小時接著濃縮。殘留物置入乙酸乙酯中並以飽和碳 酸氫鈉水落液洗滌2次,以水洗滌2次,以1M硫酸氫鉀水溶 液洗滌1次接著以飽和氯化鈉水溶液洗滌。有機相以無水硫 酸鈉乾燥接著濃縮。殘留物在矽膠管柱上層析,以(1:1)(v/v) 石油醚/乙酸乙酯混合物溶離。依此方式分離兩種異構物 (s,s)及(r,s)。獲得〇.1〇克白色粉末[(s,s)異構物]及〇 5〇克 [(R,S)異構物]。 (s,s)異構物: LC/MS : MH+ = 472。 NMR 500 MHz (DMSO) δ ppm: 1.25 (d,6H); 3.23 (s 2H). 3.59 (m, 1H); 3.61 (m, 1H); 3.78 (s, 3H); 3.96 (m, 1H); 4.64 (m, 1H); 5.09 (s, 1H); 6.62 (s, 1H); 7.13 (m, 3H); 8.23 (d 1H)· 12.53 (s,1H)。 (R,S)異構物: 86214 -46- 1313680 LC/MS : MH+ = 472。 Ξ NMR 500 MHz (DMSO) δ ppm: 1.26 (t,3H); 3.23 (s,2H); 3.62 (m, 1H); 3.71 (m, 1H); 3.78 (s, 3H); 3.97 (m, 1H); 4.00 (m, 1H); 5.10 (s, 1H); 6.56 (s, 1H); 7.13 (m, 3H); 8.26 (d, 1H); 12.59 (s,1H)。 實例23 : 2-[2-[2-(3,5-二氟苯基)乙醯基胺基]_(2S)-(3-曱氧基 丙醯基)胺基]-5-(1-甲基乙基)遠唾_4_複酸甲酯(化合物59) 0.21克實例22所得之2-[2-[2-(3,5-二氟苯基)-2-羥基乙醯 基胺基]-(2S)-(3-甲氧基丙醯基)胺基]_5_(1_甲基乙基)嘍唑 -4-羧酸甲酯於30毫升二甲基曱醯胺之溶液在〇°c與〇〇9克 N-曱基嗎啉、0.42克PyBOP混合接著與0.14克3,5-二氟苯基 乙酸混合。 反應回至周圍溫度且混合物攪拌18小時。反應介質予以 蒸發。殘留物置入乙酸乙酯中並以飽和碳酸氫鈉水溶液洗 滌2次,以水洗滌2次,以1M硫酸氫鉀水溶液洗滌1次接著以 飽和氯化鈉水溶液洗滌。有機相以無水硫酸鈉乾燥接著濃 縮。殘留物在矽膠管柱上層析,以1:1 (v/v)石油醚/乙酸乙酯 混合物溶離,獲得〇. 1 2克白色固體。 LC/MS : MH+ = 456。 NMR 500 MHz (DMSO) δ ppm: 1.26 (t, 3H); 3.28 (d, 3H); 3.55 (s5 2H); 3.57 (m, 2H); 3.78 (s, 3H); 3.97 (m, 1H); 4.64 (m, 1H); 6.98 (d, 2H); 7.08 (m, 1H); 8.57 (d, 1H); 12.54 (s, 1H) 〇 實例24 : 2-[2-[2-(3,5-二氟苯基)乙醯基胺基]-(2S)-丁醯基胺 基]-5-(1-甲基乙基)P塞唑_4_羧酸曱酯(化合物51) 實例24.1 : 2-[(2S)-2-胺基丁醯基胺基]-5-(1-甲基乙基)嘧唑 86214 -47- 1313680 -4-羧酸甲酯 ' 2_03克2_(2S)_(第三丁氧基羰基)胺基-丁酸於50毫升ν,Ν-二甲基甲醯胺中與1.92克實例1所得之2-胺基-5-(1-甲基乙 基)Ρ塞唑_4_羧酸甲酯、5.72克PyBOP及1.07克Ν-甲基嗎啉偶 合’層析後,獲得2.50克白色粉末。BOC基於TFA中去保護, 以鹼洗滌後’獲得1 _60克白色固體,其未經純化用於下一步 驟: LC/MS: MH+= 286。 實例24.2 : 2-[2-[2-(3,5-二氟苯基)乙醯基胺基]-(2S)-丁醯基 胺基]-5-(1-甲基乙基)P塞吐_4_瘦酸甲醋 步驟24.1所得之2-[(2S)-2-胺基丁醯基胺基]-5-(1-甲基乙 基)嘧也-4-羧酸曱酯於ν,Ν-二甲基甲醯胺中,如實例5.2所 述程序與0.38克3,5-二氟苯基乙酸、1_丨4克PyBOP及0.22克 N-甲基嗎淋偶合,層析後獲得〇 66克白色粉末。 LC/MS : MH+ = 440。 NMR 500 MHz (DMSO) δ ppm: 0.79 (t, 3H); 1.26 (d, 6H); 1.73 (m, 2H); 3.78 (s, 3H); 3.96 (m, 1H); 4.36 (m, 1H); 5.06 (s, 1H); 6.56 (s, 1H); 7.13 (m, 3H); 8.22 (d, 1H); 12.46 (s, 1H)= aD = -73° (c = 1.0, MeOH) 貫例25 : 2-[2_[2_(3,5·二氟苯基)乙醯基胺基]-(2S)-戊醯基胺 基]-4-甲基嘍唑_5-:^甲基苯基乙基羧醯胺(化合物176) 使用實例9所述方法獲得上式化合物。 - 實例25·1 : 2-胺基甲基嘍唑-5-N-甲基-N-苯基乙基羧醯胺 5·58克實例2所述方法製備之2_胺基_4_曱基嘍唑_5_羧酸 甲醋於四氫呋喃中與7.19克二碳酸二-第三丁酯及0.18克二 86214 -48- 1313680 甲胺基吡啶反應,獲得6.90克白色粉末,其未經純化就此使 用。 LC/MS : MH+ = 187。 NMR 300 MHz (CDC13): 1.45 (s,9H); 2.48 (s,3H); 9.80 (寬 s, 1H)。 藉實例9.2所述方法偶合獲得藉BOC在胺上予以保護之2-胺基-4-甲基p塞σ坐-5-N-甲基-N-苯基乙基叛醯胺。此係利用 1.5 0克2 -弟二丁氧!幾_基版基-4 -甲基a塞- 5 -酸乙自旨於1 〇 〇 毫升Ν,Ν-二甲基甲醯胺與0.88克羥基苯并三唑水合物、ο.% 克EDAC.HC1及0.78克Ν-曱基-Ν-苯基乙胺進行反應。層析獲 得1.10克白色粉末。 LC/MS : ΜΗ+ = 376。 (M-BOC)+ = 276。 藉實例9.3所述方法使BOC保護基去保護。獲得0.90克白 色粉末之2-胺基-4-甲基噻唑-5-N-甲基-N-苯基乙基幾醯胺。 LC/MS : MH+ = 276。 ' 貫例25.2 : 2-(2-胺基-(2S)-戊醯基胺基)_4_甲基喧吨_5-N-甲 基-N-苯基乙基幾g盘胺 0.90克步驟25.1所得之2-胺基-4-甲基u塞嗅_5_N-甲基苯 基乙基叛醯胺與0.78克(S)-BOC-正纈胺酸藉實例5步驟5.1 之方法偶合。在矽膠上層析以1:1 (v/v)乙酸乙酯/石油醚混合 物溶離後,獲得1.05克白色發泡體。 一 LC/MS : MH+ = 475。 L05克上述所得化合物於25毫升三氟乙酸中藉步驟9_3所 述方法去保護。獲得0.80克白色固體。 86214 -49- 1313680 LC/MS : MH+ = 375。 : 貫例25.3 · 2-[2-[2-(3,5-二氟苯基)乙醯基胺基]_(2S)_戊醯基 胺基]-4-甲基嘧唑-5-N-甲基_N_苯基乙基羧醯胺 依循實例5 ·2之相同程序。 0.80克2-(2-胺基- (2S)-戊酿基胺基)-4_甲基d塞吐- 5-N-甲基 -N-苯基乙基羧醯胺於5〇毫升N,N-二甲基甲醯胺中與1.19克 PyBOP、0.23克N-甲基嗎淋及0.40克3,5-二氟苯基乙酸偶 合,在珍膠管柱上層析以1:1 (v/v)乙酸乙酉旨/石油謎混合物)谷 離後,獲得0.67克白色粉末。 LC/MS : MH+ = 259。 NMR 500 MHz (DMS0) δ ppm: 0-92 (t, 3H); 1.38 (m, 2H); 1.65 (m, 2H); 2.14 (s, 3H); 2.88 (m, 2H); 2.97 (s, 3H); 3.63 (s, 2H); 3.67 (m, 2H); 4.51 (m, 1H); 7.04 (d, 2H); 7.12 (t, 1H); 7.24-7.30 (m,5H); 8.55 (d,1H); 12.46 (s,1H)。 = _1〇3。(c=l,MeOH)。 下表說明本發明某些實例化合物之化學結構及物理性 質。 S6214 -50 - 1313680 86214 <p\ w NJ 3,5- 二氣苯基 3,5- 二氟苯基 3,5- 二氟笨基 3,5- 二軋苯基 3,5- 二氟笨基 c -= 5 e X X X X R2,R*2 h X G r> is p η η 73 -COR, -coiu -COR* I •COR« -COR* 71 -(CIii)sCH3 9 -CHjC(CHj)3 ! -CH2CH(CH3)j 1 1 1 -(CiWjCih -CH(CH3)i 7i OCIIj ocm3 OCH3 1 1 OCH3 OCHj 1 L一. . OClh 1 1 f 1 1 1. Rt, R· 1 1 1 1 1 1 S « σ m-m a- 0.85 (t53H), 1.29 (9H)t 1,56 (m,2H), 3J0 (t,2H).. 3.69 (t,2H), 3.77 (s,3H), 4.41 (tn,m), 6.97 (m,2H)t 7.07 (ιη,ΙΗΪ, 8.56 (d.Ui), 12.48 (s,1H)** 1.30 (d,3H), 1.31 (»1,511), 1.67-1.97 (m,5H)t 3.53 (s,!!!), 3.65 3.77 (sf3H), 4.38 (m.lfl), 6.98 (d,2H), 7-08 (mJH), 9.67 (dfIH), 12.47 (s,lH)** 0.91 (s,9H), U1 (d,3H), 3.07 (s,2H), 3.53 (s,2H), X76 (s,3H), 4.38 6.97 (d,2H)t 7.0K (m.lH), 8.57 0.89 (d,6HX 1.30 1,85 (m,lU)t 2.98 (d,2H), 3.53 (s,2M), 3.77 (s,3II), 4.38 6.98 (d,2H)t 7.09 8.57 12.50 (s.Ul)** 0.91 (q,3H), 1,30(d,3H),l_6i (m,2H), 3.06 (l,2H), 3.53 (s,21I), 3.77 (s,3H)t 4.38 (πι,ΠΙ), 6.98 (m,2H), 7.0R (ηι,ΠΙ), 8.57 (d,lll), 12.49 (s,lH)*** 1.16 (d,6H), 1.25 (d,3H), 3-53 (a,2H), 3.77 (s,3H), 3.97 (m,lH)t 4.36 (ιη,ΙΗ), 6.97 (d,9H), 7.10 8.55 (d,UI)t 12.47 (s,lH)** g并 55
ol - 1313680 X 二 p χ 〇> l· m ' l· P1 ^ ^ v 1' 沐u m 1 l· 尹1 UJ V 1' 沐V* l· P' U> 舛— l· P1 w l· ψ, V 71 3: X i Ξ Ξ X r* 7J Q a 2 Q Q η Ρ Q ή h 孑 73 h 3 o c h q h g η Ο ?3 ή ο 5C 1 n o 93 p n Q 令 〇 o Q X b o 3 7S ο s I3 B E Ο Ο κ ο Q η 8 S· o ? 1 1 I 隹 t 1 ? 7J 1 1 1 1 1 1 ( 1 2: r,a 〇 » 〇 5广 •*(inls)em ‘(Hi‘phnruu‘i> lt)V(uriu) 6〇.t ‘(Ηε‘Ρ) 86.9 ‘(Hl‘s〉6ε.ί 4(III,lu) 6VP *(ΜΖ*«) Ci£ OiX '(HZ4w) \n Oli ‘(H,‘tu) wi ‘(ll〆111) 6KI ‘(ΗΓΡ) 〇e.l*(Hd) 68Ό 1.30 (<Ι,3Η), 2.98 (t,2H), 3.38 (t,2H), 3.50 (s,2fl), 4.41 (ιη,ΙΗ), 6.98 (d,2H)t 7.07 (m,lH), 7.16-7.28 (m,5II), 8.53 (d,JHrM 0.89 (tr3ll), 1.29 (m,3H), 1.31 (3K), Ϊ.22-Ι.87 (m,IOi〇, 3.10 (t,2H), 3.53 (st2ll), 3.67 4.43 6.9» (tnr2H)} 7.07 (m,UI), 7.41 (d,lH), 8.54 (d,!H), 12.18 (s,Ul)… 1.22 (d,6H). L33 (d,3ll), 2.93 (m,lH), 3.54 (s,2H), 3.68 (s,3>l)t 4.42 (m,Ul), 6.98 (d,2H), 7.08 7.29 (d,2l〇, 7,39 (d,2H), 8.60 (d,IH), IZ68 (s,1H)** 1.27 (dt3H), 2.57 (Sj31〇, 3.50 (st2H)f 3.74 (s,3Il), 4.36 (mrlH)t 6.96 (d,2H), 7.05 8.53 (d,lH), 12.43 (S,1UT* 1 1 1 1.25 (t+d,6H), 3.65 (s,2M), 4.25 (n),2H), 4.45 (ηι,ΙΗ), 6.95 ((1,211), 7.10 (mJH), 8.05 (s,IH), 8.57 (d(IH)t 12,65 1.25 (<l,31i), 3.48 (s,2H). 3.85 (s,3H), 4.35 (m.lH), 4.47 (s,2H), 7.20-7.40 (ni,3H), 8.50 (djl{)f IZ50 (s.HI)** \ .33 (dt3H), 3.50 (s,2H), 3.67 (s,3H), 4.42 (m, 1H), 7.28-7.48 〇η(3Η), 8.57 (d.Ht), 12.70 (s,H!)** NMR (DMSO d6除非另有說明) *表示300 MHz - ** 表示360 MHz ***A*500 MHz -52- 86214 1313680
KJ ρς 化合 kn 3,5- 二氟苯基 3.5- 二氟苯基 3,5- 二氟笨基 3,5- 二氟苯基 3,5- 二氟笨基 3,5- 二氟苯基 3,5- 一氣笨基 3,5- 二氟笨基 73 Η, Η a: X OIT, II (R) OH, II (S) Η, Η I 1_ Οί I,H ⑸ X r2,r,2 CH3(CH,)r (S) C\U(〇h)^ (S) *(CH,),CHj (S) -<CHi)2CH3 (S) -(CihJjCHj (S) CH, (S) 1_ ah (S) Cih (S) ? •COR* -COR* -coiu -COR· -COR^ -COR* COR* -CORe ? (CHjK- (cn,)iCH- (CI^jCH. 1 (CH,)iCH- j 1____ _ …皿 (CHiWU (CH3),al· (CH3)1CH- 33 OCHj KR^R* OCHj OCHj oaij OC\U i · OCH] o 3: 71 .、〇 1 t 1 1 1 t Rr. R* 00 ία ά 1 1 1 1 I 7-8 o n a 5.·一 0.85 (m,3H), 1.42 (s,9H), 1.30 (m,2H), l.64(m,2H)? 3.29 (m,211), 3.79 (s,3I 〇, 4.37 (τη, 1ΪΪ), 6.98-7.09 (m,3H), M6 (d,】H),12.39 0.85 (t,3H), 1.22 (d,6II). l.27-1/>5 (ιη,ΠΙΙ), 3.190.30 (m.3H), 3.51-3.73 4.40 (m.lH), 7.09-6.90 (m,3H); 8.49 (ϋ,Πί), 12.22 0.82 (t,3H), 1.26 (d,6H), 1.26 (m,2H), 1.68 (m,2M), 3.78 (s,3H), 3.97 4.40 5.07 (d,1I〇, 6.42 (d,Ii〇, 7.12(11),311), 8.27 (d.HI), 12.51 (sJM)*** 0.80 (t,3H)f U8 (in,2ll), 1.22 (d,6H), 1.68 (m,2H), 3.78 (s,3H), 3.97 4.43 (m.lH), 5.05 (d(IM), 6.55 (d,lH), 7.13 (m,3H), 8.24 (dJH), 12.46 0.85 (tf3H), Ϊ.26 (d,6H), 1.28-1,65 (mt 411), 3.53 (m,2H), 3.78 (s,3H), 3.97 (m.IH), 4.36 6.96 {6,III), 7.08 (ιτι,ΙΗ), 8.49 (d.lll), 12.52 (S|IIi)*** i 1.25 (d,6H), 1.30 (d,3H), 3.78 (s,3H), 3.97 4.40 5.04 (d,m), 6.55 (s.UI), 7.13 R.34 (d,Ul), 12.43 (s,m)*** 1.25 (ϋ,6Η), Ϊ.30 (d,3H), 3.53 (S.2H), 3.78 (Sf3H), 3.97 4.36 6.96-7.M (m,3H), 8.56 (<1,ΠΪ), 12.47 Ilk ^ r *r* 产3 ΚΛ -A ?s 53 1! Ut 90 jSl 2鲜 CM -53 - 86214 1313680 NJ u 化合 物 3f5- 二氟苯基 3,5- 二氟苯基 3,5· 二氟苯基 i 3.5- 二氟笨基 1 1_ 3,5- 二氟笨基 3.5· 二氟笨基 3,5- 二氣笨基 73 OH, U (S) = OH, H (R) OH, I I (S) I I, Η ί_ M, H Μ, Η CU,(CH,)r (S) CH3(CHi)r (S) CH,(CH,)i- (S) CH^CIIi),- I (S) 1 ai3(cu2),. ⑻ i_ CT!3(CH2)r ⑸ CH, (S) CH3(CH2),- (S) ? -COR« -COR« -COK« -COR* -COK< -COR, -COR* -COR< X (CIl^rCM- dbCUr (CVI,)3C- (Cll3)jC- (CHj)2CH- L (CIi3)2CH- (CHj),CIl· 6 ? OCU3 OCIib OCHj OC\h NR,R# och3 L......... 〇C(CH,)3 oaij 31 1 1 1 1 CHj, CHj t ( 1 R7. R· t '«J o -J so 9 〇 1 r 1 a D (C-1, McOH) 0.S0(gH), U6(m,2H), 1.26 (s,9H), 1.68 (m,2in, 3.78 (S,3H). 3.97 4.43 (m.!H), 4.98 (¢1,111), 6.31 (d,Ul), 7.32 8.14 (d.lH), 12.46 (s.UT)*** 0.86 (l,3H), 1,27 (UM), L29-1.35 (m,2H), 1.63 (m,2H), 3J0 (q,2H), 3.54 (m,2H), 3.78 4.39 (m.iU), 6.98 (0,211), 7.07 (mJH), 8.47 (d.UI). 12.50 (stIH)*** 0.82 (t,3H), 1.25 (m,2H)s 1.42 (s,9H), i.69 (m,2H), 3.79 (s,3H), 4.40 (m, 1H), 5.07 (d, IH), 6.42 (ϋ,Ι H), 7,13 (m,3H),8.26 (cMH), 12.4Ϊ (sJH)”· 0.81 (UH), 1,22 (m,2H), 1.43 (s,9H), 1.67 (m,2H), 3.78 (s,3H), 4.42 5.05 (sJH), 6.55 7.12 (m,3H), 8,22 (<ΜΗ), 12.37 (s,lH)w 0.87(1,3(1), 1.24 (d,6H), 1.29-1-672.86(s,3U), 2.95 <s,3H), 3.22 (m,丨H), 3.54 (m,2H), Ή1 (m,III), 6.98 (d,2H), 7.08 8.49 12.21 (s,UI)*** 0.83 (t,3H), 1.25 (d,6H), l.23-l.72(m,6II)t 3.55 (in,2H), 3.78 (s,3Ii), 3,97 (ηΜΠ), 4.35 (η^ΙΠ), 7.09-6.97 :(m,3(-〇f 8.47 (d,Hi), 12.49 (s.HI)*** ί ..... 1.26 (df6Il), 1.34 (d,3U)t 1.51 (s,9H), 3.53 (s,2H), 3.90 (m, 1H), 4.39 (m, l H), 6,93 ((1,21 D, 7.07 (mt 1H), 8.51 (sJH)、12.40 (s,lH)·** 0.85 (m,3H), 0.96 (t,2H), 0.95-Ϊ.69 (m,14H). 2.99 (t,2H), 3.54 3.77 (OH), 4.37 (m.tH), 6.97 (^,2(1), 7.08 8,48 (d,lH)t 12.51 (s,lH)*** jll Sis m N ill gj 2:钵 N w -54- 86214 1313680 u> οα w <?. Uj Ui 么 u> w u V>J 笨令. a> 6 l· ff' »〇 P 私 to l· 舛f· 私 .1' 淋, ψτ X OH, H (S) C K Ο 3: Ο s X 〇 I Ο s ο X κ 0 s 1 73 73 η 3¾ n M Q s sS G Go ^ s Q 5 Q η Go 一壬 η 3¾ n ? 3q ? ή C ri C n 〇 73 o o ?0 ή O ?3 η Ο 7〇 ή ο ?3 ή O ? ? π X 0 Q I g X η ? 1 s ? ο ο X o n ? c o X o Q ο ? ο η ? o n ? I 1 1 1 1 I t ( Λ ο» 00 S O S: O <sj ίϋ Ον k Soft S it o 3广 0.81 (t,3H), UO (111,211), 1.26 (d,6H), i.60 (m,2H), 2,74 and 2.95 fdd,2H), 3.78 (5,3ίί), 3.95 4.15 (m,Ui).. 4.45 (πι,ΐΐΐ), 5.69 (d,IH), 7.18 (m,5H), 7.80 (d,lH), 12.44 (s,UI)*** 0.87 (t,3II), U6 (s,6H). 1.28 (Γη,2Η), 3.79 (s,3H), 3.98 (ηι,ΠΙ), 4.54 (ηι,ΙΗ), 5.28 ((UH), 6,69 .nd 6.73 (2d,IH), 7.06 (mt2H), 7.39 (m,IH), 8.Π .nd 8.21 (2d,lli). MM (sJH)*** 0.86 (gH), 1.26 (<1,611), 1.34 (m,2H), 1.73 (m,2H), 3.78 (s,3H), 3.96 4.46 (in,ill), 5.34 (d,1M), 6,44 .nd 6,49 (Ζ%\\ϊ), 7.30ιπ<»7.42 (2ιΜΗ), 8.l8.nd8.23 (2d,IU) 12.50 0.83 (t,3H), 1.23 (d,6II), 1.29 (m,2I〇t 1.69 (m,2H), 3.78 (s,3H), 3.96 (mjH), 4.39 (ηι,ΙΜ), 5.04 (3,111), 6.3t (ί,ΠΙ), 7,30-7.46 (m,4H), 8.24 (d,UI), 12.51 0.86 (t,3H), 1.26 (d,6H), 1.29 (m,2(I), 1.78 (m,2H), 3.78 (s,3H), 3.97 (m,UI), 4.46 (m.lH), 5.33 (s,lH)f 6.44 7.29 (d,2H), 7.39 (d.Ul), 7.45 (ϋ,ΠΙ), 8.24 (d.IH), 12.51 (sJH)*** 0.82 (in,3H), Κ26 (ϋ,6Η), 3.97 (πι,ΙΗ), 4.41 (m.lH), 5.03 (m,丨 Η), ¢.35 *nd 6.48 (2s,丨 Η), 7,27 7.42 (mt2H), 8,23 (m.lH), 12.48 1 0,85 (m,3M), 1-28 (d,6H), 1.30 (m,2H), 3.78 (s,3H), 3.% 4.45 (m.lH), 5.20and 5.22 (2s,1H), 6.44-6.50 (2s1lii), 7.05 (πι,ΠΪ), 7.19 (m,H〇, 7.44 8.19 «nd 8.23 (2d,III), 12.50 0.85 (t,3H), 1.28 (s,6H)( i.28 (mt2H), 1.68 (m,2H)t 3.78 (s,3H), 3.97 (m,IH), 4.44 5.00 (d,lH), 6.17 (d,!M), 7.30 (m,5U),S.17(d(lH), 12.51 (s.lll)*** NMR (DMSO d6除非另有說明) *表示300 MHz - **表示360 MHz -***表示500 MHz -55 - 86214 1313680 A nC 3,5- 二氟笨基 1'· | 二氟笨基 1 3,5- 二氣笨_基 3,5- 二氟笨基 環己基‘ ό II, II OH, Η (II) 〇H,H(S) 1 OH, H 〇S) OH,H(S) t i_ Oil, II (R) OH, H (S) οι i, n (R) R2,R’2 CH3(CHi)z- (S) CH3(CHj)i· ⑻ α七(ch山-! ⑸1 CIl3(CH,)2- ⑸ CHj(CH2)3- (S) (S) CH3(CHi)r (S) ClUCIWr ⑸ X -CORe -COR6 -COR* -COR* -COR, 1_ -cor4 -COR* -COR* 70 (CH3)aCH- CH3CH2- CHjCHi- | 1 6 (CHj)2CH. (CH,)iC!I- (CH3),CH- 7i NRiRk OCHj oai, OCHj OCH, ! i 1 OCHj OCHj och3 CIIjCHj, CXhCHi 1 « 1 1 1 1 1 Rt, r. 1 1 Us VA o t insoluble McOH o Soft 〇 w σ 0.85 〇,3H), 1.03-1.Π (m,6H), 1.20 (d,6H), 1.20-1.32 (mt2H), i.60 (m,2H), 3.Ϊ8 3.39 (πι,2Π), 3-55 (s,2H), 4.42 (mj H), 6.98 (¢1,211), 7.07 8.49 (cJTni), 12,21 0.83 (l,3H), U2 (t,3H), 1.28 1.69 (m,2H), 3.09 (m,2H), 3.78 (s,3H), 4.40 5.07 (s,lH), 6.42 (sjli), 7.12 (m,3H), 8.29 (d.lH), 12.51 (stUl)*** 0.80(1,311), t.l9(d,3H), 1.20 (m,l!l), L69 (m,21I), 3.09 (ιη,2Ή), 3.78 (s,3H), 4.41 (m.lH), 5.05 (s,lH), 6.55 (s(lH), 7.12 (ηι,3Ι〇, 8.26 (d,lH), 12.45 (s,lll)*** 0.80 (l,3H), 0.95 (in,2M), U3-I.69 (τη,ΠΗ), 2.99 (d,2H), 3.77 (ίτ3Η), 4.42 (mJH), 5.05 (s,lH), 6.55 ts,lH),7.U (111,311), 8.24 (d.lH), 12.51 (s,IH)*** 0.78 (t,3H), K18(m,4H), 1.27 (d,6H), \J\ (m,Hi), 3.78 (s,3H)t 3.97 4.42 5.05 6.56 (s.lii), 7.13 (m,3H), 8,23 (d.lli), 12.45 0.85 (t,3H), 1.25 (d,6M). 1.05-1.67 (m,I5II), 3.70 (d.lH), 13.78 (sf3H). 3.96 4.45 (m,UT), 5.34 (d,lil), 7.82 (d;lM), 12.50 (s,m)+** 0.85 (1,311),1.11-U8 (m,7H), 1.24 (d,6ttM.28 (m,U〇, 1.65-1.69 (m,7H), 3.69 (d.UI), 3.78 (s,3H), 3.97 4.50 (ni.lH), 5.46 (d,lll), 7.80 (dfUI), 12.44 (sJH)*** 1 0.84 (UH), 1.18 (m,2H), 1.26 (ni,6H), 1.64 (m,2H), 2.70 .nd 2.93 (dd,2M), 3.79 (s,3H), 3.98 (mf 1H), 4.H 4.45 5.57 (d.lH), 7.09-7.21 (m,5U), 7.95 (d.lH), 12.44 (s,Ili)*** if: g缽 X^Si N w -56 - 86214 1313680 NJ V* a 化合 物 啉. Ψτ 3,5- 二氣笨基 3,5· i 二氣笨基 1 l· 舛ν' m 3,5· 二1笨基 -^V 7J oh, ah (S) -OCHj, H{R) -OClb, H(S) | i -= X X X Ra,R’2 CH3(CH2)i- CIb(CIh)i- (S) cn3(cn,)i- (S) ClhQUr 〇S) η 1? 3q £; αι3(αΗι),- (S) (S) C^(Clhh- ⑸ -COR* •CORi -COR* ! -C0K« -cou< 1 i_ -COR« -COR* -COR, (Clb)iCH· (Clb)2CIl- (OhhCll· {cihhcn- 苯基 (ClhhCH- (CMjhCH- 73 OCHs OCIT3 OCHj OCH, OCHj NRtR, NR,K, NRTR, 73 1 1 1 1 I 1 2 CHj, H 〔:〕 R7, R« 〇 a\ u* 1 ( ξ 91<=> 0,77 U0-1.17 (m,2H), 1.35 (d,6U), 1.68 (s,3H), 3.*5 (s,3H), 4.05 4.45 (m.lH), 6.30 (s,Ul), 7.25-7.50 (111,511), 8.00 (d,III), 12.47 (s,lH),+* 0.85 (tt3Jl), 1.27 (d^H), 1.26 (m,2H), 1.70 (m,2H), 3.30 (s,3H), 3.80 (s,3U), 3.98 4.41 (m.lH), 4.77 (s,IH), 7.30 (m,5H), 8.30 (d.lll), 12.50 (s.iH)*** 0.86 (t,3I〇, 1.25 (m,2U), 1.30 (d,6H)t 1.75 (m,2M), 3.38 {s,Z\\\ 3.79 (s,3H)f 4.00 4.47 4.75 (stUI), 7.33 (m,5H), 8.22 (d,lH), 12.50(s(IH)*** 0.79 1.26 (d,6H), i.73 (m,2H), 3.78 (s,3H), 3.96 (m,UI), 4.36 5.06 (ϊ,ΠΙ), 6.56 (s,!H), 7.I3 (m,3H), 8.22 (d,IH), 12.46 (s,II〇… 0.87 (t,3Ii), 1.30 (m,2H), 1.67 (m,2H), 3.56 (s,2H)f 3.67 (s,3H), 4.43 6.98 (dt2H), 7.06 (ηι,ΪΜ), 7.44 (m,5H), 8.56((1,111), Ι2.7Ϊ 0.86 1.21 (d,6H), 1.34 (ηι,2ΓΪ), 1.62 (m,2H)( 2.20 (m,2II), 3.54 (s,2H), 3.97 (mf2l[), 4,38 (m,2M), 4.47 6.97 (dt2Fi), 7.08 (m.HI), 8,52 (djli), 12.08 (s,lH)… 0.86 (t,3H), 1.22 (d,6H), 1.35 1.63 (m,2U), 2.75 (st3H)t 3.58 (d,2H), 4.18 4.47 (ιη,ΙΙΪ), 6.98 (d,2il), 7.07 7.69 (s,U!), 8.50 (s,IH), 12.13 (s,IU)*** H P nil Ρί:Ξ3 二 J P' K =: -4 ^ SP? Ul fsj -3 ?= S t; 3 lls X适 N w -57- 86214 1313680 g <-A SC 〇a € 今 ,Ρ l· l· l· P^UJ I1 舛V l· m l· 私 73 = OH, H (R) o X X 2 = 〇 X 0H,CM3 (R) 7i 73 «α- η 一 1 o s| CHjOCHi- | (S) CUjOCIV (S) η 3: 〇〇 η w X n ag Q 3¾ n ir ^ n 1— ό g n O 53 o o n o ?3 ή Ο £= h c ?3 ό o 53 ό o 3 s Q S s s ο £ S o ? G 7) 〇 〇 o 2: o n X 2: 25 2 ? C3 g h o Q 3) I 1 1 t α b, ocib i 1 Q Q 4 1 ? 30 1 t « 1 1 3 1 ON a So» 〇 »σ a:- 0.86 (gi!),(d,611),丨·28 (m,2i〇, 1.62 (m,2I【},3·78 (s,3H), 3.97 4.41 (m,lHX 4.94 (m.MI), 5.33 (s,lfi),7_21 (m,5m,8.l3(cl,m),12.41 (s,IH)… 1.26 (g>t)t 3.23 (s,2H), 3.62 (ιη,ΙΗ), 3.71 (m,!M), 3.78 (s,3H),.1.97 4.00 5.10 (3,IH), 6.56 (s,lH), 7.13 (m,3H), 8.26 (d.lIT), 12.59 (s,IH)*** 1.25 (d,6H), 3.23 (s,2M)f 3.59 3.6i 3.78 (s,3I〇, 3.96 4.64 (in, 111), 5.09 (s.IH), 6,62 (s,UI), 7.13 (m,3H), 8.23 (d,!!!), Ϊ2.53 (s,IH)*** 1,26 (1.3H), 3.28 (df3H), 3.55 (3,211), 3.57 (m,2H), 3.78 (s,3H), 3.97 (m.lll), 4.64 (mTlH), 6.98 (d,2It), 7.08 (in, 1M), 8.57 (df 1H), 12.54 (s, 1 ft)* * * 0.86 〇,3It), 1.23 (s,6H), 1.28-1.35 (m,2H), 1.64 〇n,2H)( 3.20 (s,3H), 3.30 (m,lH), 3.52 (s,311),4.4i (m,m),6.98 (d,2Ii),7.08 8.49 <d,U〇, 12.23 (s,HI)*" 0.72(l,3H), J.06(m,lH), U6(m,111), 1.27 (d,6H), 1.58 (m,2fl),2.10 (s,3H), 3,78 (s,3H>,3_96 (m,lH),4.37 |(m,UI). 5.97 (s(IH), 7.34 vid 7.47 (2m,5H), 8.62 (s,1H), !i2.49(s,lH)*%# 0.86 (l,3H), 1.07 (mf611), M 1 (m.6i〇, Ι.2Ϊ (m,2H), Ϊ.62 (m,2)〇, 2.66 (s,3H), 2.81 (s,3H)f 3.27 3.54 (s,2H), 3.77 (ιη,ΙΗ), 4.41 (m,Ill)t 6.97 (<I,2H), 7.07 (ηι,ΙΗ), 8.48 (d.Ui), 12.20 (s.lH)*** 0.90 1.28 (d,6Vl), 1.30 (m,2H), 1.65 (s,3H), 1,71 (ιη,2Η), 3.83 (s,3H), 4.00 (ιτι,ΙΜ), 6.28 (3tUl)t 7.22-7.50 (m,5H)f 8.00 (d.lH), Ϊ2.50 (s,lH)*** NMR (DMSO d6除菲另有說明) *表示300 MHz ·**表示360 MHz -***表示500\^匕 58- 86214 1313680 3 S; 2 化合 物 O八。 上! 2,3- 二氟笨基 苯基 1_ 3,5- 二氟笨基 $ JS •0C(0)CI ί3, Η (S) o X X ^>=〇 OH, :H OM, R π, h 1_ Η, Η = R2,R,2 CH3(CHi)i- CH3(CHi)2- (s) ctuaij),- (S) n ? -—V ζΛ n CH3(CHa)r (S) CH3(CHi)r (S) ciuauh^ CHj(CHi)2- X -COR« -coiu •CORi -COR* 1 .COR‘ -COR4 1 ! -C:OR« -COR* 33 (ClU)vCH- {ClhhCH^ {ClhhClb (CJIjhCH- (CH3):CH- (CH^CH- (CH3)jC1|. {ClhhClb J OCH, OCHj oau OCH3 i oah 00143 NR7RI OCHj Λ 1 1 1 1 • 1 CH3CH,-( CHi 1 1 1 OS a 兰 e .· Os 90 0 9 1 f 1 fna 〇 » 0 ffi - 0.86 (l,3H), 1.24 (d,6H), 1.26 (m.2H), t.63 2.11 (s,3H). 3.77 (s,3M), 3.95 (m.HI), 4.45 (m.HT), 5.94 (s,IH), 7.38 (m,5H), 8.55 (d,lit), 12.48 (s,lll)… 0.86 (gri), K30 (d,6M), 1.25 (m,2H), 1.72 (m,2H), 3.81 (s,3H), 4.00 (m, III), 4.45 (ηι,ΠΙ), 4.90 «id 4.94 (dd.lH), 5.99 (m,2H), 6.13 .nd 6.26 (dd,IH), 6.86 (m,肌 8,14 (ni,lH)J2.47 12‘52(d'!H)… 0.97 (t,3H), 1.20 (d,6H), 1.40 (m,2H), 1.80 (m,2H), 3-87 (s,3H), 4,05 4.60 7.60 (m,2H), 7.80 7,99 9.30 (df 1Π), 12.70 (sj H)*** 0.85 1.26 (d,6H). 1.30 (m,2H), J.72(m,2H), 3.78 (s,3H), 3.97 4.45 (m,UI)T 5.20 .nd 5.23 (2s,1H), 6.50 «nd 6.57 (2s,IH), 7J8 (ιη,3Μ), 8,19 .nd ii.25(dd,m), I2.48(s,m)… 0.86 (m,3H), 1.26 (d,6H), 1.28 (m,2H)t I.72(m,2H), 3.78 (s,3H), 3.96 (m.lH), 4.47 (m.iH), 5.24 S.28 (2d, J H), 6.55 and 6.62 (2d, 1H), 7.17-7.36 (m,3I I), 8.19 and 8.23 (dcUH), 12.49 (sfUl)*** 0.85 (t,3H). i-26 (d,6H), 1.34 3.46 (q,211), 3.78 (s,3li), 3.97 (τη,ΙΜ), 4.36 (mJU), 7.24 (m,5il), |8J8(d,lH},12-47(s,lH)… I 0,86 (1,3Η), Ϊ.05 (m,3H), 1.07 (d,6H)t 1.08 (m,2H), 1.21 (mt2H), 2.82 and 2.92 (2s,3H)t 3.20 (m,2H), 3.30 (ιη,ΠΙ), 3,55 (s,2H), 4.41 (mJH), 6.98 (d,2H), 7,09 K1H), 8.49 12.Ϊ9 (s,\\\y** 0.79(υΐΙ),1_Ι2(ιη,2Η),Ι.27(ϋ,6ί:[),1.5Ι(Γη'2Η), 3.78 (s,3H), 3.96 4.37 (mJH), 4.91 5.34 (s,IH), 7.30 (m,5H), 8.09 (d.lH). 12.38 (s,IH)… ii{ 非0 〇 1 ^ ON辦 2终· 59- 86214 1313680 〇έ pi p 、 5 O r s n Cn Q l· 梦u* ΛιΛ ty* 7*V , 1' V 舛V .1' 舛v 私 oil,i ι(ίί) 2 1 o 3: 3: = ο X X c 1 0 Π -v o X 73 73 Q ? 3a g n — n X 3¾ Q 3 α ClhClh- (S) 1 1_ g = 2 Q P^m ίΛ n 0 〇 * h c n o r3 ό o p ή Ο 73 ή ο n O ή o ?= (CHjCHiJiCH- s S -r I o G 3 s £ s 1 s G -r 33 〇 Q o Q c* Q o Ξ 〇 Q ? o n o O s va 1 t 1 1 1 1 1 1 33 2 a » 1 ( t i 1 1 aD (C=U McOH) 0.80(m,9H),1.25(m,2H),丨,50(m,2H),丨·70(ιπ,4Ι Ι>, 3.73 (m.lM), 3.80 (s,3H), 4,45 (m.lH), 5.05 (s.lH), 6.55 (s,IH), 7.Ϊ5 (m,3H), 8.25 (d.lH), 12.45 (s,IH)… 0.87(in,9H), U7(d,6H),l.26d,39(m,4H},丨.67 (m,3H)t 3.78 (s.311), 3.90 (in,2H), 4.45 (m.lll), 5.49 (d.IH), 7.85 (cUH), 12.43 (sJH)*** 0.93 (t,3H), 1.38 (d,6H), IJ9 K74-I.90 (m.2H), 2.10 (s,3lf), 2.56 (s,2H), 3.85 (.s,31I), 4.04 (m, IH), 4.08 (m,lH), 4.5J (mjll), 5.73 (d,HI), 7.97 (d,lM), 12.50 (s,IH)*^ 0.89 (l,3H), 1.28 (d,6H), 1.33 (in,2H), 1.77 (m,2H), 3.78 (sT3H)t 3.98 (mtlH), 4.56 (m.lH), 7.70 (mt3H), 9.36 (dtIH), 12.62 0.77 (ηι,6Η), 0.83 (t,3I〇, 1.43-1.75 (m,SH)s 3.53 (m,2H), 3.70 3.77 (s,3II)t 4.36 6.98 (d,2H), 7.0B 8.46 (tUH), 12.51 (3,111)+++ 0.83 (t,3H), 1,26 (d,6H), 1.73 (mf2H), 3.78 (s,3H), 3.95 (m,lH), 4.32 (m,IH), 5.08 6.44 (s.ill). Ί.\2 8.26 (d.lH), 12.50 (s,lH)*** 1 0.79 (UH), 1.25 {mil 3.78 (S.3H), 3.96 (m,UI), 4.36 (mjn), 5.06 (s,m), 6.56 (S,1K), 7.13 (m,3H), 8.22 (d,lM), 12.46 (s,Uf)*** 0.81 (t,3H), 1.21 (d,GH), 1.22 (m,2H), 1.67 (m,2H), 2.86 (s,3H), 2.95 (s,3H), 3.22 4.44 (m,l H), 5.06 (mJH). 6.54 *nd 6.41 (2s, IH), 7.13 (m,3H), 8.26 NMR (DMSO d6除非另有說明) *表示300 MHz - **表示360 MHz -***表示500 MHz -60 - 86214 1313680 OO «ηΛ os w oe fO oc X < 承ί: l·. 舛V 1' ^ Ui 舛V l· 舛V 丨“ 舛V* p Ο S η 3 Ο X 3? n M ss o ο 1 C 3D Ο 艺 Cj ? 3 3 η o ^ Q P Q -5=.¾ w X Q 5- 3〇 S 3g π 3畜 33 ό ο ?3 η ο ή ο ?3 Π o h g ή ο ή g h C 33 p f Q Q ? | A A A S X S 33 ο Ο Q ? C ο ? o Π ? Q I § £T* 〇 g 33 1 I 1 1 1 t 1 1 33 JJ 1 NJ a M t 0/78(1^11), U4-I.25<m,211),1,30 (m,6ii),1.57 {m,2M)f 3.72 (m.lH), 3.75 (Sl3H), 3.98 (nt.lH), 4.31 (m.lIO, 7.24-7.40 (m,5II), 8.26 (d,1H), 12.45 (s.lH)*** 0,91 (t,3H), U0 (d,6H), L38 (d,3H), 1.30-1.45 (mt2ll), 1.6g (m,211), 3.R〇(m,IH), 3.85 (sf3H), 4.00 (πι,ΙΗ), 4.4R 7.21-7.30 R.30 (ΛΜ), Π.48 (UH)… 0.80(1,311), 0.85 (t,3H)f U8-K30 (ιη,2Η), U0 (dt6H), 1.60 (m,2H) 1.95 (m,2U), 3.50 (m.IH), 3.80 (s,3H), 4.00 (mt!H), 4.30 (m,2H), 7.20-7.30 (m,5H), 8.32 (d,IH)t 12.45 (s,UI)*** 0.80 (t,3H), 0.86 (gil), 1.26 (d,6H), 1.30-1.40 (m,2H)f 1.65 (m,2U), 3.50 3.80 (s,3Vl)t 3,95 4.45 (m,lll), 7.20-7.30 (m,5H), 8.30 (d,lH), 12.45 0.78(m,2M),0.90(pH), 1.20(m,2Il), i.30〇n.2H), Ϊ.70 (ni,2Il)t 2.90(m,HI), 3.85 (5.3ΙΪ), 4.40(m,III), 5.10 (s.lH), 6.42 (s,1H), 7.18 (m,3H), 8.30 (dJH), t2.55 (s,lH)… :0.75 (many 0-R^(t,3H>, i.22 (ηι,2Π), 1.70 2.90 (ϋΐ,ΙΗ), 3.80 (s,3H), 4.42 (m.lH), 5.08 (sJH), 6.48 |(s,ni)( 7.13 (m,3H), 8.25 (dtlil), 12.48 (s.UI)*** i I 0.78 (d,2H)( 0.88 (t,3l·!), 1.20 (d,2H), 1.25-1.40 (m,2H), \M (ιη,ΖΙΙ), 2.90 (mJII), 3.55 3.82(s,3U)t 4.38 7.00-7.Ϊ5 (m,3H>,8.50 (d,Ui),12.48 (s,IH)… 0.80 (m.dH), 0.85 (m,3H), 1.30 (m,2H), t.50(m,2H), 1.75 3.75 (mJH), 3.85 (s,3H). *».45 (ηι,ΙΗ), 5.11 (s,lH), 6.45 (s,IH), 7.18 (m.3H), 8.31 (d,(U), 12.60 (s,m)… NMR(DMSO d6除非男有説明) *表示300 MHz - **表示360 MHz -***表示500从^1乙 -61 - 86214 1313680 UJ {〇 o c oe ·>〇 3C 30 3 ,Ρ 满. ΐϊΗ 。力 p» l· 舛V l· 饵v 1' V p c X 2 工 ς — P: η j =9 7S 33 Q Ο s S y—v S n 3¾ Q Q «j- Sq n X 3¾ Q 3¾ JJ Π Ο 2s n 〇 A g ό o ?= g H c Q |〇 ή 0 p ο X ? Q I S I X I Ψ X ο X o o O n ? 〇 Q z ?3 I3 z 73 73 c 3J 1 < 1 1 1 /-) ? n n b 1 X ? 1 1 1 * O 1 1 2na ο M 〇 2 j— 0.89 (t,3H), 1.29 (d,6H), 1.32 (τπ,2Η), 1.67 (m,2M), 3.80 (s,3H), 4.00 4.55 4.92 (d,IH), 5.51 (d,IH), 7.20-7.40 (m,5H), 7.80 (d.lll), 12.50 0.88 (1,311), 1.28 (d,6H)f 1.26 (m.2H), 1.75 (m,2M)t 3.50 (Γη,2Η), 3.80(s(3H), 4.00 (mj 11), 4.40 6.70-7.10 (m,4H), 8.25 (sJH), 9.55 (sJM), 12.45 (s,l!!)*♦* 0.85(1,311), 1,28 (d,6H), 1.30^,21-1), l.60(m,IM), 3.60 3.80 (sJH), 4.00 (in,I (I), 5.10 (s,2H), 6.86-7.46 (m,9H), 8.18 (tUH), 12.42 (sJII)*** 0.85 (t,3H), 0.90 (m,3H), 1.30 (m,2H), 1.30 (d,6M), 1.60 2.00<m,2l·!). 3.S0 (s,3li),3.9R (nUW), <U6 (πι,ΙΜ), 8.0R (dflH), 12.40 (sjll)*** 0.R9 (l,3H). 1.28 (t,3H), 1.35 1.65 (m,2H), 3.5S (ιυ,ΖΗ), 4.28 (m,2H). 4.40 (ιη,ΠΙ), 6.98 (d,2II)f 7.08 (t.lH), 8.05 (s.IH), 8.50 (d,U:I), 12.67 (s,IM)*** 0.88 (1,31-!), 1.22 (d,6HX U0(m,2M), 1.68 (m,2U), 2.87 (s,31I), 2.98 (S.3H), 3.25 4.45 (inJHl, 5.10 !(s,1H), M2 (sJH), 7.18 (in,5H)f 8 JO (dTIH), 12.20 (s,Ul)… P •,Ui 2 -W ^ 與 30 〇 一 KJ S Lj V«一 b: S 0.78 ind0.90 (2l,3H), 0.60-2.00 (m,15H)f 1.25 .nd 1.35 (2d,6H), 3.30(mJMX 3.80 (2s,3H), 4.00 4.25md 4.45 (2m,IH), 7.20-7.35 (m,5U), 8.30 12.45 (m,tH)… NMR (DMSO d6除非另有說明) *表示300 MHz ·**表示360 MHz ***表示500\11^ -62 - 86214 1313680 s 〇 O * ό CN o l· 舛v m !' 舛V* m 〇 X 沐. ^r n p §-\ 71 >° X X o s X 2 JT: X o 3 o X •Ύ· o 5 ? S 3q n X M o ^ X n X wo w X n X 〇 ^ X n o f 2 Q n ? G £; G w- w = 73 h c h U ό o 73 ή o X ό c ?c (S o 33 h Q ό o r ? A h s ? I X £ W· Q G £; Q ? Q Π 73 O ? Q ? c Q o Q ? 〇 o n 〇 o 7S 1 1 1 1 t ( 1 1 30 50 t 1 I 1 1 1 oe 十 Oi oe a !?« ^ Ισ fBS Ui NJ —* SSg 2SS 〇<·/»>- 5?§ 35~ as? ss? :心 * 15 ao 0.92 〇,3H), L36 (m,2H), 1.71 (m,2H), 2.96 (m,2M), 3.44 (m,2H)t 3.6J (s,!H), 3.R4 (s>311), 4.47 (πι,ΙΗ), 7.12 (d,2H), 7.16 (Ι,ΙΗ), 7.23-7.36 8.53 (d,UI), 12.55 (s’lll)… 0.77 (d,3H), 0.R5 (t,3H), 0.95 (d,3H), \.26 (d,6it)f 1.32 (m,2H), t.70 (m,2H), i.95 (ηι,ΙΗ), 3.72 (m,lH), 3.78 (st3H), 3.98 (πι,ΙΗ), 4.50 (m,UT), 5.45 (s,lU), 7.80 Ϊ2.45 (s,lH)*** 0.90 (U3H), U4 (m,2H), 1,30 (s,6H), 1.77 (m,2H), 3.85 (s,3H), 4.05 4.48 (m.lHX 5,97 wd 6.05 <2s,IH), 7.50 (m,511)T 8.80 12.62 0.87 (t,3H), 1.22 (d,6H), U2 («1,211), 1.70 3.78 (S.3H), 3^8 (m.lH), 4.52 (τη,ΙΗ), 5.90 .nd 6.00 (2sflH), 7.44 (m,5H), R,70(d,lH), 12.55 (s.IH)*** 0.90 (UH), 0.93 (s,9H),1.30 (d,6H),i.32 (m,2H), 1.71 l(m,2H), 3.58 (d,UI), 3.82 (S.3H), 4.02 (πι,ΙΙί), 4.52 5.60 7.82 (d,Ui), U.45 (s,U〇”* ί 0.86 (UH), 1.25 (d,6H), Ϊ.28 (m,2H), 1.68 (m,2U)t 1.74 (mt2H), 2.51 〇nt2H), 3.78 (s,3i:D, 3.91 (mjll), 3.97 4.43 (nvlH), 5.65 (s,Ui), 7.13-7.26 7.91 (d.lH), 12.47 0.90 (t,3H), 1.26 (111,211), 1.38 (d,6Il), Ϊ.69 (m,2H), 3.86 {s,3H), 4.05 (m,lH), 4,08 (ni,!H), 4.53 (rn,IH), 4.92 (m,1H), 5.33 (mJTI), 5,41 ((],UI), 7.25-7.45 8.05 (d,l 11),12.50(3,川广" NMR (DMSO d6除非另有說明) •表示300 MHz - **表示360 MHz -***表示500从^1乙 -63 - 86214 1313680
i I o 1 β c c 化合 物 3,5- 二氣笨基 (CHjCHOidi- (CH3CHi),CH- 3-氣笨基. (Cii,)3C- i_ 3,5· 二氡苯基 3,5· 二氟笨基 l· 舛V 33 OH, Η OH, H (R) OH, H (S) OH, U (S) OM, H 1 >° -= CHjiCH,),- (S) CHilCHjJr (S) (S) CH^CLI,),- ⑸ CH3(CH,)r ! ⑻ 1 [_ CHjiCMi),- (S) CH3(C!I2)r (S) Clh(C\hh^ ⑶ X -coiu -COR* -CORe j -COR* : -COR* -COHi L·___ n 〇 7: -COR< 71 {cihhcn- (CH,)2CH- (CH3),CH- (CibJjCCHa- 9 OCH, OCtb OCih OCHj NR,R, 1________ — nr7i^ OCHj OCHj I 1 ) 1 丨 ch3, ch3 CUj, CIIj 1 1 R7, R· 1 1 1 1 1 1 \ 1 〇 » ϋ Xr· 0.82(m,3H), I.IO(m,2H), 1.27 1.6) (ιη,2ίϊ), 2.83 .nd 2.95 (2m,1H), 3.77 (s.311), 3.96 (nirlH), 4.21 (mjr〇, 4:43 5.68 »nd 5.81 (2d,IH), 6.93-7.01 7.84 md 7.97 (20,1»), 12.46 (s.lll)*** 0.80 (t,3H), 0.90 (m,61 i), 1.20 (m,2H), 1.30 (d,6H), 1.34 1.55 (m.HI)T 1.74 (m,2H)t 3.86 4.00 (111,2η), 4,53 (ιτι,ΙΓΙ), 5.42 (dj ίϊ). 8.00 (d.lM), 12.54 (,〇H)… 0.86 (t,3H), 0.93 (m.6H), 1.24 (m,2H), 1.32 (d,6H), 1.38 (m,4H)t 1.55 (m.IH), 1.72 (m.2I:〇, 3.78 (s,3H), 3.9S 4.05 4.55 (ηι,ΙΗ), 5.55 (d.lH), 7.92 (ti,m),i2.30 (s,lHT" 0.87 ((,3H)3 i.20(m,2H), 1.22 (U.6H), 1.70 (m,2Ji), X80 (5,311), 4.00 4.43 5.02 6.44 (s, 1H), 7.30 7.45 (s, 1II), 8.20 <d,III), 12.45 (ΜΗ)·" 0.87 (t,3H), 0.90 (s,9H), 1.25 1.33 (mt2H), 1.6K 2.89 (s,3H), 2.97 (s,31I), 3.57 (s,IH), 4.34 5.56 (S,1H), 7.84 (d,l H)t 12.15 (sJH)*** ! 0.89 (t,3H), 1.23 (d,611), K37 (m,2H), 1.73 (mt2M)( 2.88 i(s,3H), 2.95 (s,3H)f 3.24 4.58 7.72 9.36 (djll), t2.36 1 0.86 (l,3H)f 0.9Ϊ (3,9Η), 1.34 (m,211), 1.66 (in,2H), 3.12 (m,2H), 3.58 {m,2K), 3.76 (s,3ff), 4.^0 7,02 (d,2n>, 7.09 (UH), M9 (山川),12.50 0.92 (lr3H), 1.34-1.43 (m,7H), 1.69-1.84 (mt5H)( 2.00 (m,2H), 3.61 (d,2H), 3.69 (mJM), 3.84 (s,3H), 4.47 (m.lVI), 7.06 (d,2H), 7.25 (t.lfi), R.55 (dJH), 12.55 (sJH)… ill 0 - §; 2鲜 N W 64- 86214 1313680 i Cs 〇. N. 化合 物 3,5- 二氟苯基 1' 羚w 沐V 3> 二氟笨基T 1 3,5. -一氣苯基 3,5. 二氟笨基 1_ 3,S· 二氟笨基 7i p: on, u (R.) Oli, VI (S) 1 OH, U OH· H (R) 1 OlUl(S) _x X R2,R.2 CIIKCHiV (S) CIU(CH,)r (S.) CH3(C11,)i- (S) chjCCH,),- ⑸ 1 〇h(CHi)r | (S) 1 0113(011,)!- (S) 1_ CU^CHOi- (S) (S) Λ -COR< •COR* •COR, -COR* -COR* 1 -COR, -CORi -COR* (CH3),CH- 笨基 笨基 (CH3)tCU- _1 (CHj)iCM- 1 L — — b b b OCHiCHj 0(¾ OOh OCII3 OClh i —… OCHs OCH3 OC\h 1 I 1 1 1 < ( 1 R7, Re 1 1 1 1 1 1 1 1 aD (C-), McOin 0.87 ((,311), 1.32 (d,6M), J.35 (m,2H), 1.61 (m,2H), 3.54 3.96 (mJII), 4.24 (in,2H), 4.37 (ιη,ΙΗ), 6.96 (d,2II), 7.07 8.46 (d,Ul), 12.50 0.86 {〇\l), 1.26-1.36 (m.2H), i-75 (m,2H), 3.69 4.48 5.Π (s,IH), 6.59(s,IH), 7.14 (br«d.,3H), 7.34 «nd7.49 (2s,JH), 8.35 (d.lH), 12.84 (s.Ul)*** 0.84 (t,3H), J.I9-U1 (m,2II), 1.74 (m,2H), 3.69 (s,3H), 4.50 5.09 (mjlt), 6.58 (sJH), 7.50 (brotdi^H), 7.45 .nd7.51 (2s,5H), 8.31 (d,lH), 12.75 (s,IH)*** 0.88 (1,311), 1.27 (d,6K), 1.35 (m,2H), 1.67 (m,2H), 3-50 (mt2H)t 3.»0 (9.3H), 4.00 4.3R (m.UI), ^.〇〇 (d,lH), 7.25 (d,lM), 7.50 (d,IH), 8.35 (d,!II), 12.50 (S,1H)… 0.70-0.80 (m,3H), 1J2-1.20 (m,3I〇, 1.20-1.35 (m,2H). ).30 1.60 (in,2II), 3.15 (m.lH), 3-80 (s,3H), 4.05 (m,2H), 4.40 (m,IH), 5.43, 5.55 «nd 5.80 (3d,lH), 0.95-7.30 (m,5H), 7.60 .nd 7,95 (2d,lHX 12.30-12.50 0.R3 (1,311), 1.24 (m,2H), 1.69 3.82 (s,3VI), 4.37 4.48 (s,2H), 5.07 (sJH), 6.55 (s,lH)T 7J3 7.33 (m,5II), 8.26 (d,lH), 12.59 (rJH)*** i i〇,81(UH),122 丨.68 (m,2ii),3.83 (s,3H),4.40 (mJM), 4.44 (5,211), 5.06 (s,lfi), 6,56 (s,lH), 7.15*7.24 〇n,3H), 7.32 (m,5M), 8.24 (d,l K), 12.52 (δ,Π!)*** 0.87 (t,3H), 1.32 (ιτι,2ϊ〇, Ϊ.61 (m,2H), 3.55 (m,2H), 3.83 (s,3tt), 4.39 4.61 (S.2U), 6.9R (0.2H), 7.10 (MH)f 7,30(m,5H), 8.49 ((Ι,ΠΙ), 12.55 (s,lH)^ + >5 〇 1 2: ON許 5=3 -65 - 86214 1313680 § N) B s. 5 4 l· η V i: 舛V 1' P W >iV (X 舛· έΗ ‘ l· P' ^ m ll 猶 \ w 琳 7S OHt H(S) o 3: 'X 2 o f· X 3 .= Ο jE >° 2 Ο 3 7J In Clb(au)r (S) Q « Q CH3(aii)r (S) Q 5- •-" £; Q w* P^-I n s N ·*·*> V3 Π w X n = 3q g Cj o h O 75 h o ή O 33 ή o ? h O ό o 73 ό O p n X s .I w^ o s s G n n Q ? o o 〇 σ g o ? o 3: o O n o 9 ? 1 1 1 1 1 1 1 I p 1 1 t 1 f I t 1 a D (C=l, McOH) 0.86 (l,3H), 1.28 (d,6H), 1.31 (m,2H), 1.72 3.79 (s,3Il)f 3.98 4.48 5.2Ϊ (9,111), 6.59 (br〇.d> 1H), 7.21 (m,3H), 8.22 12.51 (β,ΙΗ)*** 0.89 (1,311), 1.29 (d,6II), J.33 (m,2M), 1.71 (m,2H), 3.80 (s,3H), 3.% (m.mx 4.47 5.30 (d.Ui), 6.58 (d.UJ), 7.Ϊ9 (m,2H), 7.26 (m,IH), 8.26 12.57 (s,Ui)… 0.85 (l,3H), 1.27 (d,6M), 1.31 (m,2Ii), 1.72 (m,2H), 3.79 (s,3H), 3.97 4.19 (mJH), 5.25 (s,lH)f 6.62 (br«d. IM). 7.22 (mt2H), 7.36 (m.lH), 8.2I (djll), l2,53(s,lH”" 0.87 (l,3H), l.28(d,6H)t l.36(ni,2M), 1.67 (m,2I〇, 3.70 (m,2H), 3.78 (〇ϋ), 3.98 (mJH), 4.36 (m.lH), 6.90 md 6.92 (d+l, 2H), 7.33 (d,lH)t 8.41 12.58 (s,ni)… 0.85 (m,3U)t 1.26 (m^U), 1.28 (d,6H), 1.69 (mt2H), 3.78 (s,3H), 3.98 4.47 (in, Hi), 5.22 (s,2H), 5.33 (2(1,114), 6.07 >nd 6.11 (2ϋ,ΠΙ), 6.90-7.50 (m,8H) 8.00 (m,Ui), 12.48 (s,UI)*** 10.91 1.32 (d,6M), U7 (mf2H), 1.78 (m,2H), 3.79 (s,3 HM.02 (m,1H),4.56 (m, m),7.63 (t,1H), 7.80 (d.IH), 7.94 7.99 (s,lH), 9.33 (d.lH), 12.66 |(s,UI)… 0.87 (i,3M), 0.97 (s,9H), 1.24 (m,2H)r 1.72 (m,2H), 3.12 3.80 (s,3H), 4.41 (mJHl, 5AQ (<!,ΠΓ), 6.45 (d,lH), 7.10 (ηι,3Η), 8.30 (d.IH), 12.50 (s,lH)*** 0.81 0.90 (s,9(I), 1.21 1.69 3.08 (m,2H),3.77 (s,:m乂 Ί.44 (m,lH),5.07 (s,111), 7.17 (in,3H), 8.28 (d,U1)**- NMR (DMSO 除非另有說明) *表示300 MHz - **表示360 MHz -***表示500 >^^ 66 - 86214 1313680 86214 u> SJ δ NJ 90 岭 人 A l· 〇 T1 Ctt O J1 iK 1' P M 舛V έκ ? c p 〇 3 p O := 3 o ο 3 ? 73 o 3q O X 3| o w X n 3¾ ^ P n H Q 〇3 n π -S5 η w X 33 ή i tS o h c 73 n O Z3 h c 73 h o 53 8 £3 (CIb)2CH- — o s 呈 n I ί 7i o n ? o Π 3 g c Π c n ? o o ? Ο ο 7S 1 1 b/ 1 1 1 I 7i p « 1 1 1 1 1 1 0.30 (m,2I-n, 0.38 (m,2H), 0.R6 (t,3H), 1.03 1.27 (d,6H), 1.30 (m,2H), 1.67 (m,2H), 3.55 (m,III)t 3.78 (sT3H), 3.99 (ιη,ΙΗ), 4.50 5.37.nd 5.50 (2dTiH), 7.76 wd 7.84 (2cUH),丨 2.50 0,33 (m,2H),ϋ·37 (hi,2H), 0,90 (l,3H), 1.09 (m,IH),1.30 1.34 1.71 (m.lU>,3,W (s,3H), 4.03 (mMl), 4.59 5.55 7.88 (d,lll>,12.52 (3,1H)*" 0.87 (l,3H), 1.28 (d,6H), 1.29 1.63 2.98 (in,2H), 3.52 (m.ZH), 3.62 (m.2H), 4.20 (m,lH)^.46 (ιη,ΙΗ), 6.98 (¢1,211), 7.10 (Ι,ΙΗ), 7.28 (m,2H), 7.70 7.90 (m(2H), 8.53 12.20 (sJH)*** 0,94 (1,3H), 1,37 (d,6H), 1.42 (m,2H), 1.78 (mt2H), 3.85 (s,3H). 4.06 (πι,ΙΗ), 4.28 4.56 4.66 7.10 (cUH), 8.-10 (d,iH), 12.58 0.92 (t,3H), 1.27 (m,2H), 1.32 (dt6H), 1.77 (naH), 3.84 (s,3H), 4.05 (ιη,ΠΙ), 4.34 4.59 (mj II), 4.64 (πι,ΗΙ), 7.08 (tUH), 8.25 12.50 0.91 i.28 (m,2H), Ϊ.30 (d,6H), 1.80 (m,2H), 3.85 (5,3η), 4.07 4.53 (mtU I), 5.31 md 5.35 (2s, 111), 6.K7 7.13 7.27 8.17 ;(m,VH)(9.66(bre«di ΠΊ), 12.49 (s,IH)*** 0.90 (gH), 1.34 (d,6il), 1.39 (m,2H), 1.77 (m,2H), 3.83 (sf3H), 4.06 (mJH), 4.50 5.36 (d,lH)t 6.56 (d,!!!), 7.25 (ιη,3Η\ 8,32 (ci,IH), 12.58 NMR(DMSOd6除非另有說明) * 表示 300 MHz· ** 表示 360 MHz-***表示500 MHz -67 - 1313680
Ui Ό 〇〇 •Cn w cn u 咿. q 1' 私· V* pt >° r-r* P: ο X 2* —· J-M τα Μ 7i Q «? 3g n 3| Q <? M n vi n ? Q ? 'W* M π 3g Q s| 73 ή Ο Τ c> o 73 n 〇 2= h c 53 n o 53 iS ο ?3 h o 73 7J ? S *g P K s Q ? ψ τ* Q X X C Q CT o n s z 2 S o o X o o Ο η ϊ • 8 X X I 1 W 1 1 < 1 7J 7i I 1 1 1 I 1 |na· 〇 * 〇 S- ^ 0,95 (lt3H), 1.35 (d,6H), 1.42 (m,2H), 1.85 (m,2H)? 3.82 (s,3H), 4.05 (m, 1H), 4.62 (m, 1H). 7.70 (d, 1M), 8.40 (dJH), 8.90 (d,II〇, 9.19 (sJH), 9.35 (d.lM), 12.65 (s’lll)… 0.84 (tJH), 1.20 (m,2H), L22 (d,6H), 1.70 (ni,2M), 3.80 (s.3H), 3.99 (mJM), 4.45 (ιη,ΙΗ), 5.07 (s.Ul), 6.49 (d.Hi), 7.37 (d,lH), 7.80 (d,lH), 8.27 (¢1,111),8.61 (s.lH), a42(broadi, ΪΗ)*** 0.92 (t,3H),\M (d,6H), V.40 (m,2H), 1.71 (m,2H), 2.86 (tu,2H), 3.54 (m,2H), 3.60 <m,2H), 4.24 (m.ll·!), 4.50 (mJII), 7.13 (d,2H), 7.18 (ί,Ι,Η), 7.25-7.36 (ni,5H), 7,80 (drlH), 8,56 (d.IH), 12.25 0.86 (t,311), i.28 (d,6H), 1.29(m,2H)f 1.61 (m,2H)t 2.47 (m,2H), 2.81 (01,211), 3.88 (s,3H)t 4.00 (m.lM), 4.46 6.98 (s.IM), 7.23 (s,IH), 7.43 (s,1H), 8.16 (d.UI), 12.44 (s,lll)*** 0.87 (m,3)l), K24 (s,6II), 1.26 (m,2II), 1.73 (m,2H), 3.80 (s,3H), 3.98 (ηι,ΙΗ), 4.45 5.08 6.i7,nd 6,27 (2d,Ul), 7.Π (ιϊ,ΙΗΧ7.41-7.48 (nUH), 8.l4(tn,lH), 12.50 (cUH)*** 0.87 (m,3IiU.25 (m,211),U8 (s,6Il), 1.75 3.83 (s.311), 4.01 (mJK), 4.48 4.94 (2dJH), !6.14.nd 6.29 (2d,lH), 6.67 (ηι,ΙΗ), 6.877.14 (ιιι,Πί), 8.Π (m,lH), 8.41 (2s,IH), 12.52 0.87 (t(3H), 1.28 (¢1,611), U6 (m,2H). 1.67 (m,2H), 3.75 (m.2H), 3.77 (s,3]I), 3.98 (mJH), 4.42 7.33 7.50 7.83 (d.lH), 7.94 (θ,ΙΗ), 8.52 12.58(3,tH)*** Jl ii'SS 〇 ' 2; 1Ϊ S5 68- 86214 1313680 a y* δ Ξ: a> 冷 l· P W 1' 舛v 3,5- | 二氟苯基 l· nv h ν' 3,5- 二氟笨基 R OH, H (S) X X X X X X X X pc X >° 73 7J CHj (S) (S) αϊκαΐι)»- (S) n CH3(CH,),- ⑸ CH3(CK2)a- ⑸ CH,(CH,)a- 7i -CH(CHj), -CH(CH,), 6 1 _____1 •COR* 8 -COR* ? -COIU -COU* -COR« 1 1 -COR* δ (CH3.):CH· 33 OCih OCHj OCHj | OCHj OCHj OClh OCHj X 1 1 1 1 1 1 1 Rt,R· 1 1 1 1 t 1 1 〇 σ 3" ^ U8(dr6H)t U2 (d,3H),3.77 (s,3M), 3.91 4.48 5.05 (stIII), 6.53 (stI H), 7.12 (int3H), 8.37 (dJH), 12.6i (s.lH)… 0.87 (U.1H), 1.27 (d,6H), U5 (m,2H), 1.64 (in,2H), 3.54 3.77 (s,3H), 3.90 (m,l H), 4.45 (mj H), 6.96-7.09 (m,3H), 8.53 (d,lH),12·69 (s,lH)… 0.87 0.98 (td,2H), 1.13 (m,3H), \.2Ί .nd U6 (2m,2TI), K59-I.70 (in,8H), 2.83 «nd 2.93 (2m,2H), 3.28 (s^Il), 3.78 (s,3H), 4.44 6.96 .nd 7.09 (mt3H), 8.54 (dJH), 12.66 (s,即…_ 0.88 (l,3M), l;32 (d,3H)( 1.66 (m,2H), 2.95 (m,2H), 3.54 (s,2l[), 3.76 (s,3HX 4.47 6.97 and 7.10 (2m,3K), 8.63 (d,lI〇, 12.66 (s.lH)*** 0.89 (l,3H), 1.30 (m,2H), 1.68 (m,2H), 3.56 3.67 (s,3H), 4.43 5.13 (s,2IT), 6.98 (d,2H), 7.08-7.47 (ιη,ΙΟΪΤ), K.58 (d,lH), 12.65 (s,UI>·,* 0.R8 (t,3H), 1.35 1.69 (m,2H), 3.61 3.68 (s,3H),4.46 (m,Ul)> 7A8 (d,2H),7.09 (UH),7_60 (m,3II), 7.96 (m,3H), 7.99 (s,lH), 8.52 (dJH), 12.78 0.95 (pH), 1.38 (d,6H), f.4J (m,2H)t 1.85 (m,2H), 3.84 (sTlH), 4.04 4.58 6.86 (s,lH), 7.86 (s,IH), 8.23 (s,m),9.20 (d.m), ί2·60 (s,m)”* * g ri 〇 g §蚌 2终 N w 86214 69- 1313680 V» C: UJ S <> 命 1' 舛V1 1' 舛V 卜 1' P' w V 私 l· 舛V 琳 l· ^ UJ 沐V l· 芦w 舛V* l·’ 舛V 2〇 OH, H (R) ο X X w X X X X ο X 工 〇 I X W o X T X X 3Ϊ ~73 η η s| n X 2q Q 3¾ η W ο ^ X Q «? Π ^ X Q 3 η X 2 X % 1 X a X X 6 X 1 a X I 6 X a X X ? 〇 h G 7〇 ό w 73 h 〇 ?= ή Ο 5S h c o ? ή S 73 〇 5 C- o n o o X h ? O o X % Ο Σ ο ff o ο X 31 1 1 1 1 1 < 1 33 ? 1 1 go Ο Q Λ 1 1 S·- 0.80 (t,3H). 0.90 (3,3H), K22 (m,2H), 1.66 and L73 (2mt4H)t 2.98 3.78 (s^H), 4.49 (m.IH), 5.09 (s.lll), 6.43 (MH), 7.14 (m,5I〇, 8.38 (d.lll), 12.68 (s,li〇*** 0.80 (t,3H), 0.90 1.22 (in,2H), 1.68 and 1.72 (201,411), 2.98 (m,2M), 3.78 (5,311), 4.52 (πι,ΓΗ), 5.06 (s,lH), 6.55 (sJM), 7.17 (m,3K), 8.31 (tUH), 12.68 0.87 (t,31l)r U8 (tl,6H), \21 (t,3H), K30 (m,2H), i.65 3.55 (s,2H), 3.90 4.25 (m,2M)t 4.43 (m,lH), d.80-7.13 (m,3HX 8.5J (d,IH), !2/>6 (sTlM)*** ?° H ^ P bi μ μ ^ pp ξ i ^ i ? f hi 5 = f ϊ V S 涅 s' S ^ 3 〇 r ? •3 M V 5 a - NJ 〇J s υ* L· ^ 0.83 (t,3H), Μ 9 (d,6H)t 1.22 (ιτι,2Η), L70 3.77 (ΜΗ), 3.91 (ηι,ΙΗ), 4.48 (ιη,ΙΗ), 5.07 (sJH), 6.42 (s,II!), 7.12 (m,3H), 8.34 (dJH), 12.67 (β,\Η)^* ________ ____ 0.81 (1,311), U8 {dfiU), 1.22(m,2H)t 1.71 (m,2H), 3.77 3.90 (ιη,ΪΗ), Ί.50 (ηι,ΙΗ), 5,06 (sJH), 6.54 (sJH), 7.12 (m»3H), 18.30 12.66 (s,1H)^* 1.17 (d,6H), Ϊ.35 (d,3H), 3.77 (s,3tl), 3.91 4.49 OtiJH), 5.04 (ϋ,ΙΗ), 6.47 (s,\U\ 7.12 (m,3H), 8.37 (d,lH), 12.62 (s,lH)… U 5 (d,6H), 1.32 (d,3K), 3,53 (s,2H), 3.77 (s,3M), 4.04 4.47 6.97-7.09 (m,3II), 8.59 (d,Il!), 12.66 (、川),,* NMR (DMSO d6除非另有說明) *表示300 MHz - **表示360 MHz · ***表示500 ^11^
86214 70- 1313680 δ p s S vC l·/ 90 u O' 穿$ (CH3)3C- 3,5- 二氟笨基 l· 沐V 3,5- 丨 二氟笨基 ! 3,5- 二氟笨基 1_ 3,5- 二氟笨基 l· 舛V 柄 1' 外V 33 OH. H(S) >° OH, H (R) OH, H (S) X X X X X X X X 73 C\h(C\l3)2~ (S) CH3(CIl3)r (S) C\h{ClU)y (S) 1 CH,(CH2)r (S) CIb(CH2)2- (S) CH3(ai3)r (S) (S) Ciij(c 屮)K (S) 70 a ? o 6 o -CHjCH, -CH,CH, S -CHiCHiCHj)! o J o •{OHihCHi -COR* -COR‘ -COKi -COR« -COR« ! 1________ -COU, -COR4 -COR* 33 OCHy OCIIj OCIb OCHj 1 . OCHj OCHj 1 OCHj OCHj ? 1 1 ! t 1 t « Rr, R* 1 1 1 1 Ox v〇 SO i3 do Ul o 0^0 0.87(1.311),0.91 (s,9H), 1.2! (〇H), i.27(m,2HX 1.69 Cm,2H), 3.01 (m,2H), 3.57 (d,ir〇, 3,78 (s.3l〇, 4.57 5.56((1,111), 7.85 (d,lH), 12.63 (st\Urf* 0.92 (l,3H), L20 (UH), K38 U8 (tn,2H), 3.00 (m,211), 3.80 (s,3I1), 4.64 (m,IH),7.72 (m,3H), 9.45 (dJII), 12.95 0.89 (1,3H), 1.24 (d/ιΜ), ).28 (m,2H), U7 (m,2H), 3.04 (m,2H), 3.83 (s,3H), 4.52 5.15 (s,lH), 6.48 (s,IH),7,18 (nUIT), 8.40 (d,lH),丨2.65 (s,m),*, 0.82 (t,3H), 1.20 (d,611), 1.26 (mt2H), 1.72 (m,211), 2.99 (m,2H), 3.78 (8,311), 4.49 (m.lH), 5.10 (s,HI), 6.43 (s.lH), 7.16 8.36 (d,lH), 12.70 0.S8 1.29 (m,2H), 1.65 00,211), 2.55 (s,3H),3.56 (s,2M), 3.78 (s,3M), 4.45 6.99-7.H (m,5H), 8.55 (tMH), 12.68 (s,UI)… 0.89 (t+d,12H), 1.29 (m,2II), 1.66 (πι,2Η), 2.05 (mJM), ,2.86 13.56 (5,211), 3.78 (st3M)t 4.46 (ιη,ΙΙΙ), 7.0(5-7.15 8.64 (ti.IH), |】2.68(s,lll)… 0.88 (1,311), 1.30 (t,3H), 1.37 1.63 (m,2H), 2.98 3.56 (s,2H), 3.78 (s,3H), 4.50 (m.lll), 6.81-7.25 (m.3M), 8.56 (d,m), ,U.7Us,lIir** 0.89 (2(,611), 1.37 (m,2U), 1.63 (ni,4H), 2.95 3.55 (s,2fr>, 3.76 (s,3H)t 4.43 (m.lH), 6.80-7.12 (mMl 8.55 (d,lH)T 12.68 (s,IH)*+* 〇 _#奈 g蚌 2!舜 -7卜 86214 1313680
Cv CN 90 Cs yt A 爹ί: V 3,5- 二氟苯基 l· ^ V l· U> 舛V1 3,5- 二氟苯基 1- 3,5- 二氟笨基 (CH,)5C- VO X X OH, H (R) OH, H (S) 1 i >° X X OH, H (S) >° 33 73 h*" CH,(CIl2)r (S) CIb(CH2)r (s) CIWCHaV (S) CH3(CH2)r (S) i_ CHj(CH〇r (S) ClWCH^V ⑸ ch^ch,),- (S) 73 (CH,)/ ό -CHzC(CH3)3 -CHjCiCH,)! I -ch!c(ch3)3 1_ 1 6 X ? CORyt ~C0\U -COI^ -C0R« -COR« -C0R« -COR< 73 OCH2CH3 0CI13 OCII, | och3 OCII3 och3 OCHj ? 1 I 1 1 1 1 1 R7, R« t 1 1 1 1 1 1 a D (C=t, MeOIO 0.89(1,311), 1-27 (u3II), 1.29(mt21I), 1.66 (m?2H), 1.97 (πι(2Η), 2.63 〇ii,2H), 3.00 (rn(2H), 3.57 (s,2H), 4.25 4.45 (m.iH), 6.99 (d,2I 〇,7.09 (1,1 H), 7.19-7.27 (m,5H), 8.55 12.68 (s.lH)*** 0.84 (t,3H), 0.93 (s,9H), 1.26 (m,2H), 1.71 (m,2H), 2.90- 3.00 (111,211), 3.80 (s,3li)s 4.47 (m,Ul)f 5.08 (d,ni), 6.43 (dflH), 7.17 8.35 (d,lll), 12.60 (s,lH)… _ N> o CL· s r* = ^ S Itgp *>〇 ^ ^ !3 〇 ° 公 5 s 5 S) c 0.90 (t,3H), 1.38 (m,2H), 1.75 (m,21I), 2.63 (s,3H), 3.7B (s,3H), 4.61 (mJH), 7.69 (m,3H), 9.43(cUH)*** 0.87 (t,3H), 0.94 (s,9H), 1.31 (m,2H); 1.66~(ιη,2Η)^2^9-3.05 (m,2H), 3.59 (s,2H), 3.77 (s,3H), 4.48 (ιηΛΗ), C>.98 (¢1,211), 7.10 8.54 (d,UI), Ϊ2.65 0.82 (t(3H), 1.26 (m,2H), 1.69 (m,2M), 2.63 (s,3H), 3.77 (s,3H), 4.50 (ηι,ΓΜ), 5,07 (d,Ul)t 6.55 (dJH), 7.16 (mt3H), 8.31 12.65 (sMl)*** 1 0.95 (t,3H), 1.34 (Si9H), 1.35 (t,3I;T), 1.40 (m,2H). 1.75 (m,2H), 3.04 (m,2H), 3.98 (s,3H), 4.62 (m.lH), 9.03 (dJH), 12.85 >1 ill ||S § _#佘 -ϊ 1¾ N w 1 -72- 86214 1313680 S pi 5 z 3,5- 二氟苯基 V 和 3 5- 1 二(笨基 ! l· P1 u, ^ V 3,5- 二氟苯基 ! 1_ ^v 3,5* 二l篆基 p jr X X X X X p~ X I X OH, H (R) OH, H (S) 7i 71 M αι3(⑶,):· ⑸ CHj(Clh)r αϊ3(αι!):·1 ⑶ CH3(CIU)r (S) ? y: n CU3(CIU)r (S) 1_ CH)(CH2)i- 3J ί S :-1 (CHi^CHiCHi)!; 1 (CH1),CH(CHJ)I (CH,)/ ό (CH,)/ ό p •COR ‘ -CORi COR* 1 -cm» ; -COR« 1 -COR* L — -coiu NR7Rs NR,Re OClh OCHiCH3 OCHaCH, 1 〇CH,CHj OCHjCHj 33 XjCH,)3 fI0 ch3> 0 t 1 l 1 1 Ry» Rt cb s t t 1 1 1 §.;σ 0.91 (l,3H), 1.37 (m,2H), 1.67 (m,2H), 2.45 (s,3H), 2.85 (m,2H)t 3.45 (m,2H), 3.60 (g,2II), 4.53 7.0.1 (d,2TI), 7.14 7.24-7.32 7.99 (d,lM)r 8.55 (tUH), i2.44(s,lH)*** 0.92 (1,311), t.38 (m,2H), Ϊ.65 (m,2H), 2.14 (s,3H). 2.88 (ni,2H), 2.97 (S.3H), 3.63 (s,2M), 3.67 (m,2H), 4.51 (η>ΛΗ), 7.04 (d,2Il), 7.12 7.24-7.30 (m,5Tl), ».55 (d,111), 12.46 0.88 (t,3H)t 0.91 (d,6IJ), 1.37 Kill), 1.52 1.63 (m,2H), 3.00 3.63 3.78 (s,3H), 4.45 (mJH), 6.99 (d,2H), 7.10 8.56 12.67 0.82 (d,6H), 0.86 (ΐ,3Η), U8 K2H), 1.27 (UH), 1.28 (m,2H), 1.30 (m,2U), 1.47 (in,211), 1.63 (m,4H), 2,96 (ιη,ΙΗ), 3 J6 (m,2Ii), 4.24 (111,211), 4.44 6.98 (d,2M), 7J4 (1,111), 8.53 (dtlH)T 12.67 (s.JH)*** |0.»5 (1.3H), 1.26 (t.3H), 1.27 (m,2il), 1.59 (m,8H), 2.56 2-99 3.54 4.23 (τη,2Η), 4.43 6/)S (d,2H), 7.09 (UH),7.14-U0 8.52 (d,lH), 12.R2(s,IH)*** 0.82 (UH), 1*24(1,311), 1.29(ιη,2Η), 1.68 (m,2H), 1.91 2.61 (mf2HX 2.99 (in,2II), 4.21 4.46 5.07 (d,lH), 6.40 7.07-7.31 (m,8H), 832 (山川)J2.60(s,lH)*,* 1 b - S l|IS Ifs p _« W 3 NJ ·? <·«* /-v to g ?3t 30 * r* s涅 90 ϊ2;Ι >11 sis 3 Ιί? IS N ^ 86214 -73 - 1313680 CO Ut OO w 30 oe 5 a卜 l· 舛V 3,5- 二氟笨基 l· Uj 舛V 3.5- 二氟笨基 3,5- 二氟笨基 l· p u, 私 1' 舛V 3,5- 二氟笨基 2〇 X X X X X X _x X X X X X X X X X Cll3(CHi)r (S) ClbCCH^r (S) CH3(CH|)2· i CHJ(CH,)l- (S) C\h(Oh)i- (S) 1_ ⑶ CihiCU^. (S) aucuih- (S) 7J -COR* -con< -COR4 -COR* -CORi -COR* -C〇R<( i ? ~CH(C\hh o rb b \ -COR< ? 〇C(CU5)3 OCH, OCMj OCHj i ! 1 OCHj i i .. OCHj OCHj NRTR* 73 1 f 1 1 1 1 1 H, CH3 Rr, R§ t 1 1 1 I 1 1 1 a D (C=1T McOH) 0.89 (t, 3H), Ul (tl, 6H), 1.37 〇w 21 i), 1.55 (s, 9H), 1.64 (m, 2M)f 3.59 (m, 2M), 3.95 (m, 2H), 4.45 (m, IH), 7.09 (d, 2H), 7.12 (t, IH), 8.49 (s, 1U), 12.40 (s, IH)… 0.91 (l, 3H), i.34 (mt 2H), 1.39 (s, 3H)f 1.69 (m, 2H), 3.57 (m, 2H), 3.71 (s, 3H), 4.10 (m. 2H), 4.47 (in, 1Π), 7.07 (m, 6H), 7.35 (t, Ml), 8.55 (s, IH), 12.78 (sf 111)… 0.93 (t, 3Π), U9 (m, 2H), 1.68 (m, 2H), 3.6! (m, 2H), 3.73 (s, 3H), 4.82 (sf 3H)( 4.47 (m,2H), 7.06 (d, 2H), 7.04-7.Ϊ4 (mt 6I I), 7,40 (t, 1H), 8.56 (s, IH), 12.72 (s,丨 H)… 0.93 (t, 3H), 1.39 (m, 2H), 1.68 (m, 2H), 3.57 (m, 5H), 4.49 (m. III), 5.15 (s, 2H), 7.06 (d, 2H), 7J9 (t, IH), 7.34 (m,5H), 8.60 (s. IH), 12.67 (s, tH)*^ 0.92 (t,3H), 1.36 (mt2H)f 1.70 3.49 (s,3H), 丨3.61 (m.2H),4.50 (m,lH),7.02 (d,2il), 7Λ0 (t, IH), 17.53-7.62 (m, 511), 8.04 (m,2H), 8.55 (dfIH), 12.87 (s,m)… 0.93 (t, 3H), 1.32 (m, 2M), 1.70 (m, 2H), 3.66 (m,2H), 3.78 (s, 3M), 3.50 (m, iH), 6.90-6,95 (m, 3H), 7.08 (d, 2H), 7.17 (t. IH), 7.29 (I, ΪΗ), 8.58 (d, IH), 9.68 (s, IH), 12,77(5, IH)**+ 0.91 (U3H), U5 1.72 (m,2H), 3.60 (m,2H), 3.85 (s,3H), 4.47 (mJH), 7.02 (clt2M), 7.09 (t.UI), 7.10-7.47 (m,9H), 8.55 (d,IH), 12.80 + 0.91 (L3H), 1.37 (m,2H), 1.66 (m,2H)f 2.50 (s,3H), 2,75 (d,lH), 3.62 (s,2H), 4.48 7.01 (d,2H), 7.14(1,111),7,91 (d,m), 8.54 (d,lH>, 12.43 (s,Ul)… ||s g.对 2:鲜 74- 86214 1313680 Νί i X -J i 化合 物 3,5- 二氟苯基 3,5- 二氟笨基 二S基j 3,5- 二氟笨基 3,5- 二氟苯基 1_ a. 3,5- 二軋豕基 ? X X >° OH, H (R) OH, H (S) 1 X X >° X X R2,R'2 CH3(CM2)i* (S) Cllj(CII2):· (S) CHjiCH,)!- (S) CH3(CHj)r ⑸ (S) CH3(CH,)r (S) CH3(C]l2)r ? -CORi -C0R« -CORe -COR* -CORe •COR< -COR« X -CMiCH,)! -CU(Clhh OCHj OCHi OCH, οαι3 OCUi OCH, NR,Ri 1 1 t 1 1 1 C1I3| 0 R?» R* 1 1 1 ύι α> i ύι a • 1 a D (C叫, McOH) 0.98 (t,3H); 1,35-1.45 (mt2H); 1.75 (mf2ll); 3.60 (m+s,5H) ; 3.50 ; 7.06 (d,2H); 7.f 5 (UlM); 7.60 (d,1H) ; 7.77 (m,2H) ; 7.90 ; 8.55 (broads 1H); !2.90(s,lH)*” 0.99 (t,3H) ; t-47 (m,2H) ; 1.80-1.86 (2m,2H); 3.64 (S.3H1) ; 4.67 : 5.19 (s,2H); 7.08 ; 7.24 (d,IH) ; 7.30-7.50 (m,8H); 7.78 (m,2H) ; 9.46 (broad s 1H) ; 12.87 (broads IH)*** 0.94 (l,3H); 1.28-1.35 (2m,2H); 1.78 (m,2H); 3.65 (s,3H) ; 4.49 ; 5.13 (2s,3H); 6.47 (s,lH); 7.05 (tJH) ; 7.21 (m,4H) ; 7.35 (m,6H); 7.45 8.38 (dJH); 12.70 (sjll)**+ 0.89 (t,3H) ; 1.29 (m,21I) ; 1.79 (mT2H); 3.63 (s,3H); 4.54 (ιη.ΙΗ) ; 5.13 (sJH) ; 5.17 (s,2H); 6.62 (sJH); 7.07 (UlH) ; 7.23 (m,4H) ; 7.33 (m,6H); 7.43 (mJH); 8.35 (d,!H); 12.68 0.92 (t,3H) ; 1.32-U9 (m,2H); 1.75 (m.2H) : 3.64 (m,2M); 3.75 (s,3H); 4.48 (mJH); 7.06 (m.4I I); 7.13 (m,3H); 7.24 (m,lH); 7.49 (m,2H) ; 7.55 |(m,2H); 8.56 ; 12.77 (s,1H)*** i 0.96 (t,3H); 1.36 (d,6M); 1.42 (ιη,2Π); i.87 (m,2Vl); 3.85 (s,3H) ; 4.07 (mJH) ; 4.59 (m,IU); 7.38 (df 1H); 8.22 (d, IH); 8.26 (d, 1H); 9.22 (d,! 11); 12.68 <broad s,lll)*** 0.91 (m,3H); l.22(m,6H), 1.32 (m,2U); 1.69 (m,2H); 2.89 and 3.0i (2,st3H); 2.91 (m,2H); 3.07-3.40 (m,2K); 3.70 (m,2H); 3.71 (m. lll); 4.45-4.51 (2mJ H); 7.02 (m,2H); 7.18 (mf2H); 7.25 (m,2H); 7.35 (mt2H); 8.53 (m,lH); 12.25 m §姊 s鲜 rcS N ^ -75- 86214 1313680 86214 ο 90 3 i 5 3,5- 二氟苯基 η V 3,5- 二氟苯基 A 3,5- 二氟苯基 1' 舛V X X X X >=° >° _x X 工 X 33 au〇h)i- (S) ClhiClhh^ ⑸ CHjCCH,):- ! (S) CIIi(CM〇,- ⑶ CH3(CHi)r (S) -C0R< -COR« -COR« -CORs L——… -CORi 8 73 -CM(CH5)2 b ^CH{Clh)i i-b NR,Rg OCMj OCHj | OCHj OCHj oc\h λ 〇 Μ. 0 1 I 1 1 t R7, Rb t 1 ivl M 03 tn 1 1 2 n a 0 « σ 3-一 . 0.93 (t,3H) ; 1.28 (d,6H) ; 1.38 (m,2H); 1.68 (m,2H); 2.50 (m,4H) ; 2,56 (m,2H); 3.45 (m,2H) ; 3.60 (m,6H) ; 4.28 (m,1H); 4.52 (m,1H); 7.06 (d,2H); 7.14 (t,1H); 7.73 (m,1H); 8.57 (d,1H); 12.30 (broad sIH)*** 0.95 (t,3H) ; 1.39-1.44 (2m,2H) ; 1.77 (m,2H); 1.38 and 1.43 (2m,2H); 1.75 (m,2H); 3.69 (m,2H); 3.81 (s,3H); 4.48 (mt1H); 7.15 (d,2H) ; 7.22 (t,1H); 7.45 (m,1H); 7.51 (m,2H); 7.79 (d,1 H); 8.58 (broad s 1H); 12.89 (broad s1H)*** 0.94 (t,3H); 1.37 (mt2H); 1.79 (m,2H); 3.87 (S,3H); 4.54 (s,2H); 4.58 (m,1H); 7.29 (m,1H); 7.35 (m,4H); 7.75 (m,3H); 9.38 12.66 (broads 1H)*** 0.94 (t,3H) ; 1.07 (m,2H); 1.19 (m,2H); 1.32 (d,6H) ; 1.37 (m,2H); 1.80 (m,2H); 2.86 (mt1H); 3.85 (s,3H); 4.03 (m,1H); 4.50 (m,1H); 8.80 (d,1H); 12.56 (broads 0.94 (tt3H); 1.35 (m,1H); 1.40 1.71 (m(2H); 2.17 (s,3H); 3.62 (m,2H); 3.73 (sf3H); 4.47 (m,1H); 7.04 (dt2H); 7.15 (t,1H); 7.29 (broads 2H); 7.36 (mt2H); 8.56 {broad d1H); 12.78 (broads 1H)*** 0.97 (t,3H); 1.39 (m,2H); 1.75 (m,2H); 3.64 (m,2H); 3.81 (st3H); 4.11 (s,3H); 4.51 (m,1H); 7.07 (m,3H); 7.17 (m,2H); 7.38 (dt1H); 7.48 (m,1H); 8.58 (broad s,1H); 12.75 (broad s1H)*** ill ^l| ° § _ & 之势 X^i Ν'*·-
1313680 86214 NJ 2 NJ s s kj c 5 穿ί 1' ^ V m \ · o Q mm n I l· P'u, P u, V 33 jX X OH, H (S) OH, H(S) i OH, H (S) 1_ 工 X X X 7J '73 n 3: 3¾ ClbiCHj),- ! (S) Q n ^ X Q ? ^ X s 3¾ n X ? ή h Π h 8 g 73 o r 〇 G 春 -p p— ~^y) 7i 1 °^o °^o o z 33 B O Έ" 〇 n X o O X Π 1 1 1 1 1 ? 7> 1 1 1 1 ( t 0.92 (t,3H) ; 1.24-1.29 (2d,8H); 1.40 (m,2H); 1.70 (m,2H); 2.86 and 2.93 (2s,3H); 3.40 (m,1H); 3.60 (m,2H); 4.50 (m,1H); 4.60 (s) and 4.72 (m) 2H ; 7.08 (d,2H); 7.14(1,1H); 7.24 (d,1H); 7.39 (m,4H) ; 8.55 (d,1H); 12.35 (broads 1H)*** 〇 -S, § § § S ^ NJ ·· · « · :·^· .^ ω - r" ! W⑸ sf Ol . - · -· ^ nj cri cj 3 二 V笈 3 ^5^¾¾¾ . w» w· co.. ω 0.78 (d,3H) ; 0.86 (t,3H) ; 0.97 (dt3H) ; 1.34 (mr2H) ; 1.78 (m,2H); 2.06 (m,1H); 3.66 (s,3H); 3.80 (m,1H); 3.59 (m,1H); 5.17 (s,2H) ; 5.54 (sf1H) ; 7.06 (m,1H); 7.20 (m,1H) ; 7.32 (m,6H) ; 7.42 (m,1H) ; 7.89 (d,1H), 12.66 (broad s1H) 0.93 (t,3H) ; 0.96 (sf9H); 1.40 (m,2H); 1.78 :(m,2H) ; 3.62 (s(1H); 3.63 (s,3H); 4.59 |(m,1H) ; 5.17 (s,2H) ; 5.65 (s,1H); 7.07 ; 7.21 (m,1H); 7.35 (m,6H); 7.44 |(m,1H); 7.80 (d,1H) ; 12.62 (broads 1ΗΓ* 0.93 (t,3H); 1.32-1.40 (m,2H); 1.70 (m,2H); 3.60 (m,2H); 3.78 (st3H); 4.50 (mt1H); 7.03 (dt2H) ; 7.12 (t,1H); 7.40 ; 7.50 (m,2H); 7.53 (m,2H); 7.80 (m,4H); 8.58 (d,1H); 12.78 (broads 1H)*** NfffS -J CO 一 N> 公 C7......Ca> ipli -sr Ϊ NMR (DMSO d6除非另有說明) *表示300 MHz -料表示360 MHz ***裊示500 MHz 77- 1313680 86214 p KJ ? OO Ο w c 命 1' m Zy 啉· (_Λ l· ^ p( ^-Λ )' 和u> ll ψ Ua 舛V 私 l· m u» V 73 _X X o JX X o X X _工 X X X X X 73 33 CHjiCHi),- ⑸ Q 3¾ o 3¾ Q 3¾ Q ? o w = n X W o 7J 〇 o 7S ή 〇 o c 73 Π 〇 ή c τ n o ? ? h s Q s ή 'X 8 O b Q ? z 73 33 o n ? o Q ο ο s Ξ Z 7i 73 7S r5G "S . o a 1 1 1 1 33 7J 1 1 t t 1 t O 5- 0.93 (t,3H) ; 1.32 (d,6H) ; 1.34-1.41 (2m,2H); 1.70 (m,2H); 2.94and3.01 (2s,3H);3,20and 3.30 (2s,3H) ; 3.32-3.67 (4m,7H) ; 4.48 (m,1H); 7.04 (d,2H); 7.13 (t,1H); 8.55 (broadsIH); 12.28 (s, broad sIH)*** 0.94 (t,3H) ; 1.33 (d,6H) ; 1.34 (m,2H) ; 1.82 (m,2H); 3.84 (s,3H); 4.04 (m,1H); 4.60 (m,1H); 5.30 (m,1H); 6.71 (mt1H); 6.80-7.20 (m,2H); 8.15 and 8.20 (2d,1H) ;9.76 (broad d1H); 12.57 (broads 1H)*** 3 3 3 3 £ ox Vo f〇 工工IT工。 <·»·〇"«·_·» 'i™··" ·' 0.92 ; 1.32-1.41 (2m,2H); 1.67 (m,2H); 3,60 (s + m,5H); 3.66 (s,3H); 3.88 (s,3H); 4.4Θ (m,1H); 6.93 (d,1H); 7.03 (d.2H) ; 7.17 (m,3H); 8.56 (d,1H); 12.70 (broad s1H)*** 0.91 (t,3H); 1.33-1.40 (2m,2H); 1.67 (m,2H); 3.61 (m,2H); 370 (s.3H); 4.47 (m,1H); 6.93 (d,2H); 7.03 (t,3H); 7.14 (t,2H) ; 7.30 (t,1H); 7.39 (t,2H) ; 7.48 (t,1H); 7.54 (t,1H); 8.54 (d,1H); 12.78 (broads 1ΗΓ* 0.92 (t,3H) ; 1.24 (d,6H) ; 1.32 and 1.41 (2m,2H); 1.68 (m,2H); 2.86 and3.04(2s,3H) 3.07-3.18 (m,2H) ; 3.36 (m,1H); 3.60 (m,2H); 3.84 (m,1H); 4.51 (m,1H); 7.03 (d,2H); 7.11 (tt1H); 7.2-7.4 (mt2H);7.66and 7.73 (2t,1H); 8.45-8,57 (m,2H); 12.27 (broad s1H)*** ill ^ 03 3. = 〇 § ;& §.对 xS N or ω X n* 〇 c〇 borr cn -k nj 〇5 . ♦ 一q 〇· w c*> ri斑 CL 一 - . 一 〇) 0 乂!” 3 工5? W W ^ ϊ3-ϋ-3 S - · NJ •二P么工 2
78- 1313680 5: ? t-j p N η l· 辦V 舛V X n l· I* 蝌· (S) Η Ή〇 OH, H (S) _x X OHf H (S) X X X 工 7J S n 一 1 W Q Q Q —< o η p S h g 6 c r3 0 C 73 h o » η p % o b rb -p 〇 b Q 一 % ? Ο ώ O = Q ? R ? Z 73 71 Q t 1 1 1 fHOO ¥ho*\ lHiD I 71 1 1 1 1 1 1 Ο « Ό 0.91 (t,3H) ; 1.02 (st9H); 1.35 (mt2H); 1.75 (mf2H); 3.58 (s,3H); 3.59 (s,1H) ; 4.54 (m,1H); 5.66 (s,1H); 7.20-7.57 (5m,9H); 7.83 (d,1H); 12.55 (broads 1H)*** 0.85 (t,3H); 1.26-1.29 (2m,2H); 1.75 (m,2H); 3.Θ8 (s,3H); 4.47 (m,1H); 5.09 (s,1H); 6.58 (s,1H); 6,92 to7.52 (7m,12H); 8.30 (broads 1H); 12.68 (broads 1H)*** 0.93 (t,3H>; 1.35-1.40 (2m,2H); 1.70 (m,2H) ; 3.60 (m,2H); 3.68 (s,3H); 4.50 (m,1H); 7.03 (d,2H); 7.12 (t,1H); 7.55 (m^H); 7,63 (m^H); 8.57 (broads 1H); 12.88 (broads 1H)*** 0.91 (t,3H) ; 0.93 (s,9H) ; 1.34 (m,2H); 177 (m,2H); 3.61 (dt2H); 3.71 (s,3H); 4.58 (m,1H); 5.65 (d,1H); 6.93 (d,2H) ; 7.03 (d,1H) ; 7.13 (t,1H); 7.29 (t,1H); 7.36 (UH); 7.48 (t,1H); 7.51 (d,1H) ; 7.86 (d,1H); 12.66 (broads 1ΗΓ“ 0.87 (t,3H) ; 1.13 (2d,6H) i 1.16-1.18 (2m,2H); 1.63 (m,2H); 2.80 (m,2H); 2.82 and 2.98 (2s,3H); 2.97 3.15 (m,1H); 3.38 (mt1H); 3.60 (m,2H); 3.60-3.65-3.71 and 3.74 (4sf6H); 4.44 6,58 (m,1H); 6.77 (m,1H); 6.86 (m,1H); 6.97 (m,2H); 7.06 (mt1H); 8.46 (broads 1H); 12.23( broad s1H) 0.91 (t,3H); 1.33 (m,2H); 1.67 (m,2H); 3.61 (s,3H) ; 3.64 (m,2H) ; 4.43 (m,1H); 7.04 (m,2H); 7.14 (m,1H); 7.14 (m,1H); 7.22 (m,2H); 7.28 (m,1H); 7.35 (m,2H); 7.48 (m,2H); 7.57 (m,1H); 8,60 (broads 1H); 12.65 (broads 1ΗΓ** NMR (DMSO d6除菲另有說明) *表示300 MHz - **表示360 MHz -***表示500 1^^^ -79- 86214 1313680 S) fO NJ KJ s> 〇 tv» p a> X o 1' 咖· I l· η V l· X OH, H (S) OH, H (S) X X OH, H (S) X X o X X 30 s ^2g n 3¾ £ Q Q ? 2 G o ? 3〇 Q 3各 7i 8 W 8 'X h % h c tS o 7S Π o 73 33 ~p (^o °Λ_) ~P o b -Cl 1(011,), 〇- 33 O Φ e Q ? X z 73 33 70 1 1 1 1 • X X ? 1 1 1 1 > 1 2〇.ft c 0.96 (t,3H); 0.99 (s,9H) ; 1.44 (m,2H); 1.77 (m,2H) ; 3.38 (s,3H); 3.64 (s,1H); 4.64 (m,1H) ; 5.26 (s,2H); 5.68 (d,1H); 7.12 (t,1H) ; 7.24 (dt1H) ; 7.34 (d,1H) ; 7.38 ; 7.44 (m,2H); 7.82 ; 7.90 (d.1H);8.62 (cUH); 12.68 (s,1Hr* 0.Θ7 (t,3H); 0.90 (s,9H); 1.28 (m,2H); 1.70 (m,2H) ; 3.55 (s,1H); 3.59 (s,3H); 4.53 (m,1H); 4.91 (s,2H); 5.59 (d,1H); 6.83 (df2H) ; 6.90 (t,1H) ; 7.22 (mf2H); 7.34 (df1H) ; 7.40 (t,1H); 7,45 (t,1H); 7.59 7.82 (d,1H); 12.67 (s,1Hr* 2σ> ^ c*i o «β···» <·*~·^ *··*«··*<**» <****> ^ Γ* CL· (Λ 3 r- ro - - . . w 一 —工y ΟΪ U 2® 二二 00 05 w ω 5^3??? f-.-· 0.80 (d,3H) ; 0.87 (t,3H) ; 0.90 (d,3H); 1.27 (m,2H); 1.70 (mt2H); 1.9& (m,1H); 3.65 (s,3H); 3.74 (mt1H); 5.48 (d,1H); 6.88 (dt2H) ; 6.97 (d,1H) ; 7.09 (t,1H); 7.24 (t,1H) ; 7.20 (m,2H); 7.30 (m,1H); 7.34 (d,1H); 7.85 (d,1H); 12.63 (ε,1ΗΓ* 0.92 (t,3H); 1.25 (d,6H) ; 1.38 (m,2H); 3,05 (m,2H) ; 3.61 (m,2H); 3.88 (m,1H); 4.43 (m,1H); 4.51 (m,2H); 7.04 (dt2H); 7.15 (t,1H) ; 7.27 (m,1H); 7.36 (s,4H); 8.52 (d_1H)/12.55 (broads 1 Hr* 0.91 (t,3H); 1.29 (m,2H); 1.79 (m,2H); 4.58 (m,1H); 5.15 (d,1H); 6.48 and6.63 (2s,1H); 7.12 (m,3H); 7.42 (m,4H); 7.58 (m,1H); 7.59 (st2H); 8.34 and 8.40 (2d,1H); 12.41 (broads 1H)*** NMR (DMSO d6除非另有說明) *表示300 MHz - **表示360 MHz -***表示5001^1^ -80 - 86214 1313680 86214 228. 227. NJ SJ pN 225. N> to NJ NJ 化合 物 3,5- 二氟笨基 3,5- 二氣笨墓 (ch3)3c:- (CII,)3C- (CH3)3C- 3,5- 二氟笨基 VQ X X X X OH, H (S) OH, H (S) OH, H (S) X X R2,Rt2 Clh(〇h)^ (S) CH3(Clh)r ⑸ ClKCiWr (S) ab(cn,)2. ⑸ CH3<CH,)r (S) I_ CH3(CH,)r (S) -COU* -COR< -COR« i j -COR< •CORi -COHi °-Q •n °-9 τι n Tt -p 。-p ,¾ ~"γ) M3 OCHj OCHj OCMj OCIb OCIb I OCYh ? 1 1 1 1 1 1 R7» R* 1 1 1 l 1 1 〇 II ϋ 0.95 (t,3H); 1.43 (m,2H); 1.71 (m,2H); 3.66 (m+s,5H); 4.50 (m,1H); 5.18 (s,2H); 7.06-7.19 (m,8H); 7.44 (m,3H); 8.64 (d.1H); 12.72 (broads 1H广* 0.87 (t,3H) ; 1.32 (m,2H); 1.64 (m,2H); 3.57 (s,3H); 3.60 (m,2H); 4.43 (m,1H); 5.14 (s,2H) ; 6.98-7.40 ; 8.51 (d,1H); 12.63 (broads 1ΗΓ* 0.96 (t,3H) ; 0.99 (st9H); 1,35 (m(2H) ; 1.80 (m,2H) ; 3.64 (d,1H) ; 3.65 (s,3H); 4.63 (m,1H) ; 5.23 (s,2H); 5.68 (d,1H); 7.12-7.22 (m,5H); 7.45 (m,3H); 7.92 (d,1H); 12,67 (broad s 1 Hr* 0.87 (t,3H); 0.91 (st9H); 1.28 (m,2H); 1.70 (m,2H) ; 3.56 (s,2H); 3.56 (st3H) ; 4.54 ; 5.15 (s,2H); 5.60 (d,1H); 7.05 (t,1H); 7.20 (m,3H); 7.33 (m,3H); 7.39 (m,1H); 7.81 (d,1H); 12.54 (broads 1ΗΓ* 0.85 (t,3H) ; 0.91 (s,9H); 1,29 (m^H); 1.68 (m,2H); 3.53 (s,3H); 3.56 (mt2H) ; 4.52 (mf1H); 5.24 (s,2H); 5.58 (d;1H); 7.05 (UH); 7.13 (d,1H); 7.36 (d,*!H); 7,41 ; 7.54 (d,1H); 7.62 (lt1H) ; 7.73 (d,1H); 7.81 (d,1H); 12.55 (s,1H广* 0.99 (tt3H); 1.46 (m,2H); 1.77 (m,2H); 3.63 (s,3H) ; 3.66 (m,2H); 4.54 (m,1H); 5.28 (s,2H); 7.10-7,48 (several m,9H); 7.83 (t,1H); 8.63 (m,2H); 12.80 (broads 痛 3 = 0 〇 _佘 S3
-81 - 1313680 86214 PO u» A ΰ UJ M Ul fO Ui fvj y )0 a> l· Φ» u> Z b, γ'Ύ i q s n l· ^ V | l· 舛V JJ X X § 工 2 o X 2 X 工 〇 X X 2 s X 73 73 G n 3 G n ? ag 3! Q 2 g Π §| Π X n c n o ή ο τ h % n O F p ή ο » °-Q *n O 〇 ~P o -9 M3 73 z Jd X 〇 n ? s I s 7J o X o X 1 t 1 1 1 P3 7t 1 1 r 1 1 1 pnR l-"° 0.96 (l,3H); 1.40 (m,2H); 1.72 (m,2H); 2.32 (s,3H); 3.06 (s,6H); 3.62 (m,2H); 4.52 (m,1H) ; 7,08 (d,2H); 7.16 (t,1H); 8.58 (d,1H); 12.42 (broad s1H)*** 0,96 (t.3H); 1,37 (m.2H); 1.82 (m,2H); 3.66 (s,3H); 4.60 (m,1H); 4.72 (m(1H); 5.23 (s,2H); 7.01-7.50 (2m,8H); 8.62 (d,1H); 12.86 (broads 1H)*** 0.95 (t,3H); 0.99 (s,9H); 1,37 (m,2H); 1.81 (m,2H); 3.64 (m,2H); 3.67 (s.3H); 4.63 (m,1H) ; 5.22 (s,2H); 5.71 (d,1H); 7.10 (t,1H); 7.22 (dt1H) ; 7.33 (d,1H); 7.40-7.50 (m.5H) ; 7.94 (d,1H); 12.62 (broads 1H)*"* Ό.96 (1.3H); 1.39 (m,2H); 1.71 (m,2H); :2.36 (s,3H); 3.60 (s,3H); 3.62 (m,2H); 4.50 (m,1H); 5.16 (sr2H); 7.06-7.48 (6m,11H); 8.67 (dt1H); 12.77 (s,1Hr* 0.97 (t,3H); 1.02 (s,9H); 1.36 (m,2H); 1.80 (m,2H); 2.30 (sf3H); 3.65 (s,3H); 3.67 (m,2H); 4.65 (m,1H) ; 5.18 (s,2H); 5.70 (dt1H) ; 7.10-7.50 (5m,8H) ; 7.96 (d,1H); j 12.68 (broads 1H)*** —οι ω p * CJ -A CO 主 〇> X cn cn 〇> ro τ X X5 *cn—-^rrrr·· Spill 了一厶…二r〇 NMR (DMSO d6除非另有說明) *表示300 MHz ·**表示360 MHz -***表示500 1^}^ -82 - 1313680 on KJ KJ U) 〇\ s·» (Cib)3C- I 3,5- 二氟笨基 l· v 3) OH. H (SH X X •re X Π ? OHCUih- (S) CH3(CH3)r (S) X IX S -CORe i -COK* _ I -COR* ί NR7Rs OCHj nr7r. CH,, 1 0 1 H, u R7, R· « < 1 f 0.91 (t,3H); 0.95 (s,9H); 1.32and1.35 (2m,2H); 1.74 (mt2H); 2.90 (m,2H); 3.18 (broad s3H); 3.60 (d,1H); 3.71 (m,2H); 3.61 (m,1H) ; 5.63 (d,1H); 7.22-7.35 (m,5H); 7.90 (d,1H); 12.49 (broads 1H)W 0.93 (t,3H); 1.30and1.41 (2mt2H); 1.70 (m,2H); 3.61 (m,2H); 3.85 (s,3H) ; 4.53 (m,1H); 7.04 (d,2H); 7.17 (tJH); 8.21 (s,1H); 8.63 (d,1H); 12.82 (broads 1H)*** 0.85 (t,3H); 1.27 (m,2H); 1.62 (m,2H); 2.41 (s,3H); 2.78 (tt2H) ; 3.37 (lt2H) ; 3.55 (m,2H); 3.78 (s,3H) ; 4.43 (m,1H); 6.87 (t,1H); 7.08 (mt3H); 7.11 (m,2H); 7.20 (t,lH); 7.95 (broads 1H); 8.51 (d(1H); 12.38 (broad s1H) *§σ Sis 2鉢 86214 -83 - 1313680
NJ tu SJ p M 命 Ζ3 7) 71 Μ* ? $ % 1 a £ 3 £: 〇 s X 3 3: a X s B s % σ ?C 3; 2 Q ή c. n O ξ 2i S 2| i5Q s 2¾ f ί s i 3 s ? Ρ ~o. i -p °-p 7) X \ § tm 〇 o g ? 幽 1 1 1 1 ? 1 1 I i 1 gi.〇 O.B7 〇.3H} ; 0.9f (stBH); 1,27 (m,2H) ; 1.45 (rn^K) ; 1.69 (ntlH) ; 2,32 ; 3.13 ; 3.56 (dt1H); 370 (s.3H) : 4,52 ; S.57 (d.1H) ; 7,19 (m.3H) : 7.29 im.2H> : 7.B0 (d.1Hl ; 12,47 (s broad 1H}**4 sip ^ Pli! 帶!! lil! ·* 3着…b 'SSgS-i S-V.-S'-S'® 廳i fl) Vj · « «a <〇 11 gss三 s fS-fiTP pil UViPx 111! Ί S g???£ Na 03 ·* Φ、€Λ 一 V』k) ·ω為 σ ΝΡ.^5 i 合23二 iNalTcd 齡! {» Λ - · ·· i ill 誠歹2 0 §蚪 3:涅 N 86214 -84- 1313680 IJ 1 to l· P1 y n % n 1 l· 梦W .啉 .1' P' w ? | 9 s § X 3 -T- SJ 73 h) X 3¾ £- D ή Q s| S1 穴 4 孑 X 1 i i 8 έ ? i -¾ 33 i 〇 P § 〇 呈 33 1 1 1 I ? ? t » f 1 i |〇» 21° c?- 0,02 (t.3H) ; 1.16-1.28 (m.ZH) ; 1^7 Cm.2H) ;2,86 (3broad2H} ·· 3,2^ (Sbroad3H); 3.68 (S broad2H) ; 4,52 (m.1 H) : 5,08 (2d.1 H) ; ·. 6.4〇eie.5S{2d,1H); 7.09-7.26 (3m.BH) ; 7.60 (sbroad 1H) ; B.27 et 8.34 (2d.1W : \2M (s br〇adlH)M<* - tills « ·« · · Cd «〇 co^ ς*ϊ 0 11115 *· · T· sg#? Il5p 53 =Kg 貢? 1 襲! 马㈣:二 '碟 "% σ-^^,ωρ S^2SS «1 IIP Pll ^?ΐΐ 〇· ζώ -* * 〇 〇 ςώ 〇ϊ to ills? iS5|r · · · 一一 S❻s α> o « lo·^® λ σ 〇3 3 25^3 |:^S -* X >1 *2姜 ϊ§σ $ 〇 ;§; g, 2弊 N '— 86214 -85 - 1313680 表中,m r2,"攔中之(s)或(R)代表式⑴中帶有尺 或〜'(不對稱碳之立體化學性。”有&之碳而言,⑻或 (R)之表示與其中m2,一起形成氧代基之情況無關。 本發明化合物進行藥理測試,其顯示在治療上作為活性 物質之優點。 尤其測試其對心澱粉樣肽(万-A 4)產生之抑制效果。 〜殿粉樣肽(/5-A4)為較大前驅物蛋白質(稱為App)(殿粉 樣前驅物蛋白質)之片段。後者在人類或動物組織中各種細 胞中產生並存在。但其在腦组織中藉蛋白酶類酵素斷裂導 致形成以4肽,其以澱粉樣斑型態累積。負責產生澱粉樣 肽之兩種蛋白g母稱為石_及7 _分泌酶(W〇ife Mg,阿茲海默氏 疾病之分泌酶標的:鑑定及治療潛力,醫藥化學期刊,2〇〇1 年 6 月 21 日;44 (13): 2039-60)。 但已證明/3-A4肽之此逐漸沉積具神經毒性且在阿茲海 默氏疾病中扮演重要角色。 據此,藉γ -蛋白酶之抑制作用而作為占-澱粉樣肽(石 產生之抑制劑之本發明化合物可用以治療如老年痴呆、阿 ?么海默氏(Alzheimer's)疾病 '道氏(D〇wn,s)徵候群、帕金森 氏(Parkinson,s)疾病、澱粉樣血管病及/或心臟血管障礙等病 理。 該測試係依據下列方式進行。 •ϊ尤α;殿粉樣細胞測試而言’使用表現App之ctioo及psi Μ146L純種系3 0-12之CHO-K1株。該株可標的^ _分泌酶之 抑制作用。早衰素(preseniUn)與r _分泌酶活性有關(w〇lfe 86214 86- 1313680 广,早衰素在τ -分泌酶活性中所扮演之角色’生 MS, HaasS · β2〇01年2月23曰;276(8): 5413-6)及其與澱粉樣 物化學期β 仏端片段之共同表現引起肽Α1-42 (/5-Α4)分泌增 蛋白質其Ρ '洛生可藉式⑴化合物抑制待評估之/3-Α4肽產生之 加,因而# 洞培養盤與每洞lx 1〇5細胞於150微升培養介質 藥理手段° 焱在最小百分比(最終1.3%)之血清在37°C在5% 中培育^ # /谙育2.3小時後,使細胞黏著至塑膠上。產物(15 C02存在卞 DMSO 1%終濃度測試並在37°c在5% C02及 微升)以 <培育2445小時。此24-25小時培育後,細胞上 100%溼度「 ,炊液與升)移至ELISA盤中,以捕捉之抗體6Ε10處理
;tope: aal-17,INTERCHIM/SENETEK 320/10)以 (6E10 - eplt〇F
l焱明化合物存在下由細胞分泌之澱粉樣肽量。一 測定在本I 系列之>成對照肽”肽1-40”以5及10奈克/毫升平行處理。該 ELISA盤在4°C培育隔夜。 在相當於鈍化肽(偶合至生物素之狀丨_28)之競爭物存在 下間接偵測結合之肽量,接著以偶合至驗性鱗酸酶之鏈黴 肽素偵測。該受質(對-硝基苯基磷酸酯(pNPP FAST^+ -硝基 苯基磷酸醋,Sigma N2770))獲得黃色可溶反應產物,其可 在405麵讀取。該反應以〇·以EDTA溶液終止。就此目的而 言,殿粉樣肽在EUSA盤中結合後,添加5〇微升生物素化之 肽1-28至100微升細胞上澄液中龙在周圍溫度培同3〇分4里。 該ELIS A盤接著洗滌3次。藉浸入吸附紙而乾燥後,每洞添 加H)0微升鏈黴素肽-鹼磷酸醋(以terchim/Jackson免疫研究 實驗室016-050-084)並在阄園溫度培3 1小時。泫盤再度洗 86214 -87- 1313680 兄t'接著母洞添加1 〇〇微升之驗鱗酸酶受質(pNpp 1毫克/毫升) 在周圍/皿度培月30分鐘後,母洞藉添加i⑽微升〇 _ 1M 終止反應並在4〇5 nm讀取。 本發明式⑴化合物顯示小於500 nM( IC5g (5〇%抑制濃度) ’更尤其是小於100 nM。 生物測試結果顯示該化合物為心澱粉樣肽(万_A4)形成之 抑制劑。 據此,該等化合物可用以治療其中,搬粉樣肽(石_八4)形 成之抑制劑可提供治療效益之病理。特別是此病理為老年 矣呆、阿兹海默氏疾病、道氏徵候群、帕金森氏疾病、澱 粉樣血管病及/或心臟血管障礙。 、本發明化合物用以製備欲治療前述病理之醫藥之用途形 成本發明之整體標的。 本發明又提供-種醫藥,包括式⑴化合物或其與醫藥可 ,受㈣之加成鹽或式⑴化合物之水合物或溶劑化物。該 等醫藥發現可用於治療,尤其是治療前述病理。 種 本發明另一目的係有關一種醫藥組合物,包括至少1 本發明化合物作為活性成分。該等醫藥組合物包括有效, 量《本發明化合物或該化合物之醫藥可接受性鹽、水人物 或溶劑化物’及視情況之一或多種醫藥可接受性職型二 該賦型劑係依據醫藥劑型及所需投藥模式,技 已知之慣用賦型劑。 枝= 咖,、經皮或經直腸:藥::發 86214 -88 - 1313680 式(I)之活性成分或若適當為其鹽、溶劑化物或其水合物可 以與習知醫藥賦型劑之混合物之投藥單位劑形,對動物及 對人類投藥’供預防戒治療上述疾病及失調。 供投藥之適當單位劑型包含口服投藥劑型如錠劑、軟或 硬明膠膠囊、粉劑、顆粒劑、口香糖及經口溶液或懸浮液, 供舌下、頰内、氣管内、眼内或鼻内投藥或供吸入投藥之 劑型'供皮下'肌肉内或靜脈内投藥之劑型及供直腸或陰 道技藥之劑型。就局部應用而言,本發明化合物可以乳霜、 軟膏或乳液使用。 例如,以錠劑劑型投予本發明化合物之單位可包括下列 成分: 本發明化合物 5〇·〇毫克 甘露糖醇 223.75毫克 交聯羧甲基纖維素鈉 6·〇毫克 玉米澱粉 15_〇毫克 羥丙基-甲基纖維素 2.25毫克 硬脂酸鎂 3.0毫克 為了獲得所需治療或預防效果, 活性成分之劑量可在每 公斤體重每天0·1毫克至200毫克間變化。雖然該等劑量為平 均狀況下之例舉,但可有特別狀況 ’其中可使用較高或較 低知彳量.此劑量亦為本發明之一部分。依據慣用實務,對 各揭患之適當劑量係由醫師依據投藥模式、該病患之體重 及反應而決定。 各單位劑量可含0.1至1 000毫克, 較好0.1至500毫克之活 86214 1313680 性成分與一或多種醫藥賦型劑混合。此單位劑量可每天投 藥1至5次以投丁日劑量約〇_5至5〇〇〇毫克,較好〇·5至2500毫 克。 可有特別狀況其中使用較高或較低劑量;此劑量仍在本 發明範圍内。依據慣用實務’對各病患之適當劑量係由醫 師依據投藥模式、該病患之體重及反應而決定。 本發明另一目的係有關一種治療上述病理之方法,包捂 投予本發明化合物 '該化合物之醫藥可接受性鹽或水合物。 86214 90-
Claims (1)
- ®119408號專利申請案 -申請專利範圍替換本(98年4月) 拾、申請專利範圍·· 一種通式⑴之化合物:其中 R1代表: 視情況經一至三個選自齒素、羥基、三氟甲基、Cw烷氧 基、CN6硫烷基、嘧吩或苯基之取代基取代之c】_6烷基;或 C3·7^烷基、嘍吩、苯并嘧吩、吡啶基、呋喃基或苯基; 該苯基可視情況經一至三個選自_素原子、c16烷基、c16 烷氧基、羥基、亞曱二氧基、苯氧基或苄氧基之取代基 取代; 基、CN3烷基、c3 一起形成氧代基; R·2及R 2彼此獨立代表氫原子、鹵素原子、羥基、〇ι·3烷氧 C3-7環烷基、0-(:(0)-(:,-6烷基,或尺2與尺 r3代表氫原子、視情況經經基或Ci3烧氧基取代之 基; R4及R5彼此獨立代表: 氫原、視情況經C3.7環院基或苯基取代之^成基;或 C%7環烷基、笨基、莕基*_C(X)R6 ; 該C3.7環烧基及苯基視情況經—或多個選自㈣原子、經 86214-980420.doc 1313680 基、Cw烷基、Cl·3烷氧基、三氟甲基、三氟甲氧基、苯 基、苯氧基、苄氧基、_CH2〇_苯基、_〇CH2_吡啶基之取 代基取代; 該苄氧基可視情況經一至三個選自_素、三氣曱基、甲 基之取代基取代; 但條件為R4或Rs基至少其一代表_C(X)R6基; X代表氧原子或硫原子; R6代表c!·6烷氧基、羥基或_NR7Rs之基;該^^烷氧基可 視情況經苯基取代; R7及Rg彼此獨立代表: 氫原子、視情況經C3_7環烷基、(:3_7環烯基、Ci_3烷氧基、 苯基、嗎啉基或吡啶基取代之C16烷基;或 C3-7環烷基、cN6烷氧基或苯基;或 R7及Rs與其所帶有之氮原子形成氮雜環丙烷、氮雜環丁 烷、吡咯啶、哌啶或嗎啉環; 该ο%7環烷基及苯基可視情況經一或兩個選自Ci_3烷基、 容基、Cw烧氧基或鹵素原子之取代基取代; 係呈驗、與酸之加成鹽、水合物或溶劑化物態。 2.如申請專利範圍第1項之化合物,其特徵為: R1代表: 視情況經一至三個選自氟、羥基、三氟曱基、Cw硫烷美、 p塞吩或苯基之取代基取代之Cl_5烷基;或 CM環烷基、呋喃基、嘧吩、苯并嘧吩、吡啶基或笨美. 該苯基可視情況經一至三個選自鹵素原子、經基 # 、卞氧 86214-980420.doc -2' 1313680 基或亞甲二氧基之取代基取代; r2及尺'2彼此獨立代表氫原子、_素原子、經基、c“3烧基、 C3-7環烷基、Cl.3烷氧基、〇_c(〇)_Ci 4烷基,或化與。一 起形成氧代基; I代表視情況經C].3烷氧基取代之Ci4烷基; R4及R5彼此獨立代表: 氫原子、視情況經苯基或c3.7環烷基取代之Cw烷基;或 C3-7環烷基、苯基、萘基或-C(X)R6 ;該苯基視情況經一或 兩個選自鹵素、C!_3烷基、羥基、Cl 3烷氧基、三氟甲基、 二氟甲氧基、苯基、苯氧基、苄氧基、_CH2〇_苯基、 -OCH2·吡啶基之取代基取代; 該苄氧基可視情況經選自齒素、三氟甲基及曱基之取代 基取代; 但條件為至少一個心或!^基代表_C(X)R6之基; X代表氧原子; h代表Cw烷氧基、羥基或_NR?R8之基;該Cl 6烷氧基可 視情況經笨基取代; R?及R·8彼此獨立代表: 氫原子、視情況經Cw烷氧基、C3_7環烯基、苯基、嗎琳 基或吡啶基取代之Cl.3烷基;Cl·3烷氧基;或C3·6環烷基;或 R7及Rs與其所帶有之氮原子形成氮雜環丙烷、哌啶或嗎 p林環; 該苯基係視情況經一或兩個Cl_3烷氧基之取代基取代; 係呈驗、與酸之加成鹽、水合物或溶劑化物態。 86214-980420.doc 1313680 3·如申請專利範圍第!項之式⑴化合物,其特徵為·· Ri代表: 視情況經一或兩個選自經基、C,-6貌氧基、Cl.6硫院基、 三氟甲基”塞吩或笨基之取代基取代之CM貌基;或 c3-7環烷基、噻吩、苯并噻吩、吡啶基、呋喃基或苯基; 該苯基可視情況經-至三個選自自素原子、c16燒基、c16 · 烷氧基、經基、亞甲二氧基、苯氧基或爷氧基之取代基· 取代; rari2彼此獨立代表氫原子、齒素原子、經基、Ci虞氧 · 基、Cw烧基、c3_7環院基、〇_c(〇)_Ci 6烧基,或R2與% 一起形成氧代基; R3代表氫原子或視情況經經基或Ci•说氧基取代之匕6烧 基; R·4及R_5彼此獨立代表: 氫原子、視情況經C3·7環烷基或苯基取代之C17烷基;或 C3-7環烷基、苯基、萘基*_C(X)R6;該C3·7環烷基及苯基 視情況經-或多個選自函素原子、羥基、Cl.3烷基、Cl_3 烧氧基、苯基、苯氧基、爷氧基之取代基取代; 但條件為至少一個尺4或K基代表-c(x)r6之基; · X代表氧原子或硫原子; R·6代表C〗·6烷氧基、羥基或_NR7Rs之基; R7及Rs彼此獨立代表: 氫原子、視情況經C3·7環烷基、c3 7環烯基、苯基或吡啶 基取代之匚!-6烷基;或 86214-980420.doc -4 - 1313680 CM環烷基、Cm烷氧基或苯基;或 R7及Rs與其所帶有之氮原子形成氮雜環丙烷、氮雜環丁 烷、吡咯啶、哌啶或嗎啉環; 該Cm環烷基及苯基係視情況經Ci_3烷基、羥基、烷氣 基或_素原子取代; 係呈驗、與酸之加成鹽、水合物或溶劑化物態。 4. 如申請專利範圍第1項之式⑴化合物,其特徵為: Ri代表C!·4烷基或經兩個氟原子取代之苯基; R·2代表羥基及R'2代表氫原子; R3代表CU4烷基; X代表氧原子; 係呈驗、與酸之加成鹽'水合物或溶劑化物態。 5. 一種製備如申請專利範圍第!至4項中任一項之式⑴化合 物之方法,包括步驟為使式(ΙΠ)之2_胺基嘧唑與式(II)之醯基胺基酸進行肽偶合0 R3 其中Ri、R2、Rf2、R3、尺4及R5如申請專利範圍第!項之式 862I4-980420.doc 1313680 (i)定義。 6_ 一種製備如申請專利範圍第1至4項中任—項之式⑴化合 物之方法,包括步驟為使式(IV)之化合物 R02H (IV) 與式(VI)之胺進行肽偶合其中R〗、R2、R’2、R3、R4及Rs如申請專利範圍第丨項之式 (I)定義。 7. 種醫藥組合物,其包括至少一種如申請專利範圍第1至 員中任項之式⑴化合物,該化合物係呈醫藥可接受性 鹼鹽水合物或溶劑化物型式;及視需要選用之一或 多種醫藥可接受性賦型劑。 8. 種如申吻專利範圍第1至4項中任一項之式⑴化合物之 用途,該化合物係呈醫藥可接受性鹼、鹽、水合物或溶 d化物之型式’其係用以製備用於治療^澱粉樣肽以抑制 Μ可長:供治療效益之病變之醫藥品。 9. 如申請專利範圍第8項之用途,其中醫藥品係用於治療老 年痴呆、阿兹海默氏㈧zheimer,s)疾病、道氏(D_is)徵 候群、帕金森氏(Parkinsonis)疾病、澱粉樣血管病及/或心 862l4-980420.doc -6 - 1313680 臟血管障礙。 86214-980420.doc
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0209061A FR2842523A1 (fr) | 2002-07-17 | 2002-07-17 | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200413341A TW200413341A (en) | 2004-08-01 |
| TWI313680B true TWI313680B (en) | 2009-08-21 |
Family
ID=29797510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092119408A TWI313680B (en) | 2002-07-17 | 2003-07-16 | Acylaminothiazole derivatives, their preparation and their therapeutic application |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7291636B2 (zh) |
| EP (1) | EP1525193B1 (zh) |
| JP (1) | JP4680593B2 (zh) |
| AR (1) | AR040570A1 (zh) |
| AT (1) | ATE382040T1 (zh) |
| AU (1) | AU2003269018A1 (zh) |
| CY (1) | CY1107903T1 (zh) |
| DE (1) | DE60318317T2 (zh) |
| DK (1) | DK1525193T3 (zh) |
| ES (1) | ES2297198T3 (zh) |
| FR (1) | FR2842523A1 (zh) |
| PT (1) | PT1525193E (zh) |
| TW (1) | TWI313680B (zh) |
| WO (1) | WO2004009565A2 (zh) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2842523A1 (fr) * | 2002-07-17 | 2004-01-23 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| AP2005003274A0 (en) * | 2002-10-09 | 2005-06-30 | Galloway & Co | Thiazole compounds for the treatment of neurodegenerative disorders |
| CA2551611C (en) | 2003-12-26 | 2013-06-25 | Kyowa Hakko Kogyo Co., Ltd. | Thiazole derivatives for treating or preventing parkinson's disease |
| FR2865206B1 (fr) * | 2004-01-16 | 2009-02-06 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| WO2005073226A1 (fr) * | 2004-01-16 | 2005-08-11 | Sanofi-Aventis | Derives d’acylaminothiazole, leur preparation et leur application en therapeutique |
| FR2873370B1 (fr) * | 2004-07-22 | 2006-10-20 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| ATE517098T1 (de) * | 2004-01-16 | 2011-08-15 | Sanofi Sa | Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren |
| US7384968B2 (en) * | 2004-04-01 | 2008-06-10 | Pfizer Inc. | Thiazole-amine compounds for the treatment of neurodegenerative disorders |
| US20050222227A1 (en) * | 2004-04-01 | 2005-10-06 | Pfizer Inc | Oxazole-amine compounds for the treatment of neurodegenerative disorders |
| WO2006016219A2 (en) | 2004-08-03 | 2006-02-16 | Chiesi Farmaceutici S.P.A. | Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases |
| EA200801716A1 (ru) * | 2006-01-18 | 2009-04-28 | Амген Инк. | Тиазольные соединения и их применение |
| WO2007116901A1 (ja) * | 2006-04-05 | 2007-10-18 | Banyu Pharmaceutical Co., Ltd. | 新規アリールアミド誘導体 |
| CN100415709C (zh) * | 2006-05-15 | 2008-09-03 | 西北大学 | β-(3,4-二羟基苯基)-α-羟基丙酸冰片酯、其合成方法和用途 |
| DE102006048042A1 (de) * | 2006-10-11 | 2008-04-17 | Bayer Healthcare Ag | Acylaminoimidazole und Acylaminothiazole |
| AU2008276521B2 (en) | 2007-07-17 | 2011-11-03 | Amgen Inc. | Heterocyclic modulators of PKB |
| WO2009011871A2 (en) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
| KR20110071004A (ko) * | 2008-10-14 | 2011-06-27 | 액테리온 파마슈티칼 리미티드 | 페네틸아미드 유도체 및 이의 헤테로시클릭 유사체 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3796800A (en) * | 1971-11-22 | 1974-03-12 | Uniroyal Inc | Anti-inflammatory triazole compositions and methods for using same |
| FR2546520B1 (fr) * | 1983-05-27 | 1985-08-30 | Sanofi Sa | Nouveaux composes antibiotiques derives des cephalosporines |
| US5712270A (en) * | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| EP0951464B1 (en) * | 1996-11-22 | 2005-05-11 | Elan Pharmaceuticals, Inc. | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
| FR2842523A1 (fr) * | 2002-07-17 | 2004-01-23 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| AP2005003274A0 (en) * | 2002-10-09 | 2005-06-30 | Galloway & Co | Thiazole compounds for the treatment of neurodegenerative disorders |
-
2002
- 2002-07-17 FR FR0209061A patent/FR2842523A1/fr active Pending
-
2003
- 2003-07-11 WO PCT/FR2003/002194 patent/WO2004009565A2/fr not_active Ceased
- 2003-07-11 PT PT03750801T patent/PT1525193E/pt unknown
- 2003-07-11 AU AU2003269018A patent/AU2003269018A1/en not_active Abandoned
- 2003-07-11 JP JP2004522233A patent/JP4680593B2/ja not_active Expired - Fee Related
- 2003-07-11 AT AT03750801T patent/ATE382040T1/de active
- 2003-07-11 EP EP03750801A patent/EP1525193B1/fr not_active Expired - Lifetime
- 2003-07-11 DK DK03750801T patent/DK1525193T3/da active
- 2003-07-11 ES ES03750801T patent/ES2297198T3/es not_active Expired - Lifetime
- 2003-07-11 DE DE60318317T patent/DE60318317T2/de not_active Expired - Lifetime
- 2003-07-15 AR AR20030102538A patent/AR040570A1/es unknown
- 2003-07-16 TW TW092119408A patent/TWI313680B/zh not_active IP Right Cessation
-
2005
- 2005-01-14 US US11/035,803 patent/US7291636B2/en not_active Expired - Fee Related
-
2007
- 2007-09-21 US US11/859,443 patent/US7795289B2/en not_active Expired - Fee Related
-
2008
- 2008-03-07 CY CY20081100273T patent/CY1107903T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7291636B2 (en) | 2007-11-06 |
| DE60318317D1 (de) | 2008-02-07 |
| PT1525193E (pt) | 2008-02-25 |
| ATE382040T1 (de) | 2008-01-15 |
| FR2842523A1 (fr) | 2004-01-23 |
| AU2003269018A1 (en) | 2004-02-09 |
| TW200413341A (en) | 2004-08-01 |
| EP1525193A2 (fr) | 2005-04-27 |
| DK1525193T3 (da) | 2008-04-28 |
| JP4680593B2 (ja) | 2011-05-11 |
| WO2004009565A3 (fr) | 2004-04-08 |
| CY1107903T1 (el) | 2013-09-04 |
| US20080051436A1 (en) | 2008-02-28 |
| ES2297198T3 (es) | 2008-05-01 |
| JP2005538086A (ja) | 2005-12-15 |
| AR040570A1 (es) | 2005-04-13 |
| US20050182104A1 (en) | 2005-08-18 |
| EP1525193B1 (fr) | 2007-12-26 |
| US7795289B2 (en) | 2010-09-14 |
| WO2004009565A2 (fr) | 2004-01-29 |
| DE60318317T2 (de) | 2009-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI313680B (en) | Acylaminothiazole derivatives, their preparation and their therapeutic application | |
| JP5580201B2 (ja) | グルコキナーゼアクチベータとしてのアセトアミド誘導体、その製法及び医薬応用 | |
| EP1658272B1 (en) | Novel gamma-secretase inhibitors | |
| TWI314553B (en) | Tri(cyclo) substituted amide compounds | |
| CN105143201B (zh) | 苄胺衍生物 | |
| CA2722811C (en) | Pyrazole compounds as ccr1 antagonists | |
| TW200922556A (en) | Novel cathepsin C inhibitors and their use | |
| TW200948785A (en) | Heterocyclic aspartyl protease inhibitors | |
| TW200530202A (en) | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | |
| TWI353244B (en) | Cathepsin cysteine protease inhibitors | |
| TW200536847A (en) | Halogenated 3-oxohexahydrofuro (3, 2-b)pyrrole cathepsin k inhibitors | |
| TW201021798A (en) | Amide acetate derivative having inhibitory activity on endothelial lipase | |
| TWI592407B (zh) | 飢餓素o-醯基轉移酶抑制劑 | |
| JP7015092B2 (ja) | ドーパミンd3受容体拮抗作用を有する含窒素縮環化合物 | |
| CA3144201A1 (en) | Ep2 antagonist | |
| EP3049390A1 (de) | Substituierte phenylalanin-derivate | |
| FR2876692A1 (fr) | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique | |
| WO2003080042A1 (en) | Decomposition inhibitor for extracellular matrix of cartilage | |
| TW200946117A (en) | Compounds having NPY Y5 receptor antagonistic activity | |
| MX2012006652A (es) | Inhibidores de proteasa de cisteina. | |
| TW201443025A (zh) | 化學化合物 | |
| TW201103543A (en) | Novel cyclopentane derivatives | |
| TW200303205A (en) | Gastrin and cholecystokinin receptor ligands | |
| WO2001040204A1 (en) | 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient | |
| US9505743B2 (en) | Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |